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ABSTRACT 
NA22598A1 is a unique carbamoylated cyclic guanidine with a diol skipped diamine 
dipeptide.  It was shown to have antimetastatic activity against DLD-1 colon cancer cells with 
an IC50 of 0.32 μM, but the absolute stereochemistry has yet to be confirmed.  Guadinomine 
B is also a carbamoylated cyclic guanidine with a diol skipped diamine dipeptide.  It was shown 
to inhibit the T3SS virulence system of Gram-negative bacteria with an IC50 of 0.014 μM.  We 
endeavored to synthesize NA22598A1 and determine if it was mischaracterized at isolation. 
In addition, we investigated a potential mechanism of action that could produce both of the 
phenotypes exhibited by NA22598A1 and guadinomine B.   
To my family, I never could have done it without you. 
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CHAPTER 1 
SYNTHESIS OF THE CARBAMOYLATED CYCLIC GUANIDINE 
FRAGMENT OF GUADINOMINE B/NA22598A1 
1.1 Isolation of NA22598A1 and Guadinomine B 
In 1997, Fukazawa and coworkers identified a new natural product, NA22598A1, 
during a screen for antitumor compounds (Figure 1.1). 1  NA22598A1 was isolated from 
Streptomyces species NA22598, and initial tests demonstrated that it inhibited anchorage-
independent growth of a DLD-1 human colon cancer cell line.  NA22598A1 has a unique 
structure showcasing a fully reduced cyclic guanidine with an N5’ attached carbamoyl group, 
and a diol skipped diamine moiety attached to a dipeptide.  The initial identification of 
NA22598A1 did not include the determination of the absolute stereochemistry, and no further 
structural elucidation has been reported. 
The interesting biological activity as well as the stereochemical ambiguity prompted 
our interest in the natural product.  The sixteen possible stereochemical combinations called 
for a modulated synthesis that would quickly allow for access to multiple diastereomers.     
In 2007, Omura and coworkers isolated guadinomines A-E from Streptomyces  sp. K01-
0509 (Figure 1.1). 2  These compounds also contain a fully saturated carbamoylated cyclic 
guanidine.  Guadinomines A and B both showed potent activity against the type three 
secretion system (T3SS) of bacteria.   Guadinomine B and NA22598A1 bear a striking 
2 
resemblance to each other, with the only structural difference being the connectivity of the 
carbamoyl group to the cyclic guanidine (Figure 1.1).   
While the NMR data for guadinomine B and NA22598A1 were not completely 
congruous, they were similar enough that we hypothesized the structure of NA22598A1 was 
incorrectly assigned and these two compounds were in fact the same.  One possible reason 
for the discrepancy in NMR data was the difference in NMR sample conditions.  NA22598A1 
was characterized in D2O, while guadinomine B was characterized in D2O/1% TFA.  To 
investigate how the carbamoyl connectivity affected the NMR data, Dr. Vasudev Bhonde, 
synthesized two simple model substrates, X and Y (Figure 1.2). 3  He then characterized the 
models and compared their respective 13C NMR data.   
The 13C chemical shifts () for these compounds were very similar.  Therefore, he 
looked at the difference in chemical shifts () between X and Y as well as the difference 
between the Δ of the natural products (Figure 1.2).  The graphical representation shows that 
the differences between X and Y did not correlate to the differences between the natural 
products.  The differences between the natural products were a consistent positive one ppm 
shift which supported the idea that these were spectra of the same compound that had been 
referenced differently.  
1.2 Omura’s Total Synthesis of Guadinomine B 
The initial characterization of the guadinomines did not reveal the absolute 
stereochemistry of the molecules.  In order to determine the absolute stereochemistry, Omura 
and coworkers undertook the total synthesis of guadinomines B and C2. 4  The Omura lab had 
previously completed the synthesis of guadinomic acid, which confirmed a syn relationship 











































































































Figure 1.1: Carbamoylated cyclic guanidine natural products NA22598A1, and guadinomines 
A-D and guadinomic acid.
Figure 1.2: Comparison of the chemical shift differences between guadinomine B and 
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Determining the stereochemistry of the alcohol at C3 and the diamine at C6 and C7 
was initilly undertaken with guadinomine C2.  The cyclic nature of the diamine fragment in 
guadinomine C2 allowed for a truncated model system to be synthesized and compared to the 
natural product (Figure 1.3).  While the stereochemistry of the diamine was unknown, an NOE 
correlation revealed a syn-relationship between C6 and the CH3-3” of guadinomine C2.  Two 
model systems, the cis-diamine and the trans-diamine, were then synthesized.  
The synthesis of the simplified piprazinone models began with (R)-oxazolidinone 1, 
which underwent an Evans aldol reaction with valeraldehyde and subsequent removal of the 
chiral auxiliary to give α-chloro-β-hydroxy acid 2.  The dipeptide fragment (NH2-L-Ala-L-Val-
OtBu) was introduced through a peptide coupling to yield the chlorohydrin 3.  Epoxide 
formation was achieved under mildly basic conditions to form cis-epoxide 4 as a single 
diastereomer.  Azidolysis followed by reduction of the azide provided the 1,2-hydroxylamine 
5. Treatment of hydroxylamine 5 with NsCl afforded the N,O-bis-Ns intermediate, which was
promptly converted to the cis-Ns-aziridine 6 as a single diastereomer.  Aziridine 6 was opened 
with NaN3, which afforded the β-azide 7.  A Staudinger reduction followed by condensation 
with (R)-2-bromopropionic acid gave the piperadinone ring 8. Elimination of the Ns group 
and deprotection of the t-butyl group yielded the trans model compound 9 (Scheme 1.1).   
Figure 1.3: Guadinomines B and C1, C2. 
5 
Scheme 1.1: Synthesis of the trans piperadinone model of guadinomine C. 
Synthesis of the syn piperazinone utilized the same Evans aldol auxillary as the trans 
piperazinone synthesis.  Rather than removing the chiral auxilary with LiOH, a modified 
Azerad protocol was used to convert the ethyl ester as well as epimerize the alpha position, 
which facilitated the ring closing to the trans epoxide 10. The epoxide 10 was converted to the 
aziridine 11 via an azidolysis followed by a Staudinger reduction.  Aziridine 11 was activated 
with NsCl and opened with NaN3; the azidolysis resulted in an inseperable mixture of 
regioisomers 12 and 13.  Removal of the Ns group allowed for the separation of the 
regioisomers 14 and 15 with the desired regioisomer 14 being formed with modest selectivity 
14/15 = 3.7:1. (S)-2-bromopropionic acid and azido 14 were condensed followed by 
Staudinger reduction of the azide and SN2 cyclization to give piperainone 16.  Boc protection 
of 16 was achived prior to hydrolysis and condensation with the peptide to give the protected 
piperizanone model 17.  Treatment of 17 with acid provided the deprotected model compound 






Scheme 1.2: Synthesis of the syn piperazinone model of guadinomine C.  
 
The NMR spectra of both model compounds 9 and 18 were collected in 1% 
TFA/D2O.  Comparing the coupling constants between Ha and Hb, it was determined that the 
syn piperazinone, J(HaHb)= 4.5 Hz, was a closer match to the guadinomine Cs J(HaHb)= 4.2 
Hz, than the trans piperazinone J(HaHb)= 9.0 Hz.  This led to the conclusion that the diamine 
in the natural product had a syn-relationship.  However, the model system did not confirm the 
absolute stereochemistry in the natural product.  To determine if the piperazinone in the 





piperazinine 18 to incorporate the NH-D-Ala-D-Val-OH dipeptide.   
The spectra of the piperazinone with the D peptide showed better agreement to the 
natural product than the piperazinone with L peptide.  This confirmed the stereochemistry at 
the C6 and C7 positions to be S.  This observation combined with the work the Omura group 
had previously done on guadinomic acid left only one unconfirmed stereocenter at C3.  In 
order to confirm this stereocenter, both the syn-diol and anti-diol were synthesized.  The 
spectra of the anti-diol was a closer match to the natural product than that of the syn-diol.  The 
stereochemical information from the model systems was then translated into a complete 
synthesis of guadinomine C2, which upon characterization matched the natural product.  
Having confirmed the stereochemistry of all the  functionality in guadinomine C2, the Omura 
group turned its focus to guadinomine B. 
The synthesis of guadinomine B began with the construction of the anti-diol.  The 
chiral alcohol 19 was hydroborated and the resultant alcohol TBS protected to give elongated 
triol 20.  The benzyl protecting group was selectively removed and the primary alcohol 
oxidized to the aldehyde 21. A diastereoselective vinylation was utilized to form the diol unit 
22 in a 5:1 distereomeric ratio.  While the initial mixture was inseperable, removal of the TBS 
groups followed by cyclic acetal protection of the diol and benzyl protection of the primary 
alcohol allowed for the isolation of the acetonide 23 as a single diastereomer.  Subsequent 
hydroborylation oxidation followed by protection of the alcohol yielded the anti-diol 24.  
Removal of the benzyl group and oxidation to the aldehyde afforded the fully functionalized 
anti-diol subunit 25 (Scheme 1.3).   
The methods used for the construction of the piperazinone unit in guadinomine C 
transferred well to the diol unit.  (S)-1 was utilized for the Evans aldol to generate the 






Scheme 1.3: Synthesis of the anti-diol subunit of guadinomine B.  
 
followed by Staudinger reduction gave exclusively the trans-aziridine 28.  NsCl was used to 
activate 28 and it was opened with NaN3 at the alpha position to afford trans-aza amino 29.  
Reduction of the azide and Boc protection of the diamine yielded 30.  Saponification of the 
ethyl ester followed by peptide coupling to form the diamine dipeptide 31 completed the 
installation of all the functionality save for the cyclic guanidine (Scheme 1.4).  
The introduction of the cyclic guanidine began with the deprotection of the TBDPS 
group followed by oxidation to the aldehyde 32.  A modified Yamada nitro aldol using (R-R)-
salen-cobalt catalyst 33 afforded nitro alcohol 34 in 90% diastereomeric excess.  Reduction of 
the nitro group followed by guanylation gave the acyclic guanidine 35. Treatment of 35 with 
PPh3 and I2 generated the phosphonium intermediate, which was intramolecularly displaced 
by the guanidine to form the cyclic guanidine 36.  This reaction proved very effective with no  
9 





discernable side reactions.  The final functionality to be introduced was the carbamoyl group, 
which was accomplished via the addition of the unprotected guanidine nitrogen into a PMP 
isocyanate to give the carbamoylated cyclic guanidine 37.  Removal of the PMP group with 
ceric ammonium nitrate followed by treatment with acid yielded guadinomine B (Scheme 1.5).   
 
1.3 Comparison of NA22598A1 and Guadinomine B 
The model system used to evaluate the connectivity of the carbamoyl group on the 
cyclic guanidine suggested that the carbamoyl group of NA22598A1 was assigned incorrectly 
after isolation. While the results of the model system were promising, we wanted to directly 
compare NA22598A1 and guadinomine B.  Fukazawa generously provided us with a sample 
of the natural product as well as the producing bacteria.   
The sample of NA22598A1 that we obtained from Fukazawa, however, was not pure 
by 1H NMR spectroscopy or LCMS analysis.  We endeavored to purify the sample with 
methods described in the original isolation.  However, we were limited to an analytical C30 
column, the molecule had no fluorophore, it did not ionize well, and we were unable to obtain 
any pure natural product.  In order to obtain the natural product, we attempted to isolate it 
from the producing bacteria.  We scaled down the initial isolation conditions, from 20 L to 6 
L, and with the natural product being produced at approximately 1 mg/L, we hoped to obtain 
approximately 6 mg of NA22598A1. 1 2   
The initial growth culture was done in a 100 mL seed culture of 2.4% starch, 0.1% 
glucose, 0.3% peptone, 0.3% meat extract, 0.5% yeast extract, and 0.3% CaCO3 adjusted to 
pH 7.0.  The growth culture was incubated for 3 days at 27 °C.  An aliquot of the growth 
culture (10 mL) was then transferred to 1 L of the production media (6 flasks) containing 2.0% 










the fermentation carried out for 9 days.  The media was then centrifuged and the supernatant 
transferred to evaporation trays.  When the total volume of the supernatant was reduced to 2 
L, it was transferred to a previously activated Dowex 50W x2 [H+] column.  After washing 
with 1 L of H2O, the active material was eluted with 1 L of 1.5 N NH4OH.  The active fraction 
was neutralized with HCl and concentrated in vacuo.  
The concentrated active fraction was then further purified on Dowex 50W x2 activated 
with 0.05M MeCOONH4 buffer, adjusted to pH 3.7.  After washing with 0.05, 0.1, and 0.2M 
MeCOONH4, the active material was eluted with 0.4 and 0.6 M MeCOONH4.  The fractions 
were neutralized with NH4OH and lyophilized to dryness.  The crude material was then 
dissolved in a minimal amount of water and purified by HPLC on a Phenomenex Proteo C12 
column (10 i.d. x 250 mm) over a gradient of 5% MeCN/H2O to 15% MeCN/H2O with 0.1% 
TFA, at 4 mL/min detected at UV 214 nm.  The fractions collected from 13 minutes to 20 
minutes were analyzed by LCMS and showed traces of the NA22598A1 mass.  However, after 
the fractions were concentrated, there was no discernible trace of the desired mass.  It is 
unclear if this was due to a lack of natural product or our inability to detect it because of its 
poor ionization. 
 Our inability to isolate the natural product from the fermentation broth led us back 
to the impure natural product provided by Fukazawa.  With the help of Dr. Mark Petersen, 
we explored various HPLC conditions.  To that end, the crude natural product was dissolved 
in H2O and purified by HPLC on a Phenomenex Proteo C12 column (10 i.d. x 250 mm) over 
a gradient of 5% MeCN/H2O to 15% MeCN/H2O with 0.1% TFA at 4 mL/min, monitored 
at 412 nm.  The fractions from 12.5 minutes to 16 minutes were collected and concentrated. 
LCMS analysis showed a mixture of the desired NA22598A1 and the decarbamoylated cyclic 






Figure 1.4: The compounds isolated from the crude natural product mixture. 
 
decarbamoylated guanidine [M+H] = 460.3 were identical; therefore, we were unable to 
determine if the sample contained both compounds or if the natural product was fragmenting 
in the mass spectrometer. 
The next step was to take the 1H and 13C NMR spectra of NA22598A1 in 1% 
TFA/D2O and compare the results with the guadinomine B spectra (Figure 1.5). 3  Under these  
conditions, the proton spectra of NA22598A1 and guadinomine B were almost identical; 
however, the NA22598A1 spectrum had an additional triplet at 3.3 ppm that was not seen in 
the guadinomine B spectrum.  We collected the NA22598A1 spectra on a 500 MHz instrument, 
which provided higher resolution than the original spectrum taken on a 300 MHz instrument, 
(Figure 1.5). 2 
The carbon NMR spectra were less conclusive; the upfield region of the NA22598A1 
spectrum was convoluted and we were unable to conclusively match it to the guadinomine B 
spectrum.  The downfield region of spectrum, however, matched guadinomine B with the 
exception of an extra carbon at 162.5 ppm.  If the carbamoyl group of NA22598A1 had a 
different connectivity than the carbamoyl group of guadinomine B, we would have expected 
to see more variation in the carbon spectrum as predicted by the model substrates.  While the 
data was not definitive, we felt the similarities were enough to conclude that NA22598A1 and 


















1.4 The First Generation Synthesis of Guadinomine B/NA22598A1 
 The structures of guadinomine B and NA22586A1 present a number of potential 
pharmacophores that could be responsible for the observed biological activity.  When 
developing our synthetic strategy, we were mindful of the potential pharmacophores and 
endeavored to construct the molecule in such a manner that the carbamoylated guanidine and 
the diamine could be achieved independently and assessed for biological activity.  Our initial 
synthetic strategy utilized the synthesis of three separate pieces, the carbamoylated cyclic 
guanidine diol, the diamine, and the dipeptide, which could then be coupled at a late stage 
during the synthesis (Scheme 1.6).   
The synthesis of carbamoylated cyclic guanidine 39 was addressed first.  We envisioned 
that the alkyne 39 would be generated from the stereoselective reduction of 42.  The cyclic 
ene-guanidine 42 would be furnished from the hydroaminiation of propargyl guanidine 43.  
Propargyl guanidine 43 would come from the deprotection and guanylation of propargyl 
amine 44, which in turn would come from a three-component coupling with an alkyne 
generated from D-isoascorbic acid (Scheme 1.7).   
Due to a lack of literature precedent for a stereoselective reduction of an ene-
guanidine, Dr. Vasudev Bhonde developed a simplified model substrate to study this reaction 
in more depth.  The synthesis began with D-mannitol acetonide 45, which was oxidatively 
cleaved to form glyceraldehyde acetonide 46. 6  Treatment of the aldehyde with Bestmann-
Ohira reagent afforded the alkyne 47, which was subjected to a CuBr catalyzed three 
component coupling (3CC) with formaldehyde and diallylamine to give the propargyl amine 
48. 7   
A Pd-catylized di-deallylation was carried out to generate the free amine 49 followed 






Scheme 1.6: Retrosynthetic analysis of guadinomine B. 
 
Scheme 1.7: Retrosynthetic analysis of the left-hand portion of guadinomine B. 
 
 8   The hydroamination was completed with catalytic AgSbF6 and the ene-guanidine was 
treated with PMBNCO to install the carbamoyl group and furnish the model substrate 51 
(Scheme 1.8). 
With the ene-guanidine in hand, focus shifted to the stereoselective reduction.  A 
heterogeneous hydrogenation using Pd/C in MeOH produced a mixture of reduced product 
52 in 9:1 dr and the isomerized 2-aminoimidizole 53 (Scheme 1.9).  The absolute 
stereochemistry of the reduced product could not be verified by spectral analysis, but it was 
predicted that the si-face of the molecule would be blocked by the bulky Boc group favoring 






Scheme 1.8: Synthesis of the ene-guanidine 51. 
 
 
Scheme 1.9: Reduction of ene-guanidine 51. 
 
While the formation of the reduced guanidine was promising, the reaction needed to 
be optimized to increase the yield and minimize the formation of 2-aminoimidazole.  Catalyst, 
solvent, and pressure were all analyzed and it was determined that Rh/Alumina in EtOAc at 
60 psi of H2 were the ideal conditions and provided the desired product in 80% yield with a 





functional handle alpha to the acetonide.  D-isoascorbic acid was oxidized and protected to 
give lactone 54 in an 80% yield over two steps. 9  This precursor set the stereochemistry for 
what will be the diol in the final product.  The lactone 54 was reduced to the lactol 55 and 
converted to alkyne 56 through a Bestmann-Ohira reaction. 10  A copper catalyzed 3CC with 
alkyne 56, diallyl amine, and formaldehyde afforded the protected propargyl amine 44. 7 
Production of the amine 57 was achieved with apalladium catalyzed deprotection of 44.  The 
free amine 57 was converted to the propargyl guanidine 43 through a mercury (II) oxide 
guanylation with N, N’-Di-Boc-S-methylisothiourea.  The propargyl guanidine was then 
regioselectively cyclized to the ene-guanidine 58 using silver acetate (Scheme 1.10). 8   
When ene-guanidine 58 was subjected to the optimized conditions developed with the 
model substrate, no reaction occurred.  A number of common hydrogenation catalysts were 
then scanned, but never succeeded in generating more than trace amounts of the reduced 
guanidine 59 (Table 1.1). While the addition of the terminal alcohol seemed to stymie the 
typical hydrogenation catalysts, we hoped it could be used to direct the hydrogenation with 
Crabtree’s catalyst; unfortunately, the starting material persisted under these conditions.  
Transfer hydrogenation catalysts only produced the 2-aminoimidazole 60.  
The only catalyst that showed potential for optimization was platinum on carbon, 
which led to the investigation of other platinum catalysts and conditions, shown in Table 1.2. 
Unfortunately, altering the catalyst and solvent had no effect on the yield.  At high pressure, 
the internal Boc group at N5’ migrated to the N2’ nitrogen, giving 61.  We hypothesized that 
the migration ocurred because while on N5’, the Boc group is forced out of conjugation with 
the guanidine due to steric strain; migration to the N2’ position relieves the steric strain and 
allows conjugation.  In order to mitigate the Boc group migration, the terminal alcohol was 





Scheme 1.10: Synthesis of cyclic ene-guanidine 58. 
 










forming the carbamoyl guanidine 63 (Scheme 1.11). The introduction of the electron 
withdrawing carbamoyl group also addressed the potential electronic differences between the 
model substrate and this system.   
Carbamoyl ene-guanidine 63 was submitted to an exhaustive screen of reduction 
conditions including PtO2, Rh/Alumina, and Pt/Carbon, in various solvents and at various 
pressures.  To our dismay, the carbamoyl ene-guanidine 63 was unaffected by all of the 
hydrogenation conditions evaluated and only starting material was recovered.  Having 
eliminated electronic differences between the model system and the substrate of interest, we 
concluded that the hydroxymethyl group blocked the si face making the alkene inaccessible 






Scheme 1.11: Addition of the carbamoyl group. 
 
In order to address the problem of steric bulk while also providing a functional handle 
that could direct hydrogenation, selectively removing the acetonide was explored.  In the 
synthesis of amine 49, it was determined that the acetonide was removed during an acidic work 
up, generating the diol, which was subsequently converted to the guanidine 64.  Cyclization to 
afford the ene-guanidine would provide a model system to study the alcohol assisted reduction 
and its potential stereochemical ramifications.  However, when guanidine 64 was treated with 
AgOAc and AcOH, the ene-guanidine diol was not recovered.  Rather, the secondary alcohol 
was eliminated and vinyl-2-aminoimidazole 65 was formed (Scheme 1.12).  Hypothesizing that 
the acetic acid was involved in catalyzing the elimination of the secondary alcohol, the reaction 
was performed under neutral conditions, but the result was still the same vinyl-2-
aminoimidazole.   
While the result of the free diol cyclization was not as expected, the vinyl-2-
aminoimidazole provided an interesting substrate.  If the 2-aminoimidazole could be reduced, 
then a new synthetic avenue to reach the reduced guanidine would be available. When the 
vinyl-2-aminoimidazole 65 was submitted to another extensive screen of catalysts, conditions, 







Scheme 1.12: Formation of the vinyl-2-aminoimidazole. 
 
aminoimidazole persisted.  The difficulties involved with reducing the ene-guanidine led to a 
strategy where rather than reducing the double bond, it would be functionalized.   
 
1.5 Functionalization of the Ene-Guanidine  
Functionalizing the ene-guanidine also offered an opportunity to access guadinomine 
A, which still contained an ambiguous stereocenter at the alcohol alpha to the cyclic guanidine. 
We developed a strategy to epoxidize the double bond with the hope that it could be opened 
through the formation of an iminium ion which could then be reduced in situ (Scheme 1.13). 
The initial epoxidation conditions that were explored attempted to use the terminal 
alcohol to direct the epoxide formation.  A vanadyl acetylacetonate catalyst and tBOOH was 
used as a directed electrophilic oxygen source; however, the epoxide 66 was not isolated.   
Cognizant of the steric congestion, a smaller oxygen source, DMDO, was used, but this 
smaller electrophile also failed to produce the epoxide 66 (Scheme 1.14). 11 
Failure to epoxidize the ene-guanidine led to the exploration of other functionalization 
options beginning with a hydrobromination.  When the ene-guanidine 58 was treated with 
NBS in CH2Cl2, the cyclic ether 67 was generated. While there is precedence for forming a 
furan in this fashion, it was a surprise that the hemiaminal was stable enough to be isolated.  12  






Scheme 1.13: Mechanism for the epoxide opening.  
 
 
Scheme 1.14: Attempted epoxidation of the ene-guanidine. 
 
the alcohol was TBS protected and the solvent changed to H2O and DME (1:1). 13  This 
bromination did not lead to a stable hemiaminal and only produced the 2-aminoimidazole 68 
(Scheme 1.15).  
 
1.6 Second Generation Synthesis of the Left-Hand Fragment  
The persistence of the ene-guanidine 58 forced us to retool our synthesis of the cyclic 
guanidine diol fragment.  We drew inspiration from the synthesis of saxitoxin, and its use of a 
stereoselective iodoguanylation. 14  In order to utilize an electrophilic induced ring closure, the 
propargyl guanidine needed to be converted to the allylic guanidine to achieve the desire 
oxidation state of the cyclized product.  The propargyl guanidine proved to be resistant to 
typical Lindlar reduction conditions.  When the propargyl guanidine 42 was treated with 






Scheme 1.15: Bromination of the ene-guanidine 58. 
 
through the terminal alcohol, likely due to the lead.  To avoid the cyclic ether formation, the 
alcohol was TBS protected, and resubjected to Lindlar hydrogenation conditions.  Even in 
more polar aprotic solvent, EtOAc, the alkyne persisted. 
The unreacted propargylamine under typical Lindlar conditions led to the use of a 
stronger hydrogenation catalyst, Pd/C.  Initially, an aprotic solvent was used because of the 
increased strength of the catalyst; when that failed to produce any change in the substrate, 
polar protic solvents were explored.  Initial experiments with polar protic solvents produced 
either no change or complete reduction to the alkane.  Adjustments to the solvent and 
additives did not produce the alkene, which led to a change in the catalyst.  Pd(OH)2/C was 
scanned in a number of solvents from polar aprotic to polar protic; while it is a stronger 
reducing agent than Pd/C, it produced the same results (Table 1.3). 
Failing to reduce the propargyl guanidine, it became necessary to introduce the alkene 
at an earlier stage.  There was precedent for the reduction of a free propargyl amine to the allyl 
amine; therefore, the propargyl amine 57 was treated with Pd/BaSO4 and ethylene diamine in 
DMF under a hydrogen atmosphere; to our delight, this furnished the allyl amine 70 (Scheme 





Table 1.3: Attempted reduction of the propargyl guanidine. 
 
 
recovered; however, the product was simply lost in the work up and when the water wash was 
eliminated, the yields were greatly improved.  The guanylation of the allyl amine 70 was 
accomplished smoothly and provided the allylic guanidine 71 for an electrophilic cyclization. 
While both the free alcohol and the guanidine had the potential to be nucleophiles, previous 
work with the propargyl guanidine suggested that the alcohol would not be a competitive 
nucleophile.  The first electrophilic cyclization utilized NBS to generate the bromonium ion, 
and the product isolated appeared to be the cyclic guanidine as a single diastereomer.   
A minor product was detected when the reaction was run at room temperature; 
however, the negligible quantity prevented isolation. In an attempt to minimize the formation 
of the minor product, the reaction was cooled to –30 °C; however, the reduced temperature 
decreased the selectivity to 4:1 and allowed for the isolation of the minor product.  Upon 






Scheme 1.16: Reduction of the propargyl amine 57. 
 
rather than the cyclic guanidine 72 (Scheme 1.17).  The formation of the cyclic ether prompted 
the protection of the terminal alcohol; an alcohol protecting group was selected so that it could 
be selectively cleaved in the presence of the Boc groups.  A base labile benzoyl group was 
introduced after the 3-CC in an effort to increase the yields of subsequent reactions by 
decreasing the polarity of the products, which allowed for easier purification.  
The protected amine 43 was converted to the benzoate 74, and the allyl groups were 
subsequently removed to form the propargyl amine 75.  Reduction of the alkyne presented a 
challenge; previously, ethylenediamine had been used to poison the catalyst, but its basicity 
had the potential to cleave the benzoyl group.  To mitigate the problem, the less nucleophilic 
amine, quinoline, was used as an additive.  This change produced the alkene 76 in good yield 
without cleaving the benzoyl group.  The guanylation proceeded smoothly to give allylic 
guanidine 77, which was treated with NBS in MeCN at -30 °C to produce a 2:1 mixture of 
diastereomers 78a,b (Scheme 1.18). 
 
 






Scheme 1.18: Protection of the terminal alcohol an NBS cyclization. 
 
The 2:1 mixture of the cyclic guanidine was separable, but because neither of the 
compounds were crystalline, determination of the absolute stereochemistry of either 
compound was not determined. However, the functionalization alpha to the cyclic guanidine 
offered a unique opportunity to access guadinomine A.  The adjacent Boc group could be 
cyclized onto the bromide to form the cyclic carbamate, which could then be opened to reveal 
the alpha alcohol. 14  The cyclic guanidine 78 was treated with AgOAc in MeCN with the 
intention of cyclizing the boc group onto the bromine forming the cyclic carbamate.   
Unfortunately, the cyclization was unsuccessful and the bromine persisted (Scheme 1.19). 
The inability to form the cyclic carbamate led to an exploration of more traditional 
dehalogenation methods.  Initial efforts focused on Bu3SnH reductions, assuming that such a 






Scheme 1.19: Attempted cyclization of tbutyl carbamoyl group on 78. 
 
subjected to Bu3SnH and AIBN in benzene at room temperature for 12 hours; after work up, 
no product was formed and the bromide remained. 16  No formation of product led to a change 
in solvent, from benzene to toluene, and the temperature was increased to 110 °C.  Even at 
reflux temperatures in toluene, no dehalogenated product was recovered (Scheme 1.20).  
The failure of Bu3SnH to have any effect on the bromoguanidine suggested that steric 
incompatibility was playing a role in hindering the reaction. Unable to remove the bromide, 
iodine was utilized as electrophile.  The initial iodine source NIS furnished the cyclic guanidine 
in moderate yield and a 2:1 mixture of diastereomers.  The carbon iodide bond offered a 
number of new possibilities to dehalogenate the molecule.   
The first dehalogenation reaction applied to the iodoguanidine 79 was a palladium 
catalyzed hydrogenation.  We were disappointed to see that starting material remained largely 
unreduced under these conditions. There was a minor product that initially resembled a 
reversion to the Z alkene, but upon closer analysis, it proved to be the E alkene 80 (Scheme 
1.21).  While the NIS cyclization did provide the cyclic guanidine, it was in moderate yield and 
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Scheme 1.21: Iodocyclization and hydrogenation. 
 
unreliable reproducibility.  Exploring other sources of electrophilic iodine led back to the 
synthesis of saxitoxin, which utilized AgOAc to generate a more electrophilic iodine source.  
Additionally, the iodocyclization in saxitoxin produced a single diastereomer in 82% yield 
(Scheme 1.22).  The rigid nature of saxitoxin contributed to the single diastereomer formation; 
however, the high yield suggested a reversible iodonium ion formation that we hoped to be 
able to capitalize on. 14   
Allylic guanidine 77 was treated with AgOAc and I2 in Et2O at room temperature and 
stirred for 3 hours.  We were delighted to see the yield increased from 62% to 89%, but the 
diastereoselectivity was poor, furnishing a 1.3:1 mixture (Scheme 1.23).  The selectivity of this 
cyclization will be more completely addressed in Chapter 2.  Settling on conditions that 
provided the iodoguanidine in good yield, I focused on optimizing conditions to dehalogenate 
the molecule.   
The synthesis of saxitoxin also utilized a Boc group cyclization onto an iodide to form 
a cyclic carbamate; while the bromoguanidine was unresponsive to such a cyclization, the 
iodoguanidine had more literature precedent. Initially, iodoguanidine 79a was dissolved in 






Scheme 1.22: Iodocyclization utilized in the synthesis of saxitoxin. 
 
 
Scheme 1.23: AgOAc, I2 cyclization of the allylic guanidine.  
 
  To determine if the solubility of the AgOAc was limiting the cyclization, the silver 
salt was changed to AgNO3.  This change had no effect on either diasteromer and no cyclic 
carbamate was observed. Increasing the temperature from room temperature to 60 °C did not 
facilitate the cyclization with either AgOAc or AgNO3.  In the synthesis of saxitoxin, the 
addition of AcOH helped to facilitate the cyclization of the cyclic carbamate, which I hoped 
would translate to the cyclization of iodoguanidine 79a/b.  Monitoring the reaction by TLC, 
a loss of starting material was observed; however, upon NMR analysis, it was clear the internal 
Boc group was simply cleaved rather than cyclized (Scheme 1.24).  
The inability to form the cyclic carbamate led back to the optimization of 
intermolecular dehalogenation reactions. The alpha elimination seen in the palladium catalyzed 
hydrogenation prompted an exploration of radical dehalogenation reactions.  Cognizant of the 
steric constraints, I looked for a smaller radical dehalogenation reagent.  The Wood laboratory 
used tributyl borane rather than tributyl tin to cleave carbon iodine bonds, which seemed far 






Scheme 1.24: Attempted formation of the cyclic carbamate.  
 
The attempted carbamate formation with AcOH and AgOAc created concerns about 
the stability of the internal Boc group, so prior to the dehalogenation, the carbamoyl group 
was introduced.  Iodoguanidine 79 was dissolved in benzene, and benzyl isocyanate was added; 
the reaction was then stirred for 1 hour, providing the carbamoyl guanidine 81 in 98% yield.  
The carbamoyl guanidine 81 was dissolved in benzene, and water was added to the reaction 
mixture followed by tributyl borane; air was then bubbled into the solution at a rate of 1 mL/h  
to produce the dehalogenated 82 (Scheme 1.25).  The dehalogenated cyclic guanidine 82 
proceeded with minimal formation of side products.  However, the low yield prompted an 
optimization of this reaction.  I found that if the reaction was simply open to air and the 
solvent was not degassed, the yield increased considerably to 61%. Additionally, adjusting the 
work up to use a weaker base minimized the loss of the Boc groups.  
 
1.7 Deprotection of the Left-Hand Fragment 
One of the highlights of the proposed route was the separation of potential 
pharmacophores so that each could be analyzed individually.  To that end, a global 






Scheme 1.25: Dehalogenation of the carbamoylated guanidine. 
 
group, specifically because it would have to be selectively deprotected to further elongate the 
molecule. The cyclic guanidine 82 was treated with NaOH in THF and H2O at room 
temperature and stirred for 1 hour.  Upon work up, it was clear that the benzoyl group 
persisted while the carbamoyl group had been cleaved (Scheme 1.26).  The selective cleavage 
of the carbamoyl group was concerning and led to a shift in the protecting group strategy.  
Keeping in mind that the terminal alcohol still needed to be selectively deprotected, a TBS 
protection was employed.  The reaction sequence that produced the benzyl protected cyclic 
guanidine was repeated to produce the TBS protected cyclic guanidines 89a,b (Scheme 1.27).  
The TBS protected guanidine was treated with TBAF in THF, which removed the Boc 
protecting groups rather than the TBS group, generating 90a,b.  The loss of the Boc groups 
was unexpected but did not hinder the global deprotection of the left-hand fragment for 
 
 







Scheme 1.27: Synthesis of the TBS protected cyclic guanidine 89a,b. 
 
biological evaluation. The carbamoyl guanidine 90a,b was dissolved in TFA and stirred 
overnight, which successfully removed the TBS group and the ketal, to provide the triol 91a,b.  
The removal of the benzyl group appeared to be straightforward, and the triol 91a was 
submitted to hydrogenation conditions with a Pd(OH)2 catalyst.  The hydrogenation was 
unsuccessful and the pressure of H2 was increased to 60 psi, and when that produced no 
reaction, the pressure was increased to 120 psi (Scheme 1.28).  When the hydrogenation failed 
to remove the benzyl group, a radical debenzylation method was implimented.  Ammonia was 
condensed and sodium was added, followed by the triol 91a in THF; the reaction was stirred 









































































Scheme 1.28: Attempted total deprotection of cyclic guanidine 90. 
 
The inability to remove the benzyl group forced a shift in the protecting group on the 
carbamoyl guanidine.  In order to change the protecting group, a new isocyanate was 
synthesized. 2,4-Dimethoxybenzyl amine was dissolved in CH2Cl2 and a saturated NaHCO3 
solution, then cooled to 0 °C; triphosgene was then added and the reaction stirred for 30 
minutes, which furnished the 2,4-dimethoxyisocyanate 92 (DMBCNO) in 93% yield.  The 
cyclic guanidine 88 was then converted to the carbamoyl guanidine 93, which was 
dehalogenated to provide the fully protected guanidine 94.  When the fully protected guanidine 
94 was submitted to TFA, the fully deprotected triols 95a and 95b were obtained (Scheme 
1.29).  The deprotected fragments not only provided the potential pharmacophore for 
biological testing, they also allowed us to confirm the stereochemistry of the cyclic guanidine.   
The biological results will be discussed in Chapter 4. 
 
1.8 Efforts Toward the Further Functionalization of the Left-Hand Fragment 
Having a robust synthesis to create the left-hand fragment, I turned my attention to 






Scheme 1.29: Total deprotection of the left-hand fragment. 
 
unfunctionalized carbons between the diol and the diamine.  The initial synthetic plan was to 
use the diastereoselective addition of an alkyne into a nitrone developed by Merino (Scheme 
1.30). 18  In order to apply that to our synthesis, we needed to convert the terminal alcohol to 
an alkyne.  
The first hurdle we encountered was the selective deprotection of the terminal alcohol.  
The attempts to remove the TBS group inevitably led to the removal of the boc protecting 
groups as well.  This led to yet another change in the alcohol protecting group, to the TBDPS 
silyl ether.  The same synthetic route was used to reach the TBDPS cyclic guanidine 102 as 
was used to generate both the benzoyl and TBS derivatives (Scheme 1.31).  
The TBDPS group was removed with a mixture of TBAF and AcOH in THF; the 
reaction was stirred for 18 hours and produced the free alcohol 103 in 91% yield. The alcohol 
was then converted to the aldehyde 104 using Dess-Martin periodinate (Scheme 1.32).  This 
reaction proceeded smoothly; however, residual Dess-Martin reagent remained after the 
reaction was filtered.  I chose not to purify aldehyde 104 with column chromatography because 
of the potential epimerization of the stereocenter alpha to the aldehyde; also the excess Dess-






Scheme 1.30: The desired coupling of the left-hand fragment and the diamine. 
 
The aldehyde 104 was dissolved in MeOH and Bestmann-Ohira reagent was added to 
the reaction followed by K2CO3 added in portions.  This furnished the alkyne 105 in moderate 
yield but it also cleaved both Boc groups.  The unprotected guanidine posed a problem because 
the addition into the nitrone required the alkynyl anion. The lower pKa of the guanidine 
protons, as well as the carbamoyl NH, suggested that it would be difficult to generate the 
alkynyl anion species. Attempting to reprotect the guanidine, the alkyne 105 was dissolved in 
CH2Cl2 and Boc2O was added followed by DMAP and the reaction was stirred 18 hours.  The 
exocyclic nitrogen was Boc protected but the internal nitrogen remained unprotected 106; this 
was attributed to the steric constraints at that position (Scheme 1.32).  The alkynyl addition 
into the nitrone will be discussed in Chapter 3.   
Despite the challenges encountered in the synthesis of the carbamoylated cyclic 
guanidine diol fragment 106, it was completed in 11 steps with a highly reproducible route. 
The dense functionality and the need for orthogonal protecting groups added to the 
complexity of creating this fragment.  This route also provided the opportunity to create the 







Scheme 1.31: Synthesis of the TBDPS protected derivative. 
 
 





1.9 Supporting Information  
Unless otherwise noted, all starting materials were either known compounds or were 
obtained from commercial sources and used without purification. All reactions requiring 
anhydrous conditions were performed under a positive pressure of argon using flame-dried 
glassware. Dichloromethane (CH2Cl2), and triethylamine (Et3N), were distilled from CaH2 
immediately prior to use. Tetrahydrofuran (THF), diethylether (Et2O), toluene (PhMe), and 
dimethylformamide (DMF) were degassed with argon and passed through a solvent 
purification system (J.C. Meyer of Glass Contour) containing either alumina or molecular 
sieves. Flash chromatography was performed on Merk silica gel Kieselgel 60 (230-400 mesh) 
from EM science with the indicated solvent.  1HNMR spectra were recorded on a Varian VXR-
500 MHz spectrometer. The chemical shifts (d) of proton resonances are reported relative to 
CHCl3, DMSO-d5, HOD, or HD2COD using the following format: chemical shift [ multiplicity  
(s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, app = apparent), coupling 
constant(s) (J in Hz), integral].19,20 13CNMR spectra were recorded at 75, 100, or 125 MHz. The 
chemical shifts of carbon resonances are reported relative to the deuterated solvent peak. 
Infrared spectra were recorded on a Nicolet 380-FT IR spectrometer fitted with a 





To a solution of alkyne 56 (3.00 g, 19.22 mmol) in methanol was 
added diallylamine (2.37 mL, 19.22 mmol), formaldehyde (1.51 mL, 19.22 










hours at room temperature.  The mixture was filtered through a pad of Celite and concentrated 
under reduced pressure and purified by flash chromatography, (1:1 Hex/EtOAc) to yield 10, 
as a pale yellow oil. Rf = 0.71 (1:1 Hex/EtOAc),  []20D = +9.1 (c= 1.13, CH2Cl2).  1H NMR 
(500 MHz, CDCl3):  δ (ppm) 5.80 (ddt, J = 6.5 Hz, 10.5 Hz, 17.0 Hz, 2H) 5.20 (dd, J = 1.5 Hz, 
17 Hz, 2 H) 5.14 (d, J = 10.5 Hz, 2H) 4.59 (dt, J = 1.5 Hz, 8 Hz, 1H) 4.13-4.10 (m, 1H) 3.86 
(dd, J = 3 Hz, 12.5 Hz, 1H) 3.65 (dd, J = 4.5 Hz, 12.5 Hz, 2H) 3.40 (d, J = 2 Hz, 2H) 3.09 (d, 
J = 7 Hz, 4H) 1.48 (s, 3H) 1.41 ( s, 3H) ppm. 13C {1H} NMR (125 MHz, CDCl3): δ (ppm) 
135.15, 118.42, 110.43, 82.38, 82.08, 81.68, 66.75, 60.95, 56.53, 41.71, 26.91, 26.33 ppm. IR 
(neat): 3409, 2931, 1723, 1259, 1058, 923, 714 cm-1.  
 
((4S,5R)-5-(3-aminoprop-1-yn-1-yl)-2,2-dimethyl-1,3-dioxolan-4-yl)methanol (11)  
To a solution of alkyne 43 (2.96 g, 11.15 mmol) in CH2Cl2 was 
added Pd(PPh3)4 (644 mg, 0.587 mmol), and 1,3-dimethyl barbutiric acid 
(10.57 g, 66.89 mmol).  The solution was heated to reflux for 12 hours then concentrated 
under reduced pressure and redissolved in Et2O; the organic layer was washed with H2O (4 x 
100 ml).  The aqueous layer was basified with saturated NaHCO3 and NaCl (500 mg) was 
added.  The aqueous layer was concentrated under reduced pressure to give an off white solid.  
CHCl3 (300 ml) and Na2SO4 were added to the flask and the mixture stirred for 4 hours.  The 
mixture was then filtered with suction and the filtrate was concentrated under reduced 
pressure to give 57 (1.96 g, 95%) as an orange oil, which was used without further purification. 
Rf = 0.11 (10:1 CH2Cl2/MeOH), []20D = +12.9 (c= 0.8, CHCl3). 1H NMR (500 MHz, CDCl3):  
δ (ppm) 4.59 (d, J = 8 Hz, 1H), 4.10-4.08 (m, 1H), 3.87 ( dd, J = 3.5, 12 Hz, 1H), 3.66 (dd, J = 
4, 12 Hz, 1H) 3.47 (s, 2H) 1.49 ( s, 3H) 1.42 (s, 3H) ppm,  13C {1H} NMR (125 MHz, CDCl3): 










2930, 2360, 2339, 1669, 1653, 1583, 1055 cm-1.  
 
Propargyl guanidine (42) 
To a solution of 57 (437 mg, 2.36 mmol) in CH2Cl2 (25 ml) 
at room temperature was added N,N′-Di-Boc-S-methylisothiourea 
(685 mg, 2.36 mmol), Et3N (0.329 mL, 2.36 mmol), and HgO (511.4 
mg, 2.36 mmol).  The reaction was stirred 12 hours then filtered through a pad of celite.  The 
pad of celite was washed with an additional 15 mL of CH2Cl2 and the combined organics were 
concentrated under reduced pressure. Purification by flash chromatography (4:1 Hex/EtOAc) 
gave 42 (725 mg, 72%) as a colorless foam . Rf = 0.62 (1:1 Hex/EtOAc), []20D = +15.72 (c= 
1.4, CHCl3).  1H NMR (500 MHz, CDCl3):  δ (ppm) 11.39 (s, 1H), 8.41 (s, 1H), 4.56 (d, J = 7.5 
Hz, 1H), 4.24 (d, J = 5.5 Hz, 2H) 4.11-4.05 ( m, 2H) 3.83 ( dd, J = 3, 12 Hz, 1H), 3.63 (d, J = 
11.5 Hz, 1H),  1.46-1.45 ( m, 21 H), 1.38 (s, 3H) ppm. 13C {1H} NMR (125 MHz, CDCl3): δ 
(ppm) 163.26, 155.68, 153.03, 110.52, 83.47, 80.08, 81.87, 80.50, 79.64, 66.52, 70.77, 60.45, 
30.95, 28.29, 28.08, 28.03, 26.83, 26.27 ppm. 
 
(5E)-tert-butyl 2-((tert-butoxycarbonyl)imino)-5-(((4R,5S)-5-(hydroxymethyl)-2,2-
dimethyl-1,3-dioxolan-4-yl)methylene)imidazolidine-1-carboxylate (58)  
To a solution of 42 (1.18 g, 2.5 mmol) in CH2Cl2  (50 mL) at 
room temperature was added AgOAc (84 mg, 0.5 mmol) and AcOH 
(0.429 ml, 7.5 mmol).  The reaction was stirred in the dark for 4 hours.  
The mixture was concentrated under reduced pressure. Purification by flash chromatography 
(20:1 CH2Cl2/MeOH) afforded 58 (952 mg, 80%) as a yellow foam. Rf = 0.5 (20:1 












( dt, J = 2, 8 Hz, 1H) 4.63 (t, J = 8.5 Hz, 1H), 4.29 ( s, 2H), 3.82-3.76 (m, 2H), 3.65-3.61 (m, 
1H), 1.57 (s, 9H), 1.48 (s, 3H), 1.46 (s, 9H), 1.38 (s, 3H) ppm. 13C {1H} NMR (125 MHz, 
CDCl3): δ (ppm) 150.25, 109.25, 108.33, 86.063, 81.74, 73.65, 61.52, 28.16, 27.94, 27.21, 27.09 





To a solution of 58 (50 mg, 0.106 mmol) in CH2Cl2 (5 mL) was 
added N-bromosuccinimide (22.5 mg, 0.127 mmol) in portions and 
the reaction was stirred for 5 hours.  The solution was concentrated 
under reduced pressure and purified by flash chromatography (1:1 Hex/EtOAc) to give 67 as 
a pale yellow oil. Rf = 0.91 (20:1 CH2Cl2/MeOH), 1H NMR (500 MHz, CDCl3):  δ (ppm) 10.45 
(s, 1H), 9.36 (s, 1H), 4.27 (dd, J = 4, 16 Hz, 1H), 4.11-4.09 (m, 2H), 3.86-3.84 (m, 1H), 2.98 
(dd, J = 3.5, 15.5 Hz, 1H), 2.78 (dd, J = 5, 16 Hz, 1H), 1.96-1.83 (m, 2H), 1.51 (s, 9 H), 1.48 
(s, 9H), 1.42 (s, 6H) ppm.  
 
((4S,5R)-5-((Z)-3-aminoprop-1-en-1-yl)-2,2-dimethyl-1,3-dioxolan-4-yl)methanol (70) 
To a solution of alkyne 57 (53 mg, 0.286 mmol) in DMF (5 mL) 
was added Pd/BaSO4 (24 mg, 0.015 mmol), and ethylenediamine (0.02 ml, 
0.344 mmol).  The reaction was flushed with H2 and stirred under an atmosphere of H2 for 2 
½ hours.  The solution was filtered through a pad of celite which was washed with toluene (3 
x 30 mL) and the filtrate was concentrated under reduced pressure.  The amine 70 was used 





Allylic Guanidine (71) 
To a solution of 70 (492 mg, 1.70 mmol) in CH2Cl2 (25 mL) 
at room temperature was added N,N′-Di-Boc-S-methylisothiourea 
(492 mg, 1.70 mmol), Et3N (0.236 mL, 1.70 mmol), and HgO (367 
mg, 2.36 mmol).  The reaction was stirred for 12 hours then filtered through a pad of Celite.  
The pad of celite was washed with an additional 15 mL of CH2Cl2 and the combined organics 
were concentrated under reduced pressure. Purification by flash chromatography (4:1 
Hex/EtOAc) gave 71 (508 mg, 63%) as a colorless foam. Rf =  0.53 (1:1 Hex/EtOAc), 1H 
NMR (500 MHz, CDCl3):  δ (ppm) 11.46 (s, 1H), 8.47 (t, J = 5 Hz, 1H), 5.70-5.65 (m, 1H), 
5.58 (t, J = 9.5 Hz, 1H), 4.83 (t, J = 8.5 Hz, 1H), 4.44 (p, J = 7 Hz, 1H), 3.94-3.88 (m, 1H), 
3.82 (dd, J = 3.5, 12 Hz, 1H), 3.78-3.75 (m, 1H), 3.70 (dd, J = 3.5, 12 Hz, 1H) 1.49 (s, 9 H), 
1.48 (s, 9H), 1.44 (s, 3H), 1.43 (s, 3H) ppm. 13C {1H} NMR (125 MHz, CDCl3): δ (ppm) 163.33, 
156.17, 153.19, 149.12, 130.59, 129.73, 109.32, 83.36, 81.34, 79.61, 73.14, 60.52, 53.51, 38.05, 
28. 27, 28.08, 27.17, 27.02 ppm.  
 
Cyclic guanidine (72)/ Furan (73) 
A solution of 71 (300 mg, 0.633 mmol) in MeCN (10 mL) was cooled to –30 C. N-
bromosuccinimide (124 mg, 0.696 mmol) was added in portions and the reaction was stirred 
for 6 hours.  The solution was then concentrated under reduced pressure and purification by 
flash chromatography (4:1 Hex:EtOAc) gave 73 (202 mg, 60%) as a colorless oil and 74 (80 
mg, 25%) as a colorless oil. 
73: Rf = 0.21 (1:1 Hex/EtOAc),  1H NMR (500 MHz, CDCl3):  δ (ppm) 
9.26(s, 1H), 4.66-4.63  (m, 1H), 4.54 (d, J = 4.5 Hz, 1H), 4.13 (dd, J = 3, 












3H), 1.48 (s, 9H), 1.44 (s, 9H), 1.43 (s, 3H), 1.3 (s, 1H) ppm.  
72: Rf = 0.07 (1:1 Hex/EtOAc),  1H NMR (500 MHz, CDCl3):  δ (ppm): 
4.57 (s, 1H), 4.24 (d, J =9.5 Hz, 1H), 4.11-4.07 (m, 1H), 4.03-4.4.00 (m, 
1H), 3.96-3.91 (m, 3H), 3.76-3.72 (m, 1H), 1.53 (s, 9H), 1.46 (s, 9H),  




To a solution of 43 (291 mg, 1.10 mmol) in CH2Cl2 (50 mL) was 
added DMAP (67 mg, 0.548 mmol), Et3N (0.46 ml, 3.3 mmol), and 
benzoyl chloride (0.225 ml, 2.2 mmol).  The solution was stirred at room 
temperature for 3 hours.  The reaction was then washed with H2O (2 x 30 
mL) and brine (30 mL); the organic layer was dried over Na2SO4 and concentrated under 
reduced pressure.  Purification by flash chromatography (6:1 Hex:EtOAc) gave 74 (319 mg, 
78%) as a yellow oil. Rf = 0.91 (4:1 Hex/EtOAc),  []20D = +17.7 (c= 1.646, CH2Cl2). 1H NMR 
(500 MHz, CDCl3):  δ (ppm) 8.07 (d, J = 8.5 Hz, 2H), 7.57 (t, J = 8 Hz, 1H), 7.44 (t, J = 8 Hz, 
2H), 5.80 (ddt, J = 6.5, 10.5, 17 Hz, 2H), 5.21 (dd, J = 1.5, 17 Hz, 2H), 5.14 (d, 10 Hz, 2H), 
4.67 (dt, J = 2, 7.5 Hz, 1H), 4.57 (dd, J = 4.5, 11.5 Hz, 1H), 4.43 (dd, J = 5, 11.5 Hz, 1H), 4.40-
4.36 (m, 1H), 3.41 (d, J = 1 Hz, 2H), 3.10 (d, J = 7 Hz, 4H), 1.53 (s, 3H), 1.45 (s, 3H) ppm. 
13C {1H} NMR (125 MHz, CDCl3): δ (ppm) 166.12, 135.20, 133.36, 129.89, 128.57, 118.43, 
111.04, 82.11, 81.77, 79.94, 67.99, 63.46, 56.54, 41.76, 27.04, 26.48 ppm. IR (neat): 2985, 1723, 








To a solution of alkyne 74 (438 mg, 1.18 mmol) in CH2Cl2 was 
added Pd(PPh3)4 (68.14 mg, 0.059 mmol), and 1,3-dimethyl barbutiric 
acid (651 mg, 4.72 mmol).  The solution was heated to reflux and stirred 
for 12 hours then concentrated under reduced pressure and redissolved in Et2O; the organic 
layer was washed with H2O (4 x 100 mL).  The aqueous layer was basified with saturated 
NaHCO3. The aqueous layer was extracted with chloroform (4 x  35  mL) and the combined 
chloroform extracts were dried over Na2SO4 and concentrated under reduced pressure to yield 
75 (270 mg, 79%) as an orange oil, which was used without further purification. Rf = 0.06 
(10:1 CH2Cl2/MeOH),  []20D = +23.9 (c= 1.67, CH2Cl2). 1H NMR (500 MHz, CDCl3):  δ 
(ppm) 8.06 (d, J = 6.5 Hz, 2H), 7.57 (t, J = 7.5 Hz, 1H), 7.44 (t, 7.5 Hz, 1H), 4.61 (d, J = 7 Hz, 
1H), 4.56 (dd, J = 5, 11.5 Hz, 1H), 4.44 (dd, J = 5.5, 11.5 Hz, 1H), 4.34-4.30 (m, 1H), 3.41 (s, 
2H), 1.50 (s, 3H), 1.42 (s, 3H) ppm. 13C {1H} NMR (125 MHz, CDCl3): δ (ppm) 166.26, 133.39, 
129.85, 128.56, 110.88, 88.35, 79.41, 78.19, 68.04, 63.25, 31.73, 26.98, 26.60 ppm. IR (neat): 




To a solution of alkyne 75 (270 mg, 0.938 mmol) in DMF (10 
mL) was added Pd/BaSO4  (79 mg, 0.037 mmol), and quinoline (0.144 
mL, 1.21 mmol).  The reaction was flushed with H2 and stirred under an atmosphere of H2 
for 4 hours.  The solution was filtered through a pad of Celite, which was washed with toluene 
(3 x 30 mL) and the filtrate was concentrated under reduced pressure.  Purification by flash 





(10:1 CH2Cl2/ MeOH), []20D = -3.1 (c= 1.37, CH2Cl2). 1H NMR (500 MHz, CDCl3):  δ (ppm) 
8.04 (d, J = 8 Hz, 2H), 7.57 (t, J = 6 Hz, 1H), 7.44 (t, J = 8 Hz, 2H), 5.81 (dt, J = 7, 11 Hz, 
1H), 5.49 (t, J = 11.5 Hz, 1H), 4.71 (t, J = 9 Hz, 1H), 4.52 (dd, J = 4, 11.5 Hz, 1H), 4.36 (dd, 
J = 5, 12.5 Hz, 1H) , 4.00 (p, 4.5 Hz, 1H), 3.49-3.44 (m, 1H), 3.30 (dd, J = 6.5, 14 Hz, 1H), 
1.69 (s, 2H), 1.46 (s, 3H), 1.44 (s, 3H) ppm. 13C {1H} NMR (125 MHz, CDCl3): δ (ppm) 166.43, 
137.10, 133.40, 128.81, 128.60, 126.53, 109.88, 79.05, 78.74, 73.58, 63.61, 63.20, 39.14, 27.27, 
27.22, 27.04 ppm. IR (neat): 2985, 1720, 1371, 1275, 1070, 712 cm-1 
 
((4S,5R)-5-((1Z)-3-(2,3-bis(tert-butoxycarbonyl)guanidino)prop-1-en-1-yl)-2,2-
dimethyl-1,3-dioxolan-4-yl)methyl benzoate (77) 
To a solution of 76 (500 mg, 1.71 mmol) in CH2Cl2 (50 mL) 
at room temperature was added N,N′-Di-Boc-S-methylisothiourea 
(508 mg, 1.71 mmol), Et3N (0.22 ml, 1.71 mmol), and HgO (372 
mg, 1.71 mmol).  The reaction was stirred for 12 hours then filtered through a pad of celite.  
The pad of celite was washed with an additional 15 mL of CH2Cl2 and the combined organics 
were concentrated under reduced pressure. Purification by flash chromatography (4:1 
Hex:EtOAc) gave 77 (645.6 mg, 70.1%) as a colorless foam. Rf = 0.54 (1:1 Hex/EtOAc),  
[]20D = -1.8 (c= 1.57, CH2Cl2). 1H NMR (500 MHz, CDCl3):  δ (ppm) 11.43, (s, 1H), 8.38 (s, 
1H), 8.04 (d, 8.5 Hz, 2H), 7.55 (t, J = 7.5 Hz, 1H), 7.44 (t, J = 6.5 Hz, 2H), 5.84-5.79 (m, 1H), 
5.64 (t, J = 9 Hz, 1H), 4.78 (t, J = 9 Hz, 1H), 4.55 (dd, J = 3.5, 11.5 Hz, 1H), 4.38 (dd, J = 5, 
12 Hz, 1H), 4.28-4.23 (m, 1H), 4.13-4.07 (m, 1H), 4.04 (p, J = 5 Hz, 1H), 1.48 (s, 9H), 1.47 (s, 
9H), 1.45 (s, 3H), 1.44 (s, 3H) ppm. 13C {1H} NMR (125 MHz, CDCl3): δ (ppm) 166.28, 163.58, 
156.07, 153.26, 133.24, 131.51, 129.85, 129.31, 128.54, 110.06, 83.31, 79.46, 79.103, 73.64, 





1131, 712 cm-1 
 
Cyclic guanidine (78a, b) 
To a solution of 77 (280 mg, 0.47 mmol) in MeCN (10 mL) 
cooled to 0 C was added N-bromosuccinimide (92 mg, 0.517 mmol) 
in one portion and the reaction was stirred for 3 hours.  The solution 
was then concentrated under reduced pressure and purified by flash chromatography (1:1 
Hex:EtOAc) to give 78a,b (192mg 66%) as a mixture of diastereomers (2:1). 1H NMR (500 
MHz, CDCl3):  δ (ppm) 8.04 (d, J = 8 Hz, 2H), 7.53 (t, J = 7 Hz, 1H), 7.42 (t, J = 7.5 Hz, 2H), 
4.76-4.73 (m, 1H), 4.55 (d, J = 4.5 Hz, 1H), 4.41-4.37 (m, 2H), 4.29-4.25 (m, 1H), 4.17 (dd, J 
= 3, 12 1H), 3.90 (d, J = 10 Hz, 1H) 3.82 (s, 1H), 1.45 (s, 21H), 1.34 (s, 3H) ppm. 
 
Cyclic guanidine (79 a, b) 
To a solution of 77 (645.6 mg, 1.21 mmol) in Et2O (25 mL) was added I2 (243.5 mg, 
1.46 mmol) and AgOAc (370.2 mg, 1.46 mmol).  The reaction was stirred for 6 hours then 
filtered through a pad of celite and rinsed with EtOAc (2 x 30 mL); the combined organic 
layers were transferred to a separatory funnel and washed with saturated Na2S2O3.  The organic 
layer was dried over Na2SO4 and concentrated under reduced pressure. Purification by flash 
chromatography (1:1 Hex:EtOAc) gave 79a (354.1 mg, 44.3%) and 79b (327.2 mg, 41%) as  
colorless foams. 
79a:  Rf = 0.32 (1:1 Hex/EtOAc), []20D = +7.4 (c= 1.06, CH2Cl2). 1H 
NMR (500 MHz, CDCl3):  δ (ppm) 8.04 (d, J = 8 Hz, 2H), 7.53 (t, J = 
7 Hz, 1H), 7.42 (t, J = 7.5 Hz, 2H), 4.79-4.75 (m, 2H), 4.42, (dd, J = 5, 





1H), 1.50 (s, 3H), 1.46 (s, 18H), 1.33 (s, 3H) ppm. 13C {1H} NMR (125 MHz, CDCl3): δ (ppm) 
166.24, 133.43, 129.95, 129.52, 128.70, 110.86, 80.33, 73.89, 63.83, 61.29, 32.83, 31.71, 28.18, 
28.14, 27.30, 27.10 ppm.  IR (neat): 3063, 2860, 1716, 1451, 1265, 1095, 933, 708 cm-1.  
79b: Rf = 0.05 (1:1 Hex/EtOAc). []20D = -15.5 (c= 1.61, CH2Cl2). 1H 
NMR (500 MHz,  CDCl3):  δ (ppm) 8.04 (d, J = 8 Hz, 2H), 7.53 (t, J = 7 
Hz, 1H), 7.42 (t, J = 7.5 Hz, 2H), 4.75 (dd, J = 2, 12.5 Hz, 1H), 4.66 (d, 
J = 9.8 Hz, 1H), 4.44-4.40 (m, 2H), 4.30-4.22 (m, 2H), 3.96-3.92 (m, 1H), 3.85 (d, J = 14.5 Hz, 
1H), 1.51 (s, 9H), 1.45 (s, 9H), 1.35 (s, 3H), 1.30 (s, 3H) ppm. 13C {1H} NMR (125 MHz, 
CDCl3): δ (ppm) 166.42, 133.25, 129.93, 128.54, 111.11, 84.04, 81.49, 76.82, 65.89, 61.38, 
33.78, 28.36, 28.19, 27.67, 27.31 ppm. IR (neat): 3315, 2978, 1706, 1531, 1367, 1271, 1144, 
850, 712 cm-1.  
 
Carbamoyl cyclic guanidine (79b) 
To a stirring solution of 79b (327.2 mg, 0.496 mmol) in 
benzene (10 mL) was added benzyl isocyanate (0.065 mL, 0.537 
mmol).  The reaction was stirred for 3 hours then concentrated 
under reduced pressure. Purification by flash chromatography (1:1 Hex:EtOAc) gave 81b 
(354.5 mg, 89.9%) as a colorless oil. Rf = 0.57 (1:1 Hex/EtOAc). 1H NMR (500 MHz, CDCl3):  
δ (ppm) 9.31 (t, J = 6 Hz, 1H), 8.06 (d, J = 8.5 Hz, 2H), 7.54 (t, J = 7 Hz, 1H), 7.42-7.28 (m, 
6H), 4.79 (d, J = 10 Hz, 1H), 4.68 (d, J = 8.5 Hz, 1H), 4.56-4.53 (m, 2H), 4.49 (s, 2H), 4.46-
4.43 (m, 1H), 4.38 (s, 1H), 4.34 (s, 2H), 4.23 (d, J = 12.5 Hz, 1H). 3.88 (dd, J = 9.5, 12 Hz, 
1H), 1.53 (s, 9H), 1.48 (s, 12 Hz), 1.37 (s, 3H) ppm. 13C {1H} NMR (125 MHz, CDCl3): δ 
(ppm), 166.43, 156.25, 152.74, 149.65, 146.25, 138.50, 133.24, 129.94, 128.98, 128.64, 128.52, 





36.01, 28.24, 27.45, 27.02 ppm.  
 
Carbamoyl guanidine (82b)  
To a solution of 81b (154 mg, 0.195 mmol) in benzene (3mL) 
and water (0.035 mL, 1.95 mmol) was added tibutylborane (0.19 mL, 
0.78 mmol).  Immediately following the addition, air (15.88 mL, 0.156 
mmol O2) was bubbled through the solution via syringe pump over 16 hours.  The reaction 
was quenched with NaOH (2 mL, 3 M) and H2O2 (2 mL) at the same time and stirred for 10 
minutes.  The mixture was then extracted with EtOAc (3 x 25 mL) and the combined organic 
layers were dried over Na2SO4 and concentrated under reduced pressure. Purification by flash 
chromatography (4:1 Hex:EtOAc) gave 82b (77.9 mg, 60%) as a colorless oil. Rf = 0.56 (1:1 
Hex/EtOAc).  1H NMR (500 MHz, CDCl3):  δ (ppm) 9.34 (s, 1H), 8.04 (d, J = 8.5 Hz, 2H), 
7.55 (t, J = 7.5 Hz, 1H), 7.45-7.42 (m, 2H), 7.33-7.26 (m, 7H), 4.56-4.42 (m, 5H), 4.36-4.32 
(m, 1H), 4.11 (d, J = 11 Hz, 1H), 4.04-3.96 (m, 2H), 3.85-3.79 (m, 1H), 2,17-2.13 (m, 1H), 
1.94-1.88 (m, 1H), 1.46 (s, 9H), 1.45 (s, 9H), 1.43 (s, 3H), 1,40 (s, 3H) ppm. 13C {1H} NMR 
(125 MHz, CDCl3): δ (ppm), 166.3, 157.3, 152.9, 149.5, 147.5, 138.4, 133.3, 129.8, 128.6, 127.3, 




To a solution of 43 (2.04 g, 7.69 mmol) in CH2Cl2 was added 
TBSCl (2.32 g, 15.38 mmol), Et3N (3.0 mL, 23.07 mmol), and DMAP 
(469 mg, 3.84 mmol).  The solution was stirred at room temperature for 





organic layer was dried over Na2SO4 and concentrated under reduced pressure.  The crude 
product was then purified by flash chromatography (4:1 Hex/EtOAc) to yield 83 in 90% yield. 
Rf = 0.95 (4:1 Hex/EtOAc) []20D = +6.1 (c= 1.35, CHCl3). 1H NMR (500 MHz, CDCl3):  δ 
(ppm) 5.83-5.75 (m, 2H), 5.20 (d, J = 17.5 Hz, 2H), 5.12 (d, J = 9.5 Hz, 2H), 4.63 (d, J = 9 Hz, 
1H), 4.08-4.04 (m, 1H), 3.75 (qd, J = 4.5 Hz, 11 Hz, 2H), 3.40 (s, 2 H), 3.09 (d, J = 6.5 Hz, 
4H), 1.47 (s, 3H), 1.39 (s, 3H), 0,88 (s, 9H), 0.06 (s, 6H) ppm.  13C {1H} NMR (125 MHz, 
CDCl3): δ (ppm) 135.4, 118.2, 110.3, 82.7, 81.2, 67.3, 62.2, 56.5, 41.8, 26.9, 26.5, 26.0, 25.9, 
25.8, 18.5 ppm. IR (neat): 3079, 2985, 2928, 2857, 2815, 1644, 1472, 1462, 1380, 1371, 1322, 




To a solution of 83 (2.93 g, 7.73 mmol) in CH2Cl2 was added 
Pd(PPh3)4 (440 mg. 0.386 mmol), and dimethyl barbateric acid (4.27 
g, 30.92 mmol).  The solution was heated to reflux and stirred for 
18 hours.  It was then cooled to room temperature washed with NaHCO3 (3 x 250 ml), the 
organic layer was dried over Na2SO4 and concentrated under reduced pressure.  The crude 





Amine 84 (1.79 g, 5.88 mmol) was dissolved in DMF, followed by the addition of 





flushed with H2.  The reaction was stirred under and H2 atmosphere for 
6 hours, then filtered over a bed of Celite, washed with toluene, and 
concentrated under reduced pressure.  The crude material was passed through a plug of silica 
(5:1 CH2Cl2/MeOH) and used without further purification.  
 
Allylic Guanidine (86) 
The allyl amine 86 (554 mg. 1.83 mmol) was dissolved in 
CH2Cl2, followed by the addition of Et3N (0.26 mL, 1.83 mmol), 
HgO (398 mg, 1.83 mmol), and N,N′-Di-Boc-S-
methylisothiourea (553.6 mg, 1.83 mmol) and the reaction was stirred for 18 hours.  The crude 
mixture was filtered through a pad of Celite, and concentrated under reduced pressure.  The 
crude compound was purified by flash chromatography (10:1 Hex/EtOAc), to give 86 in 70% 
yield as a white foam.  Rf = 0.83 (1:1 Hex/EtOAc),  []20D = +3.9 (c= 2.71, CHCl3). 1H NMR 
(500 MHz, CDCl3): 11.45 (s, 1H), 8.31 (t, J = 5.2 Hz, 1H), 5.76-5.69 (m, 1H), 5.62-5.55 (m, 
1H), 4.72 (t, 8.2 Hz, 1H), 4.21-4.07 (m, 2H), 3.79-3.73 (m, 1H), 3.71-3.66 (m, 2H), 1.48 (s, 
9H), 1.47 (s, 9H), 1.40 (s, 3H), 1.39 (s, 3H), 0.87 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H). 13C {1H} 
NMR (125 MHz, CDCl3): δ (ppm) 163.5, 155.9, 153.1, 130.1, 109.2, 88.0, 83.1, 81.5, 79.2, 73.0, 
61.8, 38.1, 28.3, 28.0, 27.1, 26.9, 25.9, 18.3, -5.3 ppm.  IR (neat): 3335, 2931, 1721, 1614, 1412, 
1367, 1311, 1251, 1227, 1130, 1081, 1057, 835, 776 cm-1 
 
Cyclic Guanidine (87a,b) 
To a solution of 86 (2.2 g, 4.05 mmol) in Et2O (100 mL) was added I2 (1.23 g, 4.86 
mml) and AgOAc (811 mg, 4.86 mmol).  The reaction was stirred for 6 hours then filtered 





were transferred to a separatory funnel and washed with saturated Na2S2O3.  The organic layer 
was dried over Na2SO4 and concentrated under reduced pressure. Purification by flash 
chromatography (1:1 Hex:EtOAc) gave 87a (587 mg, 21.9%) and 87b (327.2 mg, 22.9%) as  
colorless foams. 
87a: Rf = 0.80 (1:1 Hex/EtOAc), []20D = -40.5 (c= 2.82, MeOH). 
1H NMR (500 MHz, CD3OD): 4.78-4.75 (m, 2H), 4.49 (dd, J = 1.5 
Hz, 10.5 Hz, 1H), 4.28-4.25 (m, 1H), 3.99-3.85 (m, 4H), 3.75 (dd, J 
= 2.5 Hz, 14 Hz, 1H), 1.56 (s, 9H), 1.49 (s, 9H), 1.34 (s, 3H), 1.29 (s, 3H), 0.93 (s, 9H), 0.11 
(s, 3H), 0.09 (s, 3H) ppm.  13C {1H} NMR (125 MHz, CD3OD): δ (ppm): 109.8, 83.9, 80.8, 
78.2, 75.3, 64.2, 61.2, 33.2, 27.4, 27.2, 26.7, 26.3, 25.3, 18.0, 6.1 ppm. IR (neat): 3317, 2930, 
1764, 1706, 1651, 1613, 1530, 1457, 1367, 1322, 1252, 1143, 1035, 836, 749 cm-1  
87b: Rf = 0.67 (1:1 Hex/EtOAc), []20D = +41.4 (c= 1.94, MeOH). 
1H NMR (500 MHz, CD3OD): 4.75-4.74 (m, 1H), 4.63 (d, J = 4 Hz, 
1H), 4.07 (dd, J = 3 Hz, 13 Hz, 1H), 3.79-3.69 (m, 4H), 3.22 (d, J = 
7.5 Hz, 1H), 1.55 (s, 9H), 1.48 (s, 9H), 1.45 (s, 3H), 1.31 (s, 3H), 0.91 (s, 9H), 0.08 (s, 6H) 
ppm.  13C {1H} NMR (125 MHz, CD3OD): δ (ppm): 156.4, 109.6, 83.9, 82.0, 80.2, 78.1, 61.4, 
54.4, 33.2, 27.2, 26.9, 26.3, 26.1, 25.2, 17.9, 6.4 ppm. IR (neat): 2979, 2931,1767, 1709, 1654, 





To a stirring solution of 87a (587 mg, 0.877 mmol) in benzene (20 mL) was added 












concentrated under reduced pressure. Purification by flash 
chromatography (1:1 Hex:EtOAc) gave 88a (589 mg, 83.6%) as a 
colorless oil. Rf = 0.83 (1:1 Hex/EtOAc). 1H NMR (500 MHz, 
CDCl3): 9.27 (t, J = 6 Hz, 1H), 7.32-7.27 (m, 4H), 7.26-7.23 (m, 1H), 4.67-4.63 (m, 2H), 4.56 
(dd, J = 2, 11.5 Hz, 1 H), 4.50 (ddd, J = 6, 15, 21 Hz, 2H), 3.87-3.80 (m, 2H), 3.79-3.64 (m, 
2H), 3.30 (d, J = 7.5 Hz, 1H), 1.51 (s, 9H), 1.49 (s, 9H), 1.48 (s, 3H), 1.36 (s, 3H), 0.90 (s, 10H), 
0.09 (s, 3H), 0.08 (s, 3H) ppm.  13C {1H} NMR (125 MHz, CDCl3): 156.9, 152.5, 149.3, 138.6, 






To a stirring solution of 87b (623 mg, 0.931 mmol) in 
benzene (20 mL) was added benzyl isocyanate (0.12 mL, 0.931 
mmol).  The reaction was stirred for 3 hours then concentrated 
under reduced pressure. Purification by flash chromatography (1:1 Hex:EtOAc) gave 88b (650 
mg, 87.0%) as a colorless oil. Rf = 0.82 (1:1 Hex/EtOAc). 1H NMR (500 MHz, CDCl3): 9.30 
(t, J = 5.5 Hz, 1H), 7.30 (d, J = 5 Hz, 4H), 7.25-7.24 (m, 1H), 4.67-4.65 (m, 1H), 4.57-4.49 (m, 
2H), 4.29-4.20 (m, 2H), 4.16 (d, J = 12 Hz, 1H), 4.06-4.02 (m, 1H), 3.94 (dd, J = 2, 11 Hz, 
1H), 3.87-3.80 (m, 2H), 1.53 (s, 9H), 149 (s, 9H), 1.43 (s, 3H), 1.35 (s, 3H), 0.90 (s, 9H), 0.09 


















To a solution of 88a (589 mg, 0.734 mmol) in benzene 
(7mL) and water (0.13 mL, 7.34 mmol) was added tibutylborane 
(0.72 mL, 2.93 mmol).  Immediately following the addition of 
tributylborane, air (60 mL, 0.58 mmol O2) was bubbled through the solution via syringe pump 
over 16 hours.  The reaction was quenched with NaOH (2 mL, 3 M) and H2O2 (2 mL) at the 
same time and stirred for 10 minutes.  The mixture was then extracted with EtOAc (3 x 25 
mL) and the combined organic layers were dried over Na2SO4 and concentrated under reduced 
pressure. Purification by flash chromatography (4:1 Hex:EtOAc) gave 89a (221.4 mg, 44.5%) 
as a colorless oil. Rf = 0.76 (1:1 Hex/EtOAc). 1H NMR (500 MHz, CDCl3): 9.34 (t, J = 6 Hz, 
1H), 7.32-7.23 (m, 5H), 4.50 (d, J = 5.5 Hz, 2H), 4.44-4.39 (m, 1H), 3.97 (d, J = 11.5 Hz, 1H), 
3.93-3.89 (m, 1H), 3.80-3.74 (m, 2H), 3.72-3.69 (m, 1H), 3.66-3.63 (m, 1H), 1.97 (t, J = 6 Hz, 
2H), 1.50 (s, 9H), 1.48 (s, 9H), 1.35 (s, 3H), 1.31 (s, 3H), 0.86 (s, 9H), 0.04 (s, 6H) ppm.  13C 
{1H} NMR (125 MHz, CDCl3): 157.3, 152.9, 149.7, 147.6, 138.5, 128.6, 127.3, 109.3, 83.8, 





To a solution of 88b (600 mg, 0.747 mmol) in benzene 
(7mL) and water (0.13 mL, 7.47 mmol) was added 
tibutylborane (0.72 mL, 2.93 mmol).  Immediately following the addition, air (60 mL, 0.58 





was quenched with NaOH (2 mL, 3 M) and H2O2 (2 mL) at the same time and stirred for 10 
minutes.  The mixture was then extracted with EtOAc (3 x 25 mL) and the combined organic 
layers were dried over Na2SO4 and concentrated under reduced pressure. Purification by flash 
chromatography (4:1 Hex:EtOAc) gave 89b (198.4 mg, 39.2%) as a colorless oil. Rf = 0.76 
(1:1 Hex/EtOAc). 1H NMR (500 MHz, CDCl3): 9.35 (t, J = 5.5 Hz, 1H), 7.33-7.22 (m, 6H), 
4.51 (ddd, J = 5.5, 15.5, 21 Hz, 2H), 4.32-4.30 (m, 1H), 4.11 (d, J = 11.5 Hz, 1H), 4.00-3.96 
(m, 1H), 3.77 (dd, J = 3, 8 Hz, 1H), 3.71 (d, J = 4 Hz, 2H), 3.67-3.63 (m, 1H), 2.08 (dt, J = 3, 
14 Hz, 1H), 1.85 (dt, J = 9, 9 Hz, 1H), 1.49 (s, 9H), 1.47 (s, 9H), 1.37 (s, 3H), 1.34 (s, 3H), 0.87 
(s, 9H), 0.05 (s, 6H) ppm.  13C {1H} NMR (125 MHz, CDCl3): 157.2, 152.9, 149.6, 147.5, 138.5, 
128.6, 127.3, 109.4, 83.9, 81.7, 80.4, 77.4, 75.9, 62.9, 54.0, 47.1, 44.1, 38.4, 28.2, 27.4, 27.1, 





To a stirring solution of 88a (275 mg, 0.411 mmol) in 
benzene (20 mL) was added DMB isocyanate (74 mg, 0.411 
mmol).  The reaction was stirred for 3 hours, then concentrated 
under reduced pressure. Purification by flash chromatography 
(1:1 Hex:EtOAc) gave 93a (174 mg, 49.1%) as a colorless oil. Rf 
= 0.82 (1:1 Hex/EtOAc). 1H NMR (500 MHz, CDCl3): 9.20 (t, J = 5.5 Hz, 1H), 7.17 (d, J = 
7.5 Hz, 1H), 6.39-6.35 (m, 2H), 4.62-4.57 (m, 2H), 4.51 (dd, J = 1.5, 11 Hz, 1H), 4.37 (ddd, J 
= 6, 14, 20.5 Hz, 2H), 3.83-3.82 (m, 2H), 3.80 (s, 3H), 3.77-3.76 (m, 2H), 3.75 (s, 3H), 3.66-





9H), 0.07 (s, 3H), 0.06 (s, 3H) ppm.  13C {1H} NMR (125 MHz, CDCl3): 173.1, 160.5, 158.7, 
157.1, 152.1, 149.2, 130.1, 119.5, 109.5, 103.6, 98.5, 84.3, 82.5, 80.1, 75.8, 64.1, 59.5, 55.5, 55.3, 





To a stirring solution of 88b (329.1 mg, 0.492 mmol) in 
benzene (20 ml) was added DMB isocyanate (88.1 mg, 0.492 
mmol).  The reaction was stirred for 3 hours then concentrated 
under reduced pressure. Purification by flash chromatography 
(1:1 Hex:EtOAc) gave 93b (204 mg, 47.9%) as a colorless oil. Rf = 0.82 (1:1 Hex/EtOAc). 1H 
NMR (500 MHz, CDCl3): 9.22 (t, J = 6 Hz, 1H), 7.14 (d, J = 8.5 Hz, 1H), 6.39-6.35 (m, 2H), 
4.60 (dt, J = 1.5, 10.5 Hz, 1H), 4.38 (ddd, J = 5.5, 14.5, 19 Hz, 2H), 4.11-4.07 (m, 1H), 4.00-
3.98 9m 1H), 3.91 (dd, J = 3, 11 Hz, 1H), 3.82 (s, 3H), 3.81-3.76 (m, 2H), 3.75 (s, 3H), 1.49 (s, 
18H), 1.38 (s, 3H), 1.28 (s, 3H), 0.88 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H) ppm.  13C {1H} NMR 
(125 MHz, CDCl3): 160.4, 158.6, 156.5, 152.3, 149.7, 145.9, 129.6, 119.4, 110.8, 103.7, 98.4, 
84.4, 83.3, 80.1, 76.8, 64.6, 57.8, 55.4, 45.6, 39.6, 37.0, 28.3, 28.2, 27.3, 27.2, 26.1, 18.6 ppm.  
 
(R)-2-imino-4-((2S,3R)-2,3,4-trihydroxybutyl)imidazolidine-1-carboxamide (95a) 
94a (39.5 mg, 0.054 mmol) was dissolved in TFA and stirred 
for 18 hours.  The reaction was concentrated and tritrated with Et2O  
to give the TFA salt of 95a (9 mg, 72%) as a white solid. 1H NMR (500 MHz, D2O): 4.17-4.06 
















3.41 (m, 2H), 1.78 (ddd, J = 6.5, 10, 5.5 Hz, 1H), 1.68 (ddd, J = 3, 6, 9 Hz, 1H) ppm.  13C {1H} 
NMR (125 MHz, D2O): 155.9, 74.3, 68.8, 62.5, 51.2, 50.5, 37.2 ppm.  
 
(S)-2-imino-4-((2S,3R)-2,3,4-trihydroxybutyl)imidazolidine-1-carboxamide (95b) 
94a (66.0 mg, 0.089 mmol) was dissolved in TFA and stirred 
for 18 hours.  The reaction was concentrated and tritrated with Et2O 
to give the TFA salt of 95a (8.4 mg, 41%) as a white solid. 1H NMR 
(500 MHz, D2O): 4.14-4.07 (m, 2H), 3.68-3.59 (m, 2H), 3.52-3.39 (m, 4H), 1.73-1.68 (m, 2H) 





To a solution of 43 (1.59 g, 6.2 mmol) in CH2Cl2 was added 
TBDPSCl (2.4 mL, 9.3 mmol), Et3N  (1.72 mL, 12.4 mmol), and 
DMAP (379 mg, 3.1 mmol).  The solution was stirred at room 
temperature for 18 hours, then washed with H2O (2 x 200 mL) and 
brine (200 mL), the organic layer was dried over Na2SO4 and concentrated under reduced 
pressure.  The crude product was then purified by flash chromatography (4:1 Hex/EtOAc) to 
yield 96 in 85% yield. Rf = 0.95 (4:1 Hex/EtOAc). []20D = +19.5 (c= 1.25, CHCl3). 1H NMR 
(500 MHz, CDCl3):  δ (ppm) 7.73-7.67 (m, 5H), 7.44-7.35 (m, 7H), 5.85-5.77 (m, 2H), 5.21 
(dd, J = 2.5 Hz, 17 Hz, 2H), 5.14 (dd, J = 0.5 Hz, 10 Hz, 2H), 4.80 (d, J = 7.5 Hz, 1H), 4.15 
(dt, J = 4 Hz, 7 Hz, 1H), 3.81 (qd, J = 4.5 Hz, 11.5 Hz, 2H), 3.42 (d, J = 2 Hz, 2H), 3.10 (d, J 





δ (ppm) 135.8, 135.7, 135.4, 134.9, 133.3, 133.2, 129.9, 129.7, 127.8, 118.3, 110.4, 82.8, 82.6, 
81.3, 67.5, 62.9, 56.6, 41.8, 27.1, 26.9, 26.7, 26.5, 19.4 ppm. IR (neat): 3071, 2984, 2930, 2857, 




To a solution of 96 (2.65 g, 5.26 mmol) in CH2Cl2 was added 
Pd(PPh3)4 (304 mg. 0.26 mmol), and dimethyl barbateric acid (3.31 
g, 21.04 mmol).  The solution was heated to reflux and stirred for 18 
hours.  It was then cooled to room temperature, washed with NaHCO3 (3 x 50 mL); the 
organic layer was dried over Na2SO4 and concentrated under reduced pressure.  The crude 




Amine 97 (1.80 g, 4.25 mmol) was dissolved in DMF, followed by 
the addition of quinolone (0.55 mL, 4.25 mmol) and Pd/BaSO4 (181 mg, 
0.17 mmol); the solution was then flushed with H2.  The reaction was 
stirred under and H2 atmosphere for 6 hours; it was then filtered over a bed of Celite, washed 
with toluene, and concentrated under reduced pressure.  The crude material was passed 
through a plug of silica (5:1 CH2Cl2/MeOH) and used without further purification.  
 










The allyl amine 98 (665 mg. 1.56 mmol) was dissolved 
in CH2Cl2, followed by the addition of Et3N (0.22 mL, 1.56 
mmol), HgO (339 mg, 1.56 mmol), and N,N′-Di-Boc-S-
methylisothiourea (454 mg, 1.56 mmol), the reaction was stirred for 18 hours.  The crude 
mixture was filtered through a pad of Celite, and concentrated under reduced pressure.  The 
crude compound was purified by flash chromatography (10:1 Hex/EtOAc), to give 99 in 81% 
yield as a white foam.  Rf = 0.91 (1:1 Hex/EtOAc),  []20D = -40.6 (c= 2.96, CHCl3). 1H NMR 
(500 MHz, CDCl3): 11.47 (s, 1H), 8.33 (t, J = 6 Hz, 1H), 7.72-7.67 (m, 4H), 7.45-7.35 (m, 6H), 
5.76-5.67 (m, 1H), 5.62-5.53 (m, 1H), 4.81 (t, J = 10.5 Hz, 1H), 4.23-4.09 (m, 2H), 3.81 (dd, J 
= 4.5 Hz, 9 Hz,1H), 3.78-3.75 (m,1H), 3.70 (dd, J = 4 Hz, 13.5 Hz, 1H), 1.50 (s, 9H), 1.49 (s, 
9H), 1.44 (s, 3H), 1.43 (s, 3H), 1.07 (s, 9H) ppm.  13C {1H} NMR (125 MHz, CDCl3): δ (ppm): 
163.6, 155.9, 153.1,135.7, 133.1, 130.2, 130.0, 129.7, 127.7, 127.6, 110.0, 109.3, 87.9, 83.1, 81.6, 
79.1, 73.2, 62.6, 38.3, 28.3, 28.0, 27.2, 26.9, 26.8, 19.2 ppm. IR (neat): 3330 (w), 2980, 2931, 
2859, 1720, 1638, 1614, 1412, 1367, 1311, 1250, 1227, 1155, 1130, 1078, 1058, 755, 701 cm-1 
 
Cyclic Guanidine (100 a,b) 
To a solution of 99 (623 mg, 0.93 mmol) in Et2O (20 mL) was added I2 (331 mg, 1.3 
mml) and AgOAc (220 mg, 1.3 mmol).  The reaction was stirred for 6 hours then filtered 
through a pad of Celite and rinsed with EtOAc (2 x 100 mL); the combined organic layers 
were transferred to a separatory funnel and washed with saturated Na2S2O3.  The organic layer 
was dried over Na2SO4 and concentrated under reduced pressure. Purification by flash 
chromatography (1:1 Hex:EtOAc) gave 100a (260.8 mg, 35%) and 100b (327.2 mg, 44.3%) as  
colorless foams. 





CD3OD): 7.70 (dd, J = 1.5 Hz, 7.5 Hz, 4H), 7.42-7.34 (m, 6H), 4.65 (d, J = 4 Hz, 1H), 4.41-
4.40 (m, 1H), 4.28-4.23 (m, 1H), 4.02-3.98 (m, 1H), 3.96 (dd, J = 2.5 Hz, 11Hz, 1H), 3.83 (dd, 
J = 5.5 Hz, 11.5 Hz, 2H), 1.52 (s, 9H), 1.47 (s, 9H), 1.35 (s, 3H), 1.29(s, 3H), 1.06 (s, 9H) ppm.  
13C {1H} NMR (125 MHz, CD3OD): δ (ppm): 135.4, 133.0, 129.5, 127.5, 109.8, 83.9, 78.1, 
75.3, 64.7, 61.4, 32.7, 27.3, 27.2, 26.6, 26.4, 26.2, 18.8 ppm. IR (neat): 3314, 2979, 2931, 1763, 
1706, 1652, 1613, 1530, 1367, 1321, 1254, 1216, 1144, 746, 701 cm-1 
100b: Rf = 0.77 (1:1 Hex/EtOAc), []20D = +73.4 (c= 1.10, MeOH). 1H NMR (500 MHz, 
CD3OD): 7.68 (d, J = 6.5 Hz, 4H), 7.44-7.37 (m, 5H), 4.79-4.73 (m, 2H), 4.58 (s, 1H), 4.08 (d, 
J = 12 Hz, 1H), 3.87-3.83 (m, 1H), 3.79-3.69 (m, 3H), 3.26 (d, J = 8 Hz, 1H), 1.46 (s, 3H), 1.45 
(s, 9H), 1.41 (s, 9H), 1.32 (s, 3H), 1.05 (s, 9H) ppm.  13C {1H} NMR (125 MHz, CD3OD): δ 
(ppm): 135.4, 132.8, 129.7, 127.5, 109.9, 83.9, 82.4, 78.0, 61.4, 33.5, 27.2, 27.1, 26.5, 26.2, 18.7 
ppm. IR (neat): 3310, 2979, 2931, 2858, 1763, 1709, 1652, 1617, 1528, 1473, 1428, 1368, 1319, 





To a stirring solution of 100a (385 mg, 0.48 mmol) in 
benzene (20 mL) was added DMB isocyanate (148 mg, 0.97 
mmol).  The reaction was stirred for 3 hours then concentrated 
under reduced pressure. Purification by flash chromatography 
(1:1 Hex:EtOAc) gave 101a (229 mg, 54%) as a colorless oil. Rf = 0.90 (1:1 Hex/EtOAc). 1H 
NMR (500 MHz, CDCl3): 9.23 (t, J =6.5 Hz, 1H), 7.69-7.67 (m, 4H), 7.42-7.30 (m, 6H), 7.18 





= 6, 14, 20.5 Hz, 2H), 3.94-3.89 (m,1H), 3.87-3.85 (m, 1H), 3.84 (s, 1H), 3.76 (s, 3H), 3.73-
3.67 (m, 2H), 3.36 (d, J =8 Hz, 1H), 1.50 (s, 9H), 1.45 (s, 9H), 1.27 (s, 3H), 1.07 (s, 9H), 0.93 
(s, 3H) ppm. 13C {1H} NMR (125 MHz, CD3OD): δ (ppm): 160.4, 158.6, 157.1, 152.0, 149.0, 
148.0, 135.6, 133.2, 132.8, 129.9, 129.7, 129.6, 127.8, 119.4, 109.4, 103.6, 98.4, 84.3, 82.6, 79.9, 





To a stirring solution of 100b (260.8 mg, 0.33 mmol) in 
benzene (20 mL) was added DMB isocyanate (74 mg, 0.40 
mmol).  The reaction was stirred for 3 hours then concentrated 
under reduced pressure. Purification by flash chromatography 
(1:1 Hex:EtOAc) gave 101b (207 mg, 49.1%) as a colorless oil. 
Rf = 0.90 (1:1 Hex/EtOAc). 1H NMR (500 MHz, CDCl3): 9.24 (t, J = 6Hz, 1H), 7.73-7.69 (m, 
4H), 7.42-7.36 (m, 6H), 7.16 (d, J = 8 Hz, 1H), 6.42 (s, 1H), 6.37 (dd, J = 1.5, 8 Hz, 1H), 4.61 
(d, J = 10 Hz, 1H), 4.41 (ddd, J = 6.5, 15.5, 22 Hz, 2H), 4.36 (dd, J = 14.5, 13.5 Hz, 1H), 4.25 
(dd, J = 3, 10.5 Hz, 1H), 4.17 (dd, J = 1.5, 11.5 Hz, 1H), 4.07-4.05 (m, 1H), 3.98 (dd, J = 2.5, 
11.5 Hz, 1H), 3.89-3.85 (m, 1H), 3.84 (s, 3H) 3.80 (dd, J = 9, 3 Hz, 1H), 3.76 (s, 3H), 1.50 (s, 
9H), 1.49 (s, 9H), 1.42 (s, 3H), 1.34 (s, 3H), 1.06 (s, 9H) ppm.  13C {1H} NMR (125 MHz, 
CD3OD): δ (ppm): 158.8, 152.5, 149.8, 146.0, 136.1, 133.5, 129.9, 127.9, 119.6, 110.9, 103.9, 
98.6, 84.4, 83.4, 76.9, 64.9, 60.6, 58.4, 55.6, 45.5, 39.8, 36.2, 28.4, 28.3, 27.4, 27.3, 27.1, 19.5, 








dimethoxybenzyl)carbamoyl)imidazolidine-1-carboxylate (102b)  
To a solution of 101b (712 mg, 0.720 mmol) in benzene 
(7mL) and water (0.13 mL, 7.20 mmol) was added 
tibutylborane (0.75 mL, 2.88 mmol).  Immediately followed by 
the addition, air (73 mL, 0.71 mmol O2) was bubbled through 
the solution via syringe pump over 16 hours.  The reaction was 
quenched with NaOH (2 mL, 3 M) and H2O2 (2 mL) at the same time and stirred for 10 
minutes.  The mixture was then extracted with EtOAc (3 x 25 mL) and the combined organic 
layers were dried over Na2SO4 and concentrated under reduced pressure. Purification by flash 
chromatography (4:1 Hex:EtOAc) gave 102b (198.4 mg, 39.2%) as a colorless oil. Rf = 0.76 
(1:1 Hex/EtOAc).  1H NMR (500 MHz, CDCl3): 9.33 (t, J = 7 Hz, 1H), 7.69-7.61 (m, 4H), 
7.42-7.34 (m, 6H), 7.18 (d, J = 10 Hz, 1H), 6.44-6.36 (m, 2H), 4.42-4.37 (m, 2H), 4.28-4.23 (m 
1H), 4.03-4.98 (m, 1H), 3.86 (s, 3H), 3.77 (s, 3H), 3.75-3.67 (m, 4H), 2.01-1.93 (m 1H), 1.81-
1.75 (m 1H), 1.48 (s, 9H), 1.43 (s, 9H), 1.37 (s, 3H), 1.36 (s, 3H), 1.03 (s, 9H) ppm. 13C {1H} 
NMR (125 MHz, CD3OD): δ (ppm): 160.4, 158.7, 157.3, 152.5, 149.6, 147.2, 135.6, 133.0, 
129.8, 127.7, 119.3, 109.4, 103.6, 98.4, 83.6, 81.8, 80.0, 76.9, 75.4, 63.6, 55.4, 53.9, 47.0, 39.7, 
38.2, 28.2, 28.0, 27.3, 27.0, 26.8, 19.1 ppm.  
 
(S)-N-(2,4-dimethoxybenzyl)-4-(((4S,5R)-5-ethynyl-2,2-dimethyl-1,3-dioxolan-4-
yl)methyl)-2-iminoimidazolidine-1-carboxamide (105)  
Aldehyde 104 (210 mg, 0.34 mmol) was dissolved in MeOH and cooled to 0 °C, 





mmol) was added in portions and the reaction stirred for 12 hours.  
The reaction was then quenched with NH4Cl (20 mL), and then 
washed with EtOAc (3 x 30 mL) the organic layers were dried over 
Na2SO4 and concentrated to yield 105 in 53%.  Rf = 0.40 (1:1 
Hex/EtOAc).  1H NMR (500 MHz, CDCl3): 7.02 (d, J = 10.5 Hz, 1H), 6.41-6.37 (m, 2H), 
5.00-4.97 (m, 5H), 4.27-4.11 (m, 4H), 3.88-3.84 (m, 2H), 3.82 (s, 3H), 3.75 (s, 3H), 2.32 (d, J 
= 17 Hz, 1H), 1.85-1.79 (m, 1H), 1.43 (s, 3H), 1.38 (s, 3H) ppm. 13C {1H} NMR (125 MHz, 
CD3OD): δ (ppm): 160.1, 158.1, 156.1, 1.49.1, 128.4, 117.3, 110.9, 104.0, 98.4, 79.6, 78.5, 75.5, 




Alkyne 105 (77.1 mg, 0.18 mmol) was dissolved in CH2Cl2 (20 
mL), followed by the addition of DMAP (3 mg, 0.018 mmol) and 
Boc2O (121 mg, 0.5 mmol), the reaction stirred for 18 hours.  The 
reaction was concentrated and purification by flash chromatography 
(1:1 Hex:EtOAc) gave 106 (72 mg, 77%) as a colorless oil. Rf = 0.54 (1:1 Hex/EtOAc).  1H 
NMR (500 MHz, CDCl3): 7.10 (d, J = 8.5 Hz, 1H), 6.40 (s, 1H), 6.36 (d, J = 2.5 Hz, 1H), 5.03 
(d, J = 6 Hz, 2H), 4.53 (t, J = 9.5 Hz, 1H), 4.20 (d, J = 7 Hz, 1H), 4.09-3.98 (m, 3H), 3.79 (s, 
3H), 3.75 (s, 3H), 2.32 (d, J = 14.5 Hz, 1H), 1.94-1.86 (m, 1H), 1.56 (s, 9H), 1.40 (s, 3H), 1.37 
(s, 3H) ppm.  .  13C {1H} NMR (125 MHz, CDCl3): δ (ppm): 160.5, 158.5, 155.6, 154.2, 149.1, 
129.7, 116.9, 111.4, 104.2, 98.7, 85.5, 79.0, 77.0, 75.9, 70.5, 55.7, 55.6, 54.8, 45.8, 40.3, 36.0, 
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SUBSTRATE CONTROLLED STEREOSELECTIVE IODOGUANYLATION 
 
2.1 Iodoguanylations in the Literature 
In Chapter 1, the efforts to find an alcohol protecting group that could be removed 
selectively, without deprotecting the guanidine, led to a number of acyclic precursors.  While 
the synthesis of saxitoxin produced a single diastereomer, both possible diastereomers of the 
cyclic guanidine were observed upon cyclization of the precursors. 1  The literature contained 
limited examples of this transformation on a less rigid system, many using a terminal alkene.  2 
3   
The most comprehensive study of acyclic guanidine iodocyclization came from the 
Murphy laboratory, as they explored the formation of five and six membered rings using this 
methodology. 4 5 6  When N-allylguanidines 1a and 1b were treated with K2CO3 and I2 in MeCN, 
they were converted to the 5-exo-cyclic guanidines 2a and 2b in high yield.  Additionally, the 
homoallylic guanidine 3 also cyclized in a 6-exo fashion with the standard conditions and 
proceeded in good yield to give 4 (Scheme 2.1). 
When the more substituted dimethylallyl guanidine 5 was subjected to standard 
conditions, the major compound recovered was the 6-endo cyclization product 6; however, the 
5-exo cyclization product 7 was also recovered.  As this was an unexpected result, they 






Scheme 2.1: Iodoguanylations of allyl and homoallyl guanidines.  
 
amount of base in the reaction and observed that the absence of base led solely to the 6-endo 
product, but more than 4 equiv. of base produced the 5-exo product in greater yields (Scheme 
2.2). The formation of the 5-exo product led them to conclude that a ring contraction occurred 
and the resultant aziridine was opened with I- yielding the 5-exo-product.  Unfortunately, they 
did not address the stereochemical outcome of the 6-endo cyclization. 
 
2.2 Optimizing Iodination Reagents 
Allylic guanidine 8 was subjected to the conditions developed by Murphy and 
coworkers intitally.  The acyclic guanidine 8 was dissolved in MeCN and cooled to –15 °C, 
followed by addition of I2 and K2CO3.  After stirring the reaction for 16 hours the desired 
cyclic guanidine 9 was not observed (Scheme 2.3).  I believe that the electron-withdrawing 
nature of both the adjacent guanidine and the ketal decreased the electron density of the alkene 
rendering it incapable of forming the iodonium ion with just I2.  
The synthesis of saxitoxin functionalized an electron poor ene-guanidine by generating 
a more electrophilic iodine source with AgOAc. 1  Therefore, the allylic guanidine 8 was 
dissolved in Et2O followed by the addition of AgOAc and I2, and the reaction was stirred for 
12 hours.  These conditions did produce the cyclic guanidine in a mixture of diastereomers 9a 
and 9b; however, the reaction did not go to completion (Scheme 2.4).  







Scheme 2.2: Formation of the 6-endo and 5-exo cyclizations. 
 
 
Scheme 2.3: Initial cyclization conditions. 
 
 











compound was the desired diastereomer.  Although determining the stereoselectivity was a 
high priority, initial efforts were focused on optimizing the reaction to consume all the starting 
material.  The solubility of the AgOAc in Et2O was minimal, and in an effort to increase 
solubility, more polar solvents were employed.  Both MeCN and CH2Cl2 were used as solvents; 
unfortunately, in these more polar solvents, neither diastereomer of the cyclic guanidine was 
recovered (Scheme 2.5).  The clean conversion of acyclic guanidine 8 in Et2O prompted a 
reversion to that solvent and an alteration of the silver salt to increase solubility.  Substituting 
AgNO3 for AgOAc decreased the reaction time, but a small amount of starting material 
persisted.  I was pleased to see that an increase in the amount of I2 and AgNO3 from 1.2 equiv. 
to 1.4 equiv. led to the complete conversion of the starting material 8 (Scheme 2.5).  
 
2.3 Optimization of the Stereoselectivity 
Having optimized the solvent and silver source for this transformation probing the 
stereoselectivity became the primary focus.  Considering the synthesis of saxitoxin, we 
determined that the formation of the iodonium ion must be reversible for such a high yield of 
a single diastereomer (Scheme 2.6).  Additionally, the different alcohol protecting groups 
showed various selectivity under the same conditions, which led to the exploration of various 
conditions to manipulate the selectivity.   
The previous optimization of both the solvent and the silver salt limited the variables 
that could be adjusted in the effort to manipulate selectivity; varying the reaction temperature 
was the obvious starting place.  The benzoyl protected guanidine 8 was treated with I2 and 
AgNO3 in Et2O at varying temperatures (Table 2.1).  The variation in selectivity was minor, 
but the change in the major product was promising.  The greatest diastereomeric ratio was 






Scheme 2.5: Optimization of the solvent and silver source.  
 
 
Scheme 2.6: Formation of a single diastereomer from the iodoguanylation in saxitoxin.  
 
to THF, because it had a higher boiling point.  While the previous deviation from Et2O had 
produced a complicated mixture of products, I hoped that an ethereal solvent would minimize 
the formation of side products.  The allylic guanidine 8 was treated with I2 and AgNO3 in THF 
at the same temperatures as in Et2O.  Unfortunately, this change in solvent had very little 
effect on the diastereomeric ratio (Table 2.1).  
At the time of cyclization, it was unclear which diastereomer matched the 
stereochemistry of the natural product.  Because of that ambiguity, we hoped to maximize the 
formation of each diastereomer in varying conditions.  The benzoyl substrate fluctuated 
between 2:1 and 1:2; in order to determine the effect of different protecting groups, various 
protected guanidines were subjected to the same conditions.  The protecting groups were 





Table 2.1: Cyclization of the acyclic guanidine 8.  
  
 
when exploring the selectivity, it was important to vary the size of the protecting group to 
determine if it had an effect on selectivity.  To that end, four protecting groups were explored, 
TBDPS, TBS, Bz, and Ac, which created a range of protecting group sizes to assess the 
substrate effect on the cyclization.  
All three additional substrates were synthesized in the method described in Chapter 1, 
Scheme 1.27, and subjected to the cyclization conditions optimized with the benzoyl guanidine 
8 at various temperatures (Table 2.2).  The Ac protected guanidine 10 produced a synthetically 
useful range of 13a:13b shifting from 3:1 to 1:4.  The TBS protected guanidine 11 showed a 
very similar ratio of 14a:14b as was seen in the benzoyl protected 8 cyclization. While the 
TBDPS protected guanidine 12 showed surprisingly high selectivity of 15a:15b in Et2O. 
In order to functionalize the cyclic guanidines for further elaboration into the natural 
product, the cyclic guanidines 9,13-15a and 9,13-15b were each treated with p-methoxyphenyl 
















stereochemistry, each diastereomer needed to be globally deprotected.  To achieve a clean 
global deprotection, the cyclic guanidines 15a and 15b were treated with DMB isocyanate. This 
produced carbamoylated guanidines 20a and 20b, which were then dehalogenated to give 21a 
and 21b. A simple, one-step acidic deprotection afforded the guanidines 22 and 23 (Scheme 
2.7).    
To determine the stereochemistry of the deprotected guanidines 22 and 23, the proton 
NMR spectra of each compound were compared to the NMR spectrum of guadinomine B.  
The most diagnostic protons were the C1 protons, which in the natural product were both 
doublet of doublet of doublets at 1.70 and 1.83 ppm.  The guanidine triol 23 had the same 
splitting pattern at 1.67 and 1.77 ppm while the other guanidine triol 22 had a single multiplet 
at 1.7 ppm.  It was disappointing to note that the best diastereomeric ratio, observed at room 
temperature with the TBDPS protecting group, favored the undesired diastereomer.  
However, the 4:1 ratio of the desired product that was displayed by the Ac protecting group 
at -40 °C was promising enough to utilize this method moving forward.  
The significant difference between the selectivity with the Ac protecting group and the 
TBDPS protecting group led to a more in-depth consideration of the mechanism.  The 
conformation of the alkene was governed by A1,3 strain; in order to minimize the strain, the 
ketal was perpendicular to the alkene.  This conformation positioned the protected alcohol 
behind the alkene; the larger protecting groups created a larger steric barrier to that face of the 
alkene.  The formation of the iodonium ion on the less hindered face of the molecule was 
favored.  The favored iodonium led to the desired product; however, the cyclization of the 
guanidine was slow step.  In order for the guanidine to cyclize on the favored iodonium ion, 






Scheme 2.7: An example of the final steps to form the deprotected guanidines 22 and 23. 
 
protecting groups offered less steric hindrance, which allowed for the increased distereomeric 
ratio seen at cold temperatures with the Ac group.  The temperature contributed to the 
selectivity because at colder temperatures the reversibility of the iodonium ion was slower, 
allowing the guanidine more time to cyclize.  However, at higher temperatures, the faster 
reversibility of the iodonium ion creates a higher population of the slower iodonium formation 
and the faster cyclization of the guanidine leads to the undesired product (Scheme 2.8).   
The more in-depth probe of the iodoguanylation prompted us to revisit the Boc 
cyclization to form the cyclic carbamate and gain access to guadinomine A.   The steric 
congestion, which minimized the formation of the desired diastereomer, could slow the 
formation of the cyclic carbamate with the benzoyl group in place.  Additionally, Srinivas 
Paladugu, another lab member, had been working on a similar cyclization and found that 
increasing the equiv. of AgOAc to 2 equiv. and changing the solvent to DMF led to increased 
yields.   
The TBDPS protected guanidines 20a and 20b were dissolved in DMF; AgOAc was 
added and the reaction heated to 60 °C and stirred for 12 hours.  The guanidine 20b showed 


















































































































Scheme 2.8: Rationalization of the stereoselectivity for the iodocyclization.  
 
steric clash.  The guanidine 20a was then transformed to the cyclic carbamate 24 in 81% yield 
(Scheme 2.9).  Even with the smaller Ac protecting group on 16b, no cyclic carbamate was 
formed.  The lowest energy conformation of the cyclic guanidine 16b positions the Boc group 
too far away from the iodide to form the cyclic carbamate.  The limitation of accessing the 
desired diastereomer was not ideal, but being able to manipulate the stereoselectivity of an 
iodoguanylation was a promising step. As far as we know, this is the first example of a 
stereoselective iodoguanylation.  Understanding the substrate control of the stereoselctivity 
derived from A1,3 strain could be useful for predicting the stereoselectivity of this cyclization 
in other substrates.  We believed that a 4:1 mixture of the desired to undesired stereoisomer 

























































Scheme 2.9: Cyclic carbamate formation from guanidine 20a. 
 
2.4 Supporting Information  
Unless otherwise noted, all starting materials were either known compounds or were 
obtained from commercial sources and used without purification. All reactions requiring 
anhydrous conditions were performed under a positive pressure of argon using flame-dried 
glassware. Dichloromethane (CH2Cl2), and triethylamine (Et3N), were distilled from CaH2 
immediately prior to use. Tetrahydrofuran (THF), diethylether (Et2O), toluene (PhMe), and 
dimethylformamide (DMF) were degassed with argon and passed through a solvent 





sieves. Flash chromatography was performed on Merk silica gel Kieselgel 60 (230-400 mesh) 
from EM science with the indicated solvent. 1HNMR spectra were recorded on a Varian VXR-
500 MHz spectrometer. The chemical shifts (d) of proton resonances are reported relative to 
CHCl3, DMSO-d5, HOD, or HD2COD using the following format: chemical shift [ multiplicity  
(s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, app = apparent), coupling 
constant(s) (J in Hz), integral].7,8 13CNMR spectra were recorded at 75, 100, or 125 MHz. The 
chemical shifts of carbon resonances are reported relative to the deuterated solvent peak. 
Infrared spectra were recorded on a Nicolet 380-FT IR spectrometer fitted with a 
SmartOrbit sample system. All absorptions are reported in cm-1 relative to polystyrene (1601 
cm-1). 
      
((4R,5S)-5-(3-(diallylamino)prop-1-yn-1-yl)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl 
acetate (S1) 
To a solution of 1.43 (3.94 g, 15.4 mmol) in CH2Cl2 was added 
AcCl (1.6 mL, 23.1 mmol), Et3N (4.3 mL, 30.7 mmol), and DMAP (940 
mg, 7.7 mmol).  The solution was stirred at room temperature for 18 
hours, then washed with H2O (2 x 20 mL) and brine (20 mL); the organic 
layer was dried over Na2SO4 and concentrated under reduced pressure.  The crude product 
was then purified by flash chromatography (4:1 Hex/EtOAc) to yield S1 in 79% yield. Rf = 
0.75 (1:1 
Hex/EtOAc),  []20D = +35.1 (c= 1.5, CHCl3). 1H NMR (500 MHz, CDCl3): 5.79-5.74 (m, 
2H), 5.17 (d, J = 17 Hz, 2H), 5.10 *d, J = 10 Hz, 2H), 4.47 (d, J = 7.5 Hz, 1H), 4.31 (d, J = 12 
Hz, 1H), 4.20 (s, 1H), 4.07 (dd, J = 5, 12 Hz, 1H), 3.38 (s, 2H), 3.06 (d, J = 6 Hz, 4H), 2.06 (s, 





110.9, 82.1, 81.5, 79.8, 67.7, 63.1, 56.6, 41.7, 26.9, 26.4, 20.9 ppm.  
 
((4R,5S)-5-(3-aminoprop-1-yn-1-yl)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl acetate (S2) 
To a solution of S1 (3.42 g, 11.12 mmol) in CH2Cl2 was added 
Pd(PPh3)4 (1.2 g. 1.12 mmol), and dimethyl barbateric acid (7.03 g, 44.5 
mmol).  The solution was heated to reflux and stirred for 18 hours.  It was 
then cooled to room temperature, washed with NaHCO3 (3 x 50 mL); the organic layer was 
dried over Na2SO4 and concentrated under reduced pressure.  The crude product was passed 




 Amine S2 (1.66 g, 7.3 mmol) was dissolved in DMF, and the 
reaction was flushed with N2.  Quinolone (1 mL, 7.3 mmol) and 
Pd/BaSO4 (310 mg, 0.29 mmol) were added and the solution was flushed with H2.  The 
reaction was then stirred under an H2 atmosphere for 6 hours; it was filtered over a bed of 
Celite, washed with toluene, and concentrated under reduced pressure.  The crude material 
was passed through a plug of silica (5:1 CH2Cl2/MeOH) and used without further purification.  
 
((4R,5S)-5-((Z)-3-((E)-2,3-bis(tert-butoxycarbonyl)guanidino)prop-1-en-1-yl)-2,2-
dimethyl-1,3-dioxolan-4-yl)methyl acetate (S4) 
The allylic amine S3 (303.6 mg, 1.32 mmol) was dissolved 
in CH2Cl2.  Et3N (0.2 mL, 1.32 mmol), HgO (287 mg, 1.32 mmol), 





added and the reaction was stirred for 18 hours.  The crude mixture was filtered through a pad 
of Celite, and concentrated under reduced pressure.  The crude compound was purified by 
flash chromatography (10:1 Hex/EtOAc), to give S4 in 61% yield as a white foam.   
Rf = 0.93 (1:1 Hex/EtOAc), []20D = -0.5 (c= 1.01, CHCl3). 1H NMR (500 MHz, CDCl3): 11.42 
(s, 1H), 8.33 (t, J = 5 Hz, 1H), 5.80-5.70 (m, 1H), 5.60-5.50 (m, 1H), 4.63 (dt, J = 0.5 Hz, 8.5 
Hz, 1H), 4.28 (dd, J = 3.5 Hz, 12 Hz, 1H), 4.22-4.14 (m, 1H), 4.08-4.00 (m, 2H), 3.88-3.83 (m, 
1H), 2.10 (s, 3H), 1.45 (s, 9H), 1.44 (s, 9H), 1.40 (s, 3H), 1.39 (s, 3H) ppm. . 13C {1H} NMR 
(125 MHz, CDCl3): δ (ppm) 170.8, 163.7, 156.2, 153.4, 131.4, 129.6, 110.1, 83.5, 79.6, 79.0, 
73.7, 63.2, 38.3, 28.5, 28.4, 28.3, 27.3, 27.1, 21.0, 19.3 ppm. IR (neat): 3331, 2981, 1744, 1721, 
1637, 1614, 1565, 1411, 1368, 1323, 1226, 1157, 1129, 1057cm-1 
 
Cyclic Guanidines (9, 13, 14, 15) 
A solution of 8, 10, 11, or 12 in THF or diethyl ether (0.06M) was adjusted to the 
desired temperature (see Table 2.1), and the flask covered to minimize exposure to light.  I2 
(1.4 eqiv.) and AgNO3 (1.4 eqiv.) were added and the reaction was stirred until complete by 
TLC, 3-10 hours.  The reaction was filtered through a pad of Celite and washed with EtOAc.  
The combined organics were washed with Na2S2O3 (2 x 20 mL) and dried over Na2SO4.  The 









General Procedure A: The cyclic guanidine 9a (75.9 mg, 0.12 
mmol) was dissolved in benzene  (10 mL) followed by the addition of 
a 1M solution of PMP isocyanate in benzene (0.14 mL, 0.14 mmol); 
the reaction was stirred for 3 hours.  The reaction was concentrated 
and purified by column chromatography (4:1 Hex/EtOAc) to give 16a in 67% yield as a 
colorless oil. Rf = 0.92 (1:1 Hex/EtOAc), []20D = +57.2 (c= 0.50, CHCl3). 1H NMR (500 
MHz, CDCl3):10.91 (s, 1H), 8.08-8.06 (m, 2H), 7.55 (tt, J = 1 Hz, 7.5 Hz, 1H), 7.43 (t, J = 7.5 
Hz, 2H), 7.37 (dt, J = 3 Hz, 9 Hz, 2H), 6.87 (dt, J = 3.5 Hz, 9 Hz, 2H), 4.72-4.65 (m, 3H), 4.45 
(d, J = 5 Hz, 2H), 4.16-4.12 (m, 1H), 3.79 (s, 3H), 3.51 (d, J = 8 Hz, 1H), 1.46 (s, 3H), 1.45 (s, 
9H), 1.43 (s, 9H), 1.23 (s, 3H) ppm.  13C {1H} NMR (125 MHz, CDCl3): δ (ppm): 166.2, 156.7, 
156.2, 149.7, 148.7, 148.3, 133.1, 130.7, 129.8, 129.7, 128.4, 121.8, 114.2, 110.4, 84.8, 80.9, 
80.6, 73.9, 63.8, 59.3, 55.4, 45.4, 32.8, 28.0, 27.9, 26.9, 26.5 ppm. IR (neat): 2980, 1757, 1711, 





Prepared according to General Procedure A to give 16b in 
61% yield. Rf = 0.92 (1:1 Hex/EtOAc), []20D = -38.6 (c= 1.46, CHCl3). 
1H NMR (500 MHz, CDCl3): 10.95 (s, 1H), 8.05 (dd, J = 1 Hz, 8 Hz, 
2H), 7.52 (tt, J = 1 Hz, 7.5 Hz, 1H), 740-7.36 (m, 3H), 6.86 (dt, J = 3,5 
Hz, 9 Hz, 2H), 4.80-4.78 (m, 1H), 4.72 (d, J = 9 Hz, 1H), 4.45 (dd, J = 4.5 Hz, 12 Hz, 1H), 
4.37 (s, 3H), 4.27 (dd, J = 1.5 Hz, 12 Hz, 1H), 1.53 (s, 9H), 1.48 (s, 3H), 1.36 (s, 3H) ppm.  13C 





129.8, 129.7, 128.3, 122.1, 114.2, 111.5, 84.8, 80.5, 80.4, 77.3, 65.4, 58.3, 55.5, 44.8, 35.5, 28.1, 
28.0, 27.3, 26.9 ppm. IR (neat): 2979, 1757, 1716, 1693, 1639, 1602, 1555, 1512, 1452, 1369, 





Prepared according to General Procedure A to give 17a in 63% 
yield. Rf = 0.90 (1:1 Hex/EtOAc), []20D = +103.5 (c= 1.13, CHCl3). 
1H NMR (500 MHz, CDCl3): 10.9 (s, 1H), 7.37 (dt, J = 3.5 Hz, 9 Hz, 
2H), 6.86 (dt, J = 3.5 Hz, 9 Hz, 2H), 4.69-4.61 (m, 3H), 4.29 (dd, J = 4.5 Hz, 12 Hz, 1H), 4.13 
(dd, J = 4.5 Hz, 12.5 Hz, 1H), 3.99-3.95 (m, 1H), 3.79 (s, 3H), 3.78-3.76 (m, 1H), 3.42 (dd, J 
= 1.5 Hz, 8 Hz, 1H), 2.14 (s, 3H), 1.54 (s, 9H), 1.52 (s, 9H), 1.41 (s, 3H), 1.20 (s, 3H) ppm.  
13C {1H} NMR (125 MHz, CDCl3): δ (ppm): 170.7, 156.9, 156.2, 149.7, 148.7, 148.4, 130.7, 
121.8, 114.2, 110.2, 84.8, 80.9, 80.5, 72.8, 62.3, 59.4, 55.4, 45.4, 32.7, 28.1, 27.9, 26.8, 26.3, 20.8 
ppm. IR (neat): 3314, 2979, 2931, 1763, 1706, 1652, 1613, 1530, 1367, 1321, 1254, 1216, 1144, 









Prepared according to General Procedure A to give 17b in 
65% yield. Rf = 0.90 (1:1 Hex/EtOAc), []20D = -49.1 (c= 1.50, 
CHCl3). 1H NMR (500 MHz, CDCl3): 10.95 (s, 1H), 7.37 (dt, J = 3.5 
Hz, 9 Hz, 2H), 6.85 (dt, J = 3.5 Hz, 9 Hz, 2H), 4.69 (dt, J = 2 Hz, 9 Hz, 1H), 4.56 (dd, J = 2 
Hz, 11.5 Hz, 1H), 4.30 (dd, J = 2.5 Hz, 11 Hz, 1H), 4.22-4.19 (m, 3H), 4.15 (dd, J = 5.5 Hz, 
12 Hz, 1H), 3.90 (dd, J = 9.5 Hz, 2.5 Hz, 1H), 2.09 (s, 3H), 1.54 (s, 9H), 1.52 (s, 9H), 1.45 (s, 
3H), 1.35 (s, 3H) ppm.  13C {1H} NMR (125 MHz, CDCl3): δ (ppm): 170.5, 156.3, 155.8, 155.0, 
149.4, 146.3, 130.6, 122.0, 114.2, 111.4, 84.8, 80.4, 80.3, 65.2, 58.2, 55.4, 44.8, 35.5, 28.1, 28.0, 
27.2, 26.9, 20.8 ppm. IR (neat): 2979,1750, 1714, 1639, 1555, 1512, 1368, 1305, 1229, 1149, 





Prepared according to General Procedure A to give 18a in 
65% yield. Rf = 0.91 (1:1 Hex/EtOAc), []20D = +54.3 (c= 0.88, 
CHCl3). 1H NMR (500 MHz, CDCl3): 10.93 (s, 1H), 7.37 (d, J = 9 Hz, 
2H), 6.85 (d, J = 8.5 Hz, 2H), 4.70-4.64 (m, 3H), 3.88-3.81 (m, 2H), 
3.78 (s, 4H), 3.75-3.73 (m, 1H), 3.67 (dd, J = 7 Hz, 3 Hz, 1H), 3.35 (d, J = 7 Hz, 1H), 1.52 (s, 
18H), 1.39 (s, 3H), 1.15 (s, 3H), 0.91 (s, 9H), 0.10 (s, 3H), 0.09 (s, 3H) ppm.  13C {1H} NMR 
(125 MHz, CDCl3): δ (ppm): 162.0, 159.9, 156.5, 156.1, 149.7, 148.9, 148.5, 148.3, 130.8, 121.7, 
114.1, 109.5, 84.6, 82.5, 80.8, 80.5, 75.8, 63.9, 59.6, 55.7, 55.4, 45.6, 34.3, 28.1, 27.9, 26.8, 26.5, 
26.0, 18.4, 5.4, 5.3 ppm. IR (neat): 2979, 2930, 1759, 1710, 1622, 1556, 1513, 1464, 1368, 1298, 








Prepared according to General Procedure A to give 18b in 
65% yield. Rf = 0.91 (1:1 Hex/EtOAc), []20D = -40.2 (c= 0.43, 
CHCl3). 1H NMR (500 MHz, CDCl3): 10.95 (s, 1H), 7.37 (dt, J = 3 
Hz, 9 Hz, 2H), 6.85 (dt, J = 3.5 Hz, 9 Hz, 2H), 4.69 (dt, J = 2 Hz, 9 Hz, 1H), 4.29 (dd, J = 3 
Hz, 10.5 Hz, 1H), 4.25 (dd, J = 5.5 Hz, 10.5 Hz, 1H), 4.19 (dd, J = 1.5 Hz, 12 Hz, 1H), 4.04-
4.01 (m, 1H), 3.93 (dd, J = 3 Hz, 8.5 Hz, 1H), 3.88 (dd, J = 3 Hz, 9 Hz, 1H), 3.82 (dd, J = 
4Hz, 11 Hz, 1H), 3.77 (s, 3H), 1.53 (s, 9H), 1.52 (s, 9H), 1.43 (s, 3H), 1.34 (s, 3H), 0.89 (s, 9H), 
0.08 (s, 3H), 0.07 (s, 3H) ppm.  13C {1H} NMR (125 MHz, CDCl3): δ (ppm): 156.2, 155.8, 
149.9, 149.5, 146.2, 130.7, 122.1, 114.1, 110.8, 84.6, 83.3, 80.3, 76.5, 64.3, 58.0, 55.4, 45.2, 36.5, 
28.2, 28.1, 27.3, 27.1, 25.9, 18.4, 5.2, 5.1 ppm. IR (neat): 2930, 2856, 1758, 1695, 1640, 1556, 





Prepared according to General Procedure A to give 19a in 
93% yield. Rf = 0.91 (1:1 Hex/EtOAc), []20D = +73.1 (c= 1.50, 
CHCl3). 1H NMR (500 MHz, CDCl3): 10.97 (s, 1H), 7.73-7.68 (m, 
4H), 7.44-7.37 (m, 8H), 6.87 (dt, J = 3.5 Hz, 9Hz, 2H), 4.73-4.68 
(m, 3H), 4.00-3.96 (m, 1H), 3.88 (dd, J = 4.5 Hz, 10.5 Hz, 1H), 3.79 (s, 3H), 3.78-3.74 (m, 2H), 





NMR (125 MHz, CDCl3): δ (ppm): 156.7, 156.2, 149.8, 149.0, 148.6, 135.6, 135.5, 133.2, 132.8, 
130.8, 129.8, 129.6, 127.8, 127.7, 121.7, 114.2, 109.6, 84.7, 82.6, 80.5, 75.9, 64.7, 59.7, 55.4, 
45.6, 34.4, 28.2, 27.9, 27.0, 26.9, 26.5, 19.2 ppm. IR (neat): 2979, 2931, 2858, 1755, 1709, 1614, 





Prepared according to General Procedure A to give 19a in 
80% yield. Rf = 0.91 (1:1 Hex/EtOAc), []20D = -18.8 (c= 1.39, 
CHCl3). 1H NMR (500 MHz, CDCl3): 10.97 (s, 1H), 7.76-7.70 (m, 
4H), 7.44-7.36 (m, 8H), 6.87 (dt, J = 3.5 Hz, 9 Hz, 2H), 4.70 (dt, J = 1.5 Hz, 9 Hz, 1H), 4.42 
(dd, J = 6 Hz, 10.5 Hz, 1H), 4.32 (dd, J = 3 Hz, 10.5 Hz, 1H), 4.27 (dd, J = 1.5 Hz, 11.5 Hz, 
1H), 4.10-4.07 (m, 1H), 4.00 (dd, J = 2 Hz, 11 Hz, 1H), 3.91-3.87 (m, 2H), 3.79 (s, 3H), 1.54 
(s, 9H), 1.53 (s, 9H), 1.48 (s, 3H), 1.40 (s, 3H), 1.07 (s, 9H) ppm.  13C {1H} NMR (125 MHz, 
CDCl3): δ (ppm): 156.4, 156.0, 150.2, 149.6, 146.4, 136.0, 135.9, 133.5, 133.4, 130.9, 129.9, 
129.8, 127.9, 127.8, 122.3, 114.3, 110.9, 84.7, 83.4, 80.5, 76.6, 64.8, 58.6, 55.6, 45.1, 42.9, 35.8, 
28.3, 28.2, 27.4, 27.2, 27.0, 19.4 ppm. IR (neat): 2977, 2931, 1758, 1695, 1606, 1556, 1512, 



















Cyclic guanidine 19a (396.4 mg, 0.46 mmol) was dissolved in 
DMF, followed by the addition of AgOAc (107 mg, 0.91 mmol) and 
the reaction was heated to reflux for 24 hours.  The reaction was cooled 
to room temperature and diluted with Et2O and H2O.  The aqueous layer was washed with 
Et2O (3 x 50 mL) and the organic layers were combined and dried over Na2SO4, then 
concentrated and purification by flash chromatography (4:1 Hex/EtOAc) gave 23 (130 mg, 
35%) as a colorless oil. Rf = 0.62 (1:1 Hex/EtOAc)  1H NMR (500 MHz, CDCl3):  δ (ppm) 
7.72-7.67 (m, 5H), 7.43-7.36 (m, 7H), 6.99 (d, J = 8 Hz, 1H), 6.39 (s, 1H), 6.29 (d, J = 10.5 Hz, 
1H), 5.06-5.07 (m, 3H), 4.61 (d, J = 11.5 Hz, 1H), 4.42 (dd, J = 6, 11.5 Hz, 1H), 4.24 (dd, J = 
2, 12 Hz, 1H), 4.10-4.03 (m, 1H), 4.02-3.95 (m, 2H), 3.90-3.83 (m, 2H), 3.79 (s, 3H), 3.71 (s, 
3H), 1.56 (s, 9H), 1.53 (s, 3H), 1.48 (s, 3H), 1.03 (s, 9H) ppm. 13C {1H} NMR (125 MHz, 
CDCl3): δ (ppm) 160.1, 158.1, 155.6, 154.5, 148.7, 148.4, 135.8, 133.1, 129.8, 127.8, 127.7, 
116.8, 111.3, 103.9, 98.5, 85.4, 83.6, 76.4, 64.6, 61.2, 55.4, 41.6, 39.9, 30.9, 28.3, 28.1, 28.0, 
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FORMATION OF THE DIAMINE 
 
3.1 Alkyne Addition into the Serine Derived Nitrone  
In the original vision for the synthesis of guadinomine B, the carbamoylated guanidine 
diol fragment would be coupled with the diamine fragment through a stereoselective alkynyl 
addition to a nitrone.  The nitrone was synthesized by Dr. Vasudev Bhonde, from D-
methylserine; the terminal alcohol was TBDPS protected to form 1, which was then treated 
with DIBAl-H to form the aldehyde 2. Aldehyde 2 was then converted to the nitrone 3 by the 
addition of N-benzylhydroxylamine (Scheme 3.1). 
In Chapter 1, the synthesis of the alkyne 1.106 was described; despite the loss of the 
internal Boc group, I chose to attempt the alkynyl addition.  The alkyne nitrone coupling was 
selected based on the work of the Merino group, which optimized the anti-selective addition 
of an alkyne into a nitrone by the introduction of the TBDPS group on the terminal alcohol 
of the nitrone. 1 The use of iPrMgCl as the base serves a two-fold purpose; it deprotonates the 
alkyne and it can also coordinate the nitrogen of the alpha amine and the  oxygen of the 
nitrone, which stabilizes the nitrone in a confirmation that leads to a single diastereomer 
(Figure 3.1). 
The alkyne 4 was dissolved in THF and cooled to 0 °C; iPrMgCl was added and the 






Scheme 3.1: Synthesis of the nitrone 3. 
 
 
Figure 3.1: Rationalization for the selectivity into the nitrone. 
 
stirred for 3 hours and warmed to room temperature.  Upon work up, there was no change in 
either the nitrone or the alkyne; this was attributed to the acidic protons on the guanidine and 
the carbamoyl group (Scheme 3.2).  Considering that the iPrMgCl could be coordinating to 
the guanidine or the carbamoyl group and promoting the deprotonation of those groups over 
the alkyne, LDA was employed, hoping that the extra bulk would favor the alkyne 
deprotonation.  The alkyne in THF was cooled to -78 °C and the LDA was added, the reaction 
was stirred for 15 minutes before the nitrone was added and then warmed to 0 °C and stirred 
for 6 hours.  This reaction was also unsuccessful; in an effort to force the deprotonation of 
the alkyne, the reaction was performed with 5 equiv. of LDA, but this also failed to produce 
the product (Scheme 3.2).  
Facing the problem of deprotonating the alkyne selectively, a Lewis acid coupling 
strategy was explored.  Using literature precedence, Zn(OTf)2 was the first Lewis acid 






Scheme 3.2: Attempted alkynyl addition into the nitrone.  
 
iPr2Net; after 20 minutes, the nitrone was added and the reaction was stirred for 18 hours.  2  
The consumption of the starting material by TLC was promising, but after purification, the 
NMR spectrum showed no product but rather the deprotection of the guanidine 5 (Scheme 
3.3).  The failure of this reaction was attributed to the potential of the carbamoyl guanidine to 
coordinate the zinc ion, keeping it from forming the zinc-alkyne bond.  In an effort to mitigate 
the sequestration of the Lewis acid, InCl3, which is larger than zinc and less likely to form a 
tight bond with the carbamoyl guanidine, was used. 3  The alkyne 4 was dissolved in CH2Cl2 
followed by InCl3 and iPr2Net; after 5 minutes, the nitrone was added and stirred for 18 hours.  
Observing no consumption of starting material, the reaction was heated to reflux for 3 hours.  
This reaction also failed to produce product and cleaved the guanidine Boc group (Scheme 
3.3).  
To eliminate the problem of deprotonating the guanidine, the protected amine 6 was 






Scheme 3.3: Attempted Lewis acid addition of the alkyne into the nitrone.  
 
followed by the addition of Zn(OTf)2 and iPr2Net; this was stirred for 20 minutes, the nitrone 
was added, and the reaction stirred overnight.  Unfortunately, this reaction produced no 
appreciable product.  By utilizing the bisalkyne, the problematic acidic protons were also 
eliminated, allowing for the reexamination of strong bases.  The bisalkyne 7 was dissolved in 
THF and cooled to 0 °C and iPrMgCl was added; the reaction stirred for 30 minutes before 
addition of the nitrone.  The reaction was then stirred 18 hours; upon work up, the starting 
material was recovered.  Similarly, when bisalkyne 7 was dissolved in THF and cooled to 0 °C 
followed by the addition of LDA and the nitrone, no product was recovered (Scheme 3.4).  
Finally, a copper catalyzed alkyne addition into the nitrone was attempted. 4  Bisalkyne 7 was 
dissolved in MeCN, followed by the CuBr and the nitrone; this reaction was stirred overnight, 
but even after 24 hours, there was no reaction (Scheme 3.4). 
Our inability to couple the alkyne to the nitrone forced us to rethink the coupling 
strategy; this led to the idea of using the aldehyde formed prior to the alkyne 7 as the functional 











































































































3.2 β-lactam Diamine Formation  
While the proposed synthetic scheme had the advantage of separating the potential 
pharmacophores, it posed the significant challenge of installing the two-carbon linker between 
the diol and the diamine at a late stage.  When the initial synthetic plan of the alkyne addition 
into the nitrone failed, other synthetic strategies that could produce the two-carbon linker 
while maintaining stereochemical fidelity were considered.  A metal catalyzed metathesis was 
discounted because the dense functionality of the substrates would be incompatible with the 
catalyst.   
The total synthesis of nakadomarin A utilized a Julia olefination on a pyrrolidinone, 
which could be a useful transformation in installing the diamine (Scheme 3.5). 5  The diamine 
could come from a precursor functionalized β-lactam 8 which could be coupled with aldehyde 
9 (Scheme 3.5).   
The synthesis of the β-lactam began with L-malic acid, which was suspended in 
xylenes; O-benzylhydroxylamine was then added and the reaction was heated to reflux for 6 
hours. The reaction was cooled to 0 °C overnight and the succinamide 10 was collected as 
colorless crystals. 6  In the literature, succinamide 10 was transformed to the ethyl ester 11 by 
treating it with nBuLi and EtOH in THF.  However, these conditions only produced the butyl 
addition (Scheme 3.6).  This led to the optimization of the base, to identify a base that would 
not be a competitive nucleophile.  A number of bases were substituted into the reaction, but 
the best results were observed with LHMDS.  A solution of LHMDS in THF was cooled to 
–10 °C and EtOH was added; the reaction mixture was stirred for 20 minutes before the 
succinamide 10 was added.  The reaction was then stirred for 2 hours and quenched with 
NH4Cl (Scheme 3.6).  While the literature only reported a single regioisomer, a mixture of 






Scheme 3.5: The inspiration and for the β-lactam and the envisioned coupling. 
 
 
Scheme 3.6: Formation of the succinamide 10 and subsequent opening. 
 
The regioisomers were easily separated by column chromatography, but distinguishing 
them from one another with simple spectroscopic analysis was difficult.  Both ethyl esters 11a 
and 11b were subjected to Mitsunobu conditions to form the β-lactam, assuming that the 
undesired regioisomer would not react.  This assumption was correct and the desired 
regioisomer, 11b, was identified and formed the β-lactam 12 in good yield (Scheme 3.7).  The 
purification of this compound proved to be difficult, as it coeluted with the DIAD.   
A closely monitored palladium catalyzed hydrogenation removed the benzyl group 





hydrogenation did produce small amounts of the free β-lactam. 7  This hydrogenation was also 
not affected by the residual DIAD from the Mitsunobu reaction and the debenzylated β-
lactam 13 was much easier to separate (Scheme 3.8).  The β-lactam 13 was then treated with 
TsCl and Et3N in CH2Cl2, which produced the tosylated β-lactam 14 (Scheme 3.8).   
The tosylated β-lactam 14 was similar to substrates developed by Miller and coworkers 
that underwent C3 functionalization and N-O bond reduction. 7  Utilizing the known 
methodology, an azide was introduced at the C3 position in a stereoselective manner.  The 
tosylated β-lactam 14 was dissolved in MeCN, followed by iPrNEt2 and TMSN3, and the 
reaction was stirred for 24 hours.  The azide substituted β-lactam 15 was formed in modest 
yield (Scheme 3.9).  The introduction of the azide generated the precursor to the diamine.  The 
ethyl ester was then successfully reduced to the alcohol with NaBH4 in MeOH to form 16 
(Scheme 3.9).   
The next step was to introduce the thiotetrazole 17, which was generated from tbutyl 
isothiocyanate and NaN3; this reaction proceeded in high yield. 8  To install the thiotetrazole, 
the alcohol of the β-lactam 16 needed to be converted to a leaving group.  While this step 
could be eliminated by a Mitsunobu reaction, the Staudinger reduction that would likely occur 
under those conditions led to an SN2 strategy.  The alcohol 16 was treated with TsCl in pyridine 
to generate the tosylate 18 (Scheme 3.10).  To form the thioether 19, the tetrazole 17 was 
dissolved in THF and cooled to 0 °C; NaH was then added and reaction was stirred for 10 
minutes before the addition of the β-lactam 19; the reaction was then heated to reflux and 
stirred for 12 hours (Scheme 3.10).  The final conversion to the sulfone 20 was achieved with 
an ammonium molybdate oxidation. 
Before attempting the Julia olefination on the complex aldehyde 8, a model system 






Scheme 3.7: Formation of the β-lactam 12. 
 
 
Scheme 3.8: Formation of the tosylated β-lactam 14. 
 
 
Scheme 3.9: Formation of the azide substituted β-lactam 16. 
 
 






THF/DMF and cooled to -10 °C, then Cs2CO3 was added in portions and reaction was stirred 
18 hours, but no reaction occurred (Scheme 3.11). 5  Comparing the sulfone 20 and the 
pyrrolidinone used in the synthesis of Nakadomarin A, the most notable difference was the 
N-alkylation; therefore, the sulfone 20 was transformed into the N-benzyl sulfone 22.  The 
thioether 19 was treated with BnBr and NaH in DMF to produce the N-benzylthioether 21, 
which was then oxidized to the sulfone 23 (Scheme 3.11).  When sulfone 22 was subjected to 
the same conditions as sulfone 20, again no reaction occurred.  Unsure if the sulfone was being 
deprotonated by the Cs2CO3, a stronger base used.  Sulfone 22 was dissolved in DMF and 
cooled to –78 °C; KHMDS and benzaldehyde were then added and the reaction was stirred 
for 3 hours.  This reaction led to a complex mixture of products, but one notable product was 
the enamine 23 (Scheme 3.11).   
The formation of the enamine 23 was a surprising result.  It suggested that the initial 
deprotonation occurred alpha to the sulfone, but rather than adding into the aldehyde, it 
eliminated to the enolate leading to the enamine 23.  I believed that the azide was contributing 
to the stabilization of the favored enolate and hoped that converting azide to the protected 
amine would favor the deprotonated sulfone.  The attempts to reduce the azide on sulfone 22 
were unsuccessful, which led to the reduction of the azide earlier in the synthesis.   
In an attempt to reduce the azide as cleanly as possible, the β-lactam 16 was reduced 
with a palladium catalyzed hydrogenation; the in situ Boc protection of the newly formed amine 
24 was accomplished with the addition of Boc2O (Scheme 3.12).  The conversion of the azide 
to the Boc protected amine added steric bulk to the β-lactam 24 and the subsequent tosylation 
was unsuccessful.  When the β-lactam 24 was treated with MsCl, in MeCN, the mesylate 25 
was formed in good yield (Scheme 3.12). The mesylate 25 was then converted to the thioether 






Scheme 3.11: Julia olefination model reaction. 
 
 








ammonium molybdate oxidation furnished the sulfone 28. 
  We chose to treat this sulfone with an alkoxide base hoping that the reversibility of 
the deprotonation would increase the population of the sulfone anion.  tBuOH was added to 
THF and cooled to –78 °C; LHMDS was then added and the reaction was stirred for 40 
minutes before the addition of the sulfone 28 and benzaldehyde.  The reaction was stirred for 
2 hours and the majority of the sulfone remained unreacted; however, the eliminated product 
29 was also recovered (Scheme 3.12). 
 
3.3 Aziridine Strategy to Form the Diamine  
The fragmentation of both the azide substituted β-lactam 23 and the protected amine 
derivative 28 led to a new strategy for the formation of the diamine.  Looking to Omura’s 
synthesis of guadinomine B, an aziridine was considered as a synthon for generating the 
diamine.   Still considering the Julia olefination as a method to couple the guanidine diol 8 and 
the diamine, a synthetic route that would allow the instillation of the sulfone adjacent to the 
aziridine was developed.  Hoping to avoid an elimination similar to the β-lactam, the aziridine 
would be opened prior to attempting the Julia olefination.   
The synthesis of the aziridine began with D-diethyltartrate, which was treated with 
SOCl2 to generate the dioxathiolane 30. 9  NaN3 was then used to produce the azahydrin 31; 
the meso nature of the dioxathiolane eliminated any regioisomer concerns with the azahydrin.  
To form the aziridine 31, the azahydrin 31 was dissolved in DMF and cooled to 0 °C and PPh3 
was added in portions.  The reaction was then warmed to 85 °C and stirred for 12 hours 
(Scheme 3.13).  The bisester aziridine 32 was dissolved in EtOH and cooled to 0 °C; NaBH4 
was then added and the reaction stirred for 18 hours to form the hydroxyaziridine ethyl ester 






Scheme 3.13: Synthesis of the hydroxyaziridine ethyl ester 33. 
 
achieved with a Boc protection.   
However, to eliminate a competitive electrophile in the form of a carbonate, the 
alcohol was protected.  The hydroxyaziridine 33 was dissolved in DMF and treated with 
TESCl, DMAP, and Et3N to furnish the protected hydroxyaziridine 34 (Scheme 3.14).  The 
aziridine was then Boc protected to give the activated aziridine 35.  Various azide sources were 
then used in an attempt to open the aziridine.  The protected aziridine 35 was dissolved in 
MeOH; TMSN3 was added and the reaction heated to 70 °C for 3 days; unfortunately, only 
starting material was recovered.  Attempting to increase the electrophilicity of the aziridine, 
BF3·OEt2 was employed in conjunction with TMSN3, but the starting material persisted.  
Moving on to a different azide source, the protected aziridine 34 was dissolved in DMF and 
NaN3 was added; the reaction was stirred for 2 days.  This reaction also failed to produce the 
product 36 (Scheme 3.14).  Because of the inability to open the aziridine and the concern that 
a Julia olefination with an adjacent strained ring system would be unsuccessful, this route was 






Scheme 3.14: Failure to produce the diamine 35. 
 
3.4 Completion of the Right-Hand Fragment of NA22598A1 
The difficulty of coupling the guanidine diol 8 and the diamine fragment caused a shift 
in our aims, and I chose to synthesize the diamine dipeptide fragment 37.  To accomplish this, 
the β-lactam strategy was employed again.  Before activating the β-lactam, the alcohol was 
protected as the TBS ether to provide the protected β-lactam 38.  Treatment with Boc2O and 
DMAP in CH2Cl2 provided the substrate 39 which would form the diamine dipeptide upon 
opening (Scheme 3.15).  
The dipeptide 40 which would act as the nucleophile for opening the β-lactam 39 was 
formed through a peptide coupling in high yield (Scheme 3.16).  The removal of the Boc group 
was achieved cleanly with a TFA deprotection and formation of the TFA salt 41.  The 
dipeptide 41 was stirred with Et3N in CH2Cl2 followed by the addition of the β-lactam 39, and 
the reaction was stirred for 18 hours (Scheme 3.16).  This reaction did not produce the diamine 
dipeptide; taking steric congestion into account, the β-lactam 39 was opened with LiOH to 
form the carboxylic acid 42; this reaction proceeded in very good yield. 10  A subsequent 
peptide coupling was utilized to form the protected diamine dipeptide 43 (Scheme 3.16).  
Deprotection was achieved with a Pd(OH)2/C catalyzed hydrogenation in a 1:1 mixture of 






Scheme 3.15: Formation of the activated β-lactam 39. 
 
 











While it was disappointing to be unable to couple the guanidine diol 8 and the diamine 
fragment, we were happy to see the formation of the diamine dipeptide fragment.  This 
fragment allowed us to explore the biological potential of the diamine dipeptide, discussed in 
Chapter 4.  
 
3.5 Supporting Information  
Unless otherwise noted, all starting materials were either known compounds or were 
obtained from commercial sources and used without purification. All reactions requiring 
anhydrous conditions were performed under a positive pressure of argon using flame-dried 
glassware. Dichloromethane (CH2Cl2), and triethylamine (Et3N), were distilled from CaH2 
immediately prior to use. Tetrahydrofuran (THF), diethylether (Et2O), toluene (PhMe), and 
dimethylformamide (DMF) were degassed with argon and passed through a solvent 
purification system (J.C. Meyer of Glass Contour) containing either alumina or molecular 
sieves. Flash chromatography was performed on Merk silica gel Kieselgel 60 (230-400 mesh) 
from EM science with the indicated solvent.  
1HNMR spectra were recorded on a Varian VXR-500 MHz spectrometer. The 
chemical shifts (d) of proton resonances are reported relative to CHCl3, DMSO-d5, HOD, or 
HD2COD using the following format: chemical shift [ multiplicity  (s = singlet, d = doublet, t 
= triplet, q = quartet, m = multiplet, app = apparent), coupling constant(s) (J in Hz), 
integral].11,12 13CNMR spectra were recorded at 75, 100, or 125 MHz. The chemical shifts of 
carbon resonances are reported relative to the deuterated solvent peak. 
Infrared spectra were recorded on a Nicolet 380-FT IR spectrometer fitted with a 








The protected propargyl 6 (1.00 g, 3.9 mmol) was dissolved in EtOAc 
(100 mL); IBX (2.19 g, 7.8 mmol) was then added and the reaction heated to 
reflux for 18 hours.  It was then cooled to room temperature and filtered 
through a pad of Celite.  The resulting aldehyde was used without further 
purification.  The aldehyde (1.12 g, 4.39 mmol) was dissolved in MeOH, Bestmann-Ohira 
reagent was then added, K2CO3 (1.82 g, 13.17 mmol) followed in portions, and the reaction 
was stirred for 4 hours.  The reaction was quenched with AcOH; the methanol was removed 
and the reaction mixture was diluted with EtOAc and washed with H2O (3 x 100 mL); the 
organic layer was dried over Na2SO4 and purified by column chromatography (1:1 
Hex/EtOAc) to give 7 in 54% yield as a yellow oil. Rf = 0.81 (1:1 Hex/EtOAc), 1H NMR (500 
MHz, CDCl3):  δ (ppm) 5.84 (ddd, J = 5.5, 11.5, 17 Hz, 2H), 5.31-5.19 (m, 4H), 4.72 (dt, J = 
2.5, 11.5 Hz, 1H), 4.62 (dd, J = 3.5, 11 Hz, 1H), 3.50 (d, J = 2.5 Hz, 2H), 3.19 (d, J = 11 Hz, 
4H), 2.58 (d, J = 3.5 Hz, 1H), 2.07 (s, 3H), 1.49 (s, 3H) ppm.  13C {1H} NMR (125 MHz, 
CDCl3): δ (ppm) 135.1, 118.3, 111.6, 109.9, 79.3, 75.1, 71.3, 56.4, 41.6, 26.6, 26.5 ppm. 
 
(S)-1-(benzyloxy)-3-hydroxypyrrolidine-2,5-dione (10) 
O-benzylhydroxylamine (23.12 g, 187.7 mmol) was added to xylenes (1 
L) and L-malic acid was added.  The reaction flask was fitted with a Dean-Stark 
trap and reflux condenser and the reaction was heated to reflux and stirred for 4 hours. The 
reaction was then cooled to 0 °C for 18 hours. The precipitate formed was filtered and washed 
with toluene (3 x 50 mL).  10 was collected as colorless crystals (85 % yield, 16.69g) and was 











(m, 2H), 7.38-7.37 (m, 3H), 5.11 (s, 2H), 4.53 (dd, J = 4, 8.5 Hz, 1H), 3.02 (dd, J = 8.5, 18 Hz, 
1H), 2.60 (dd, J = 4.5, 18 Hz, 1H) ppm. 13C {1H} NMR (125 MHz, CDCl3): δ (ppm) 168.8, 
133.1, 130.1, 129.7, 128.7, 79.0, 64.5, 35.3 ppm. 
 
Ethyl (S)-4-((benzyloxy)amino)-2-hydroxy-4-oxobutanoate (11a) 
A solution of LHMDS (12.5 mL, 1M) and EtOH (0.5 mL, 8.7 
mmol) in THF (200 mL) was cooled to   –10 C.  The succinamide (1.30 
g, 5.8 mmol) was added in portions and the reaction was stirred for 1 hour.  The reaction was 
then quenched with NH4Cl (aq) (50 mL) and the THF removed by rotary evaporation.  The 
remaining slurry was then diluted with EtOAc and water. The aqueous layer was extracted 
with EtOAc (2 x 100 mL) and the organic layers were combined and dried with Na2SO4.  The 
solvent was removed by rotary evaporation and the crude material was purified by column 
chromatography (1:1 Hex/EtOAc) to give 11a in 74% yield.  Rf = 0.61 (EtOAc), 1H NMR 
(500 MHz, CDCl3):  7.37-7.32 (m, 5H), 4.87 (s, 2H), 4.46-4.41 (m, 1H), 4.21 (q, J = 7 Hz, 2H), 
2.59 (dd, J = 2.5, 14.5 Hz, 1H), 2.47 (dd, J = 7.5, 14.5 Hz, 1H), 1.27 (t, J = 7 Hz, 3H) ppm. 
13C {1H} NMR (125 MHz, CDCl3): δ (ppm) 173.4, 167.9, 135.3, 129.36, 128.9, 128.8, 78.4, 
67.5, 62.2, 37.7, 14.2 ppm.  
 
Ethyl (R)-1-(benzyloxy)-4-oxoazetidine-2-carboxylate (12) 
To a solution of 11a (5.00 g, 18.7 mmol) in THF was added DIAD (3.7 
mL, 18.7 mmol) and PPh3  (4.9 g, 18.7 mmol).  The reaction was stirred for 1 
hour.  The solvent was removed by rotary evaporation and the crude material was purified by 
column chromatography (1:1 Hex/EtOAc).  The material recovered was a mixture of 12 and 





Ethyl (R)-1-hydroxy-4-oxoazetidine-2-carboxylate (13) 
To a solution of 12 and DIAD in MeOH was added Pd/C (1.95 g, 1.84 
mmol).  The solution was flushed with H2 and the reaction was stirred under an 
atmosphere of H2 for 1 hour.  The reaction was filtered through a pad of Celite and washed 
with CH2Cl2.  The filtrate was concentrated under reduced pressure and crude material was 
purified by column chromatography (1:1 Hex/EtOAc).  13 was isolated, in 76% yield over 2 
steps, as a colorless oil (2.22 g).  Rf = 0.51 (EtOAc), 1H NMR (500 MHz, CDCl3):  4.36 (dd, J 
= 2, 5.5 Hz, 1H), 4.26 (dq, 2, 7.5 Hz, 2H), 3.01 (dd, J = 5.5, 13.5 Hz, 1H), 2.76 (dd, J = 2.5, 
13.5 Hz, 1H), 1.30 (t, J = 7 Hz, 3H) ppm. 13C {1H} NMR (125 MHz, CDCl3): δ (ppm): 169.5, 
164.6, 62.3, 57.4, 36.9, 14.2 ppm.  
 
Ethyl (R)-4-oxo-1-(tosyloxy)azetidine-2-carboxylate (14) 
To a solution of 13 (1.34 g, 8.4 mmol) in CH2Cl2 was added TsCl (1.6 g, 
8.4 mmol) and Et3N (1.17 mL, 8.4 mmol).  The reaction was stirred for 1 hour 
and the solvent was removed under reduced pressure.  The crude material was purified by 
column chromatography (4:1 Hex/EtOAc).  The product was isolated as a yellow oil in 81% 
yield (2.14 g).  Rf = 0.91 (1:1 Hex/EtOAc), 1H NMR (500 MHz, CDCl3): 7.88 (d, J = 8 Hz, 
2H), 7.38 (d, J = 8.5 Hz, 2H), 4.44 (dd, J = 3.5, 6.5 Hz, 1H), 4.32-4.25 (m, 2H), 3.03 (dd, J = 
6.5, 14.5 Hz, 1H), 2.92 (dd, J = 3, 14 Hz, 1H), 2.46 (s, 3H), 1.34 (t, J = 7 Hz, 3H) ppm. 
 
Ethyl (2R,3S)-3-azido-4-oxoazetidine-2-carboxylate (15) 
To a solution of 14 (2.14 g, 6.8 mmol) in MeCN was added Hunig’s base 
(3.26 mL, 18.7 mmol) and TMSN3 (1.8 mL, 13.6 mmol).  The reaction was stirred 





pressure and the crude material was purified by column chromatography (1:1 Hex/EtOAc).  
The product was isolated as yellow oil in 42 % yield (528 mg). Rf = 0.87 (1:1 Hex/EtOAc), 1H 
NMR (500 MHz, CDCl3): 6.91 (s, 1H), 4.67 (d, J = 2 Hz, 1H), 4.25 (dq, J = 3, 7.5 Hz, 2H), 
4.06 (d, J = 2.5 Hz, 1H), 1.29 (t, J = 7.5 Hz, 3H), 13C {1H} NMR (125 MHz, CDCl3): δ (ppm): 
169.1, 163.8, 69.9, 62.5, 55.8, 14.2 ppm 
 
(3S,4R)-3-azido-4-(hydroxymethyl)azetidin-2-one (16) 
NaBH4 (108 mg, 2.86 mmol) was added to a solution of 16 (528 mg, 2.86 
mmol) in MeOH.  The reaction was stirred for 1 hour and quenched with NH4Claq.  
Solvent was removed by rotary evaporation; the resulting solid was suspended in 3:1 
CHCl3/MeOH.  The slurry was filtered through a pad of Na2SO4 and the filtrate was 
concentrated.  It was purified by column chromatography (1:1 Hex/EtOAc) to give 16 as a 
colorless oil in 74% yield (303 mg). Rf = 0.05 (1:1 Hex/EtOAc), 1H NMR (500 MHz, CD3OD): 
4.52 (s, 1H), 3.89 (dd, J =3.5, 12 Hz, 1H), 3.74 (dd, J= 4.5, 12 Hz, 1H), 3.70-3.68 (m, 1H) ppm. 
13C {1H} NMR (125 MHz, CD3OD): δ (ppm): 66.1, 61.6, 57.4, 50.9 ppm.  
 
((2R,3S)-3-azido-4-oxoazetidin-2-yl)methyl 4-methylbenzenesulfonate (17) 
To a solution of 16 (303 mg, 2.13 mmol) in pyridine (1 mL) was added TsCl 
(609 mg, 3.2 mmol); the reaction was stired for 3 hours.  Pyridine was removed under 
reduced pressure, the crude reaction mixture was purified by column 
chromatography (1:1 Hex/EtOAc) and the product was isolated as a colorless oil in 60% yield 
(380 mg).  Rf = 0.42 (1:1 Hex/EtOAc), 1H NMR (500 MHz, CDCl3): 7.78 (d, J = 8 Hz, 2H), 
7.37 (d, J = 8.5 Hz, 2H), 4.37 (t, J = 2 Hz, 1H), 4.25 (dd, J = 4, 11.5 Hz, 1H), 4.14 (dd, J = 5.5, 





163.5, 145.9, 130.3, 128.0, 68.3, 68.9, 54.3, 21.8, 14.3 ppm.  
 
(3S,4R)-3-azido-4-(((1-(tert-butyl)-1H-tetrazol-5-yl)thio)methyl)azetidin-2-one (19) 
The tetrazole 17 (216 mg, 1.36 mmol) was dissolved in THF (20 
mL) followed by the addition of NaH (55 mg, 1.36 mmol); the reaction 
was stirred for 10 minutes before the azide 18 (202 mg, 0.68 mmol) was 
added; the reaction was heated to reflux and stirred for 18 hours.  It was then quenched with 
NH4Cl and washed with EtOAc (3 x 50 mL); the organic layers were combined and dried over 
Na2SO4.  Purification by column chromatography yielded 19 in 47% yield as a pale yellow oil.  
Rf = 0.39 (1:1 Hex/EtOAc), 1H NMR (500 MHz, CDCl3): 6.55 (s, 1H), 4.50 (s, 1H), 4.05 (t, J 
= 6 Hz, 1H), 3.74 (dd, J = 1.5, 6 Hz, 1H), 3.64 (dd, J = 5, 15 Hz, 1H), 1.73 (s, 9H) ppm. 13C 




The thioether 19 (75 mg, 0.25 mmol) was dissolved in EtOH (2 
mL) and cooled to 0 °C and a solution of Mo7O24(NH4)6 (27.8 mg, 0.023 
mmol) in H2O2 (0.3 mL) was added; the reaction was warmed to room 
temperature and stirred for 18 hours.  The reaction was then washed with EtOAc and the 
sulfone 20 was obtained in 98% yield without further purification. Rf = 0.72 (1:1 Hex/EtOAc), 
1H NMR (500 MHz, CDCl3):  4.67-4.66 (m, 1H), 4.36 (dd, J = 4.5, 14.5 Hz, 1H), 4.23-4.21 (m, 
1H), 4.14 (dd, J = 7.5, 14.5 Hz, 1H), 1.85 (s, 9H) ppm. 13C {1H} NMR (125 MHz, CDCl3): δ 








The thioether 19 (61 mg, 0.21 mmol) was dissolved in DMF (3 
mL) and cooled to 0 °C. BnBr  (0.1 mL, 0.63 mmol) was added followed 
by NaH (103 mg, 0.26 mmol) and the reaction was stirred for 3 hours. It 
was then quenched with NH4Cl and the aqueous layer was extracted with Et2O (3 x 25 mL); 
the organic layers were combined and dried over Na2SO4 and purified by column 
chromatography (1:1 Hex/EtOAc) to give 21 in 83% yield. Rf = 0.52 (1:1 Hex/EtOAc), 1H 
NMR (500 MHz, CDCl3): 7.39-7.27 (m, 5H), 4.55 (d, J = 24.5 Hz, 1H), 4.32 (d, J = 25 Hz, 





The thioether 21 (48 mg, 0.13 mmol) was dissolved in EtOH and 
cooled to 0 °C; a solution of Mo7O24(NH4)6 (14 mg, 0.011 mmol) in H2O2 
was added and the reaction warmed to room temperature and stirred for 
18 hours.  The reaction was then diluted with CH2Cl2  and washed with H2O; the organic layer 
was dried over Na2SO4 and concentrated to give 22 in 83% yield.  Rf = 0.82 (1:1 Hex/EtOAc), 
1H NMR (500 MHz, CDCl3): 7.39-7.31(m, 5H), 4.83 (d, J = 2Hz, 1H), 4.57 (d, J = 15.5 Hz, 
1H), 4.36 (d, J = 15.5 Hz, 1H), 4.22 (dd, J = 3.5, 15 Hz, 1H), 4.01-3.98 (m, 1H), 3.81 (dd, J = 








The sulfone 22 (26 mg, 0.064 mmol) was dissolved in DMF 
and cooled to -78 °C.  KHMDS (0.18mL, 0.77 mmol) was added 
followed by benzaldehyde (0.01 mL, 0.077 mmol) and the reaction 
was stirred for 3 hours.  It was then quenched with NH4Cl and diluted with H2O and Et2O, 
the aqueous layer was extracted with Et2O (3 x 25 mL), and the organic layers were combined 
and washed with brine. The organic layer was then dried over Na2SO4 and purified by column 
chromatography (1:1 Hex/EtOAc) to give 23 in 61% yield.  Rf = 0.63 (1:1 Hex/EtOAc), 1H 
NMR (500 MHz, CDCl3): 9.32 (d, J = 6 Hz, 1H), 8.18 (d, J = 5.5 Hz, 1H), 7.38 (d, J = 4Hz, 
5H), 4.73 (d, J =6 Hz, 2H), 2.04 (d, 1Hz, 1H), 1.72 (s, 9H) ppm.  
 
tert-butyl ((2R,3S)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)carbamate (24) 
The azide 16 (248 mg, 1.75 mmol) was dissolved in EtOAc (20 mL) 
followed by Boc2O (1.14g, 5.2 mmol) and Pd/C (18.6 mg).  The reaction flask 
was then flushed with H2 and stirred under an atmosphere of hydrogen for 2 
hours.  The reaction was then filtered through a pad of Celite and purified with column 
chromatography (EtOAc) to give 24 in 77% yield.  Rf = 0.05 (EtOAc), 1H NMR (500 MHz, 




The β-lactam 24 (100 mg, 0.46 mmol) was dissolved in MeCN, Et3N (0.13 
mL, 0.92 mmol) and MsCl (0.06 mL, 0.69 mmol) were then added, and the 





by column chromatography (1:1 Hex/EtOAc) to give 25 in 72% yield. Rf = 0.20 (EtOAc), 1H 
NMR (500 MHz, CDCl3): 6.78 (s, 1H), 5.58 (d, J = 7.5 Hz, 1H), 4.53-4.49 (m, 1H), 4.34-4.30 
(m, 1H), 3.94-3.93 (m, 1H), 3.07 (s, 3H), 1.43 (s, 9H) ppm. 13C {1H} NMR (125 MHz, CDCl3): 




The tetrazole 17 (73 mg, 0.46 mmol) was dissolved in THF, 
followed by NaH (18 mg, 0.46 mmol), and the reaction was stirred for 
10 minutes before the addition of the β-lactam 25 (98 mg, 0.33 mmol).  
The reaction was then heated to reflux and stirred for 15 hours.  It was quenched with NH4Cl, 
and diluted with EtOAc; the aqueous layer was washed with EtOAc (3 x 20 mL).  The organic 
layers were combined and washed with brine before being dried over Na2SO4 and purified 
with column chromatography (1:1 Hex/EtOAc) to give 26 in 71% yield.  Rf = 0.31 (EtOAc), 
1H NMR (500 MHz, CDCl3): 6.47 (s, 1H), 5.34 (d, J = 7 Hz, 1H), 4.59 (d, J = 6.5 Hz, 1H), 
4.10-4.07 (m, 1H), 3.86 (dd, J = 2, 16.5 Hz, 1H), 3. 58 (d, J = 14.5 Hz, 1H), 1.72 (s, 9H), 1.43 
(s, 9H) ppm.  13C {1H} NMR (125 MHz, CDCl3): δ (ppm): 166.2, 155.2, 80.9, 63.2, 61.6, 60.6, 




The thioether 26 (93 mg, 0.26 mmol) was dissolved in DMF 
(3 mL) followed by BnBr (0.18 mL, 1.04 mmol); the reaction was 





was stirred for 1 hour.  The reaction was quenched with NH4Cl and diluted with EtOAc; the 
organic layer was washed with H2O (3 x 20 mL) and brine then dried over Na2SO4 and purified 
by column chromatography (1:1 Hex/EtOAc) to give 27 in 81% yield.  Rf = 0.42 (EtOAc), 1H 
NMR (500 MHz, CDCl3): 7.28-7.24 (m, 5H), 4.26 (d, J = 16 Hz, 1H), 3.85 (s, 1H), 3.42 (dd, J 
= 4.5, 4Hz, 1H), 1.63 (s, 9H), 1.42 (bs, 9H) ppm.  13C {1H} NMR (125 MHz, CDCl3): δ (ppm): 




The thioether 27 (106 mg, 0.198 mmol) was dissolved in 
EtOH and cooled to 0 °C; a solution of Mo7O24(NH4)6 (22 mg, 0.018 
mmol) in H2O2 was added and the reaction warmed to room 
temperature and stirred for 18 hours.  The reaction was then diluted with CH2Cl2  and washed 
with H2O; the organic layer was dried over Na2SO4 and concentrated to give 28 in 83% yield.  
Rf = 0.72 (1:1 Hex/EtOAc), 1H NMR (500 MHz, CDCl3): 7.28 (bs, 2H), 7.19 (bs, 3H), 4.96-
4.45 (m, 2H), 4.43-4.19 (m, 1H), 4.12 (bs, 1H), 3.83 (bs, 1H), 1.80 (s, 9H), 1.46 (bs, 9H) ppm. 




The sulfone 28 (35 mg, 0.06 mmol) was dissolved in DMF and 
cool to -78 °C KHMDS (0.17 mL, 0.77 mmol) was added followed by 
benzaldehyde (0.01 mL, 0.077 mmol) and the reaction was stirred for 





was extracted with Et2O (3 x 25 mL), and the organic layers were combined and washed with 
brine. The organic layer was then dried over Na2SO4 and purified by column chromatography 
(1:1 Hex/EtOAc) to give 29 in 61% yield.  Rf = 0.63 (1:1 Hex/EtOAc), 1H NMR (500 MHz, 
CDCl3): 7.28-7.25 (m, 5H), 5.83 (t, J = 7.5 Hz, 1H), 5.05 (d, J = 7.5Hz, 2H), 4.33 (d, J = 5.5 
Hz, 2H), 1.84 (s, 9H), 1.39 (s, 9H) ppm.  
 
diethyl (4S,5S)-1,3,2-dioxathiolane-4,5-dicarboxylate 2-oxide (30) 
Diethyl tartrate (2 mL, 11.7 mmol) was cooled to 0 °C; SOCl2 (0.98 
mL, 13.56 mmol) was added dropwise over 5 minutes followed by 5 drops of 
DMF.  The reaction was warmed to room temperature, then heated to 50 °C for 30 minutes.  
The reaction was cooled to room temperature and N2 was bubbled through the reaction for 
30 minutes to neutralize the excess SOCl2; the reaction was concentrated and the 30 was used 
crude.  
 
diethyl (2R,3S)-2-azido-3-hydroxysuccinate (31) 
Dioxathiolane 30 (1.28 g, 4.8 mmol) was dissolved in DMF and NaN3 
(9.37 g, 14.4 mmol)  was added and the reaction was stirred for 24 hours.  
CH2Cl2 (5 mL) and H2O (5 mL) were added and the reaction was stirred an additional 2 hours.  
The aqueous layer was extracted with CH2Cl2, and the organic layer was dried over Na2SO4 to 
yield 31 in 77% yield.  Rf = 0.85 (1:1 Hex/EtOAc), 1H NMR (500 MHz, CDCl3): 4.26-4.16 (m, 
4H), 2.86-2.83 (m, 2H), 1.32-1.26 (m, 6H) ppm. 13C {1H} NMR (125 MHz, CDCl3): δ (ppm): 
170.3, 62.5, 61.9, 36.4, 35.5, 14.3 ppm.  
 





The azido alcohol 31 (870 mg, 3.7 mmol) was dissolved in DMF and 
cooled to 0 °C and PPh3 was added in portions.  The reaction was allowed 
to warm to room temperature and was stirred for 1.5 hours; it was then warmed to 85 °C and 
stirred until complete by TLC.  The reaction was concentrated and purified by column 
chromatography (6:1 Hex/EtOAc) to give 32 in 63% yield.  Rf = 0.85 (4:1 Hex/EtOAc), 1H 
NMR (500 MHz, CDCl3): 4.30 (q, J = 7.5 Hz, 2H), 4.17 (q, J = 4 Hz, 2H), 1.34 (t, J = 7 Hz, 
3H), 1.28 (t, J = 7 Hz, 3H) ppm.   
 
 ethyl (2S,3S)-3-(hydroxymethyl)aziridine-2-carboxylate (33) 
The aziridine 32 (1.30 g, 6.9 mmol) was dissolved in EtOH (25 mL) 
and the reaction was cooled to 0 °C; NaBH4 (210 mg, 5.5 mmol) was added 
and the reactionwas stirred for 12 hours.  It was then quenched with NH4Cl and diluted with 
CH2Cl2  and washed with H2O (10 mL) and the organic layer was dried over Na2SO4 then 
purified by column chromatography (1:1 Hex/EtOAc) to give 33 in 71% yield.  Rf = 0.55 (1:1 
Hex/EtOAc), 1H NMR (500 MHz, CDCl3): 4.25-4.18 (m, 2H), 3.80 (dd, J = 3.5, 12 Hz, 1H), 
3.52 (dd, J = 5, 12.5 Hz, 1H), 1.29 (t, J = 7.5 Hz, 3H) ppm.  
 
ethyl (2S,3S)-3-(((tert-butyldimethylsilyl)oxy)methyl)aziridine-2-carboxylate (34) 
The aziridine 33 (327.8 mg, 2.26 mmol) was dissolved in DMF, 
followed by TESCl (511 mg,  3.39 mmol), DMAP (137.8 mg, 1.13 mmol), 
and Et3N (0.63 mL, 4.52 mmol). The reaction was stirred for 1 hour, then diluted with H2O 
and Et2O; the organic layer was extracted with brine and dried over Na2SO4.  Purification was 
done by column chromatography (4:1 Hex/EtOAc) to give 34 in 93% yield.  Rf = 0.75 (1:1 





(d, J = 27.5 Hz, 1H), 1.29 (t, J = 7 Hz, 3H), 0.95 (t, J = 8 Hz, 9H), 0.60 (q, J = 8Hz, 6H) ppm. 
13C {1H} NMR (125 MHz, CDCl3): δ (ppm): 61.8, 59.0, 37.5, 31.0, 11.6, 4.1, 1.8 ppm. 
 
 (3S,4R)-3-azido-4-(((tert-butyldimethylsilyl)oxy)methyl)azetidin-2-one (38) 
β-lactam 16 (58 mg, 0.4 mmol) was dissolved in DMF, followed by TBSCl 
(133 mg, 0.6 mmol) DMAP (25 mg, 0.2 mmol) and Et3N (0.12 mL, 0.8 mmol).  The 
reaction was stirred for 1 hour, then diluted with H2O and Et2O; the organic layer was 
extracted with brine and dried over Na2SO4.  Purification was done by column 
chromatography (4:1 Hex/EtOAc) to give 38 in 91% yield.  Rf = 0.76 (1:1 Hex/EtOAc), 1H 
NMR (500 MHz, CDCl3): 4.41 (s, 1H), 3.80-3.73 (m, 2H), 3.65-3.62 (m, 1H), 0.89 (s, 9H), 0.07 
(s, 3H), 0.6 (s, 3H) ppm.  13C {1H} NMR (125 MHz, CDCl3): δ (ppm): 164.5, 154.4, 66.7, 62.7, 




The TBS β-lactam 38 (83.6 mg, 0.32 mmol) was dissolved in CH2Cl2 
followed by Boc2O (106.7 mg, 0.5 mmol), DMAP (19.5 mg, 0.16 mmol), and Et3N 
(0.1 mL, 0.64 mmol).  The reaction was stirred for 24 hours then concentrated and 
purified by column chromatography (4:1 Hex/EtOAc) to give 39 in 98% yield. Rf = 0.86 (1:1 
Hex/EtOAc), 1H NMR (500 MHz, CDCl3): 4.66 (d, J = 2.5 Hz, 1H), 4.11 (dd, J = 3, 11.5 Hz, 
1H), 3.88 (dd, J = 1.5, 11 Hz, 1H), 3.85-3.83 (m, 1H), 1.52 (s, 9H), 0.88 (s, 9H), 0.07 (s, 3H), 
0.05 (s, 3H) ppm.  13C {1H} NMR (125 MHz, CDCl3): δ (ppm): 154.4, 84.3, 64.8, 60.3, 58.9, 






benzyl (tert-butoxycarbonyl)-L-alanyl-L-valinate (40) 
benzyl L-valinate (1.54 g, 6.3 mmol) and iPr2NEt (2 mL, 11.4 
mmol) were added to THF followed by EDCI (984 mg, 6.3 mmol), 
HOBt (971 mg, 6.3 mmol), and N-Boc-alanine (1.00 g, 5.2 mmol).  The reaction was stirred 
for 18 hours, then diluted with CH2Cl2 and H2O; the organic layer was washed with brine and 
dried over Na2SO4.  The crude mixture was purified by column chromatography (1:1 
Hex/EtOAc) to give 40 in 97% yield.  Rf = 0.86 (1:1 Hex/EtOAc), 1H NMR (500 MHz, 
CDCl3): 7.36-7.33 (m, 5H), 6.63 (bs, 1H), 5.15 (q, 12.5 Hz, 2H), 4.96 (bs, 1H), 4.57 (dd, J = 5, 
9 Hz, 1H), 4.17 (bs, 1H), 2.21-2.17 (m, 1H), 1.44 (s, 9H), 1.34 (d. J = 7 Hz, 3H), 0.90 (d, J = 
7 Hz, 3H), 0.85 (d, J = 7 Hz, 3H) ppm.  
 
(2S,3R)-2-azido-3-((tert-butoxycarbonyl)amino)-4-((tert-
butyldimethylsilyl)oxy)butanoic acid (42) 
The β-lactam 39 (600 mg, 1.68 mmol) was dissolved in THF/H2O 
(1:1) and a 1M solution of LiOH (1.68 mL, 1.68 mmol) was added. The 
reaction was stirred for 1 hour and quenched with NH4Cl.  It was then diluted with EtOAc, 
and the organic layer was washed with H2O then dried over Na2SO4 and concentrated to give 
42 in 93% yield without further purification. Rf = 0.52 (1:1 Hex/EtOAc), 1H NMR (500 MHz, 
CDCl3): 5.53 (d, J = 4 Hz, 1H), 4.08-4.-2 (m, 1H), 3.86-3.82 (m, 1H), 1.90 (m, 1H), 1.43 (s, 
9H), 0.88 (s, 9H), 0.05 (s, 6H) ppm.  13C {1H} NMR (125 MHz, CDCl3): δ (ppm): 98.6, 68.7, 








The carboxylic acid 42 (39 mg, 0.1 mmol) was 
dissolved in CH2Cl2, followed by the addition of iPr2Net (0.03 
ml, 0.14 mmol), HATU (51 mg, 0.14 mmol), and 41 (53 mg, 
0.14 mmol) and the reaction was stirred for 18 hours.  It was then washed with H2O and the 
organic layer was dried over Na2SO4.  Purification was done by column chromatography (1:1 
Hex/EtOAc) to give diamine dipeptide 43 in 91% yield.   Rf = 0.71 (1:1 Hex/EtOAc), 1H 
NMR (500 MHz, CDCl3): 7.38-7.23 (m, 5 H), 7.12 (bs, 1H), 6.93 (d, J = 6.5 Hz, 1H), 6.43 (d, 
J = 8 Hz, 1H), 6.27 (d, J = 8.5 Hz, 1H), 5.23-5.19 (m, 1H), 5.15-5.11 (m, 2H), 4.59-4.52 (m, 
2H), 4.46-4.43 (m, 1H), 4.25 (d, J = 6.5 Hz, 1H), 4.04-4.01 (m, 1H), 3.81-3.76 (m, 1H), 3.66 
(dd, J = 5.5, 10.5 Hz, 1H), 2.24-2.16 (m, 1H), 1.42 (s, 9H), 1.37 (d, J = 7 Hz, 3H), 1.25 (s, 6H), 
0.92-0.85 (m, 12 H), 0.06 (s, 6H) ppm.  13C {1H} NMR (125 MHz, CDCl3): δ (ppm): 168.9, 
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BIOLOGICAL EVALUATION OF NA22598A1 AND NATURAL  
PRODUCT FRAGMENTS 
 
4.1 Hypothesis for a Common Mechanism of Action 
The initial biological evaluations for both NA22598A1 and guadinomine B were 
phenotypic assays.  Guadinomine B exhibited inhibition of the type III secretion system 
(T3SS) of bacteria (IC50 = 0.0139 M), which was assessed with a EPEC-induced hemolysis 
assay. 1  NA22598A1 was shown to inhibit anchorage indepent growth (AIG) of a human 
colon-cancer cell line, DLD-1 (IC50 = 0.32 M), but did not inhibit anchorage dependent 
growth at the same concentration. 2  Studies showed that NA22598A1 arrests the cell cycle at 
the G1 phase and inhibits the synthesis of cyclin D1. 4 
The type III secretion system (T3SS) is a protein system unique to Gram-negative 
bacteria and is responsible for the virulence of a number of deadly strains including salmonella, 
meningitis, and pneumonia.  T3SS are highly conserved multimolecular proteins that are 
responsible for delivering effector proteins into a host eukaryotic cell.  5  There are three 
distinctive parts of the T3SS, a basal body which spans the bacterial membrane periplasm, a 
needle structure which spans the bacterial membranes and the extracellular space, and a needle 
tip that links the needle and the host membrane allowing for insertion of the translocon.  6   
Once the T3SS comes into contact with the host cells, translocators are secreted and 





Bacteria that rely on the T3SS to deliver effector proteins to the host cell can be rendered 
almost nonpathogenic by the inhibition of the T3SS. 7  T3SS producing bacteria are linked to 
more serious infections and a worse prognosis, as demonstrated by El-Sohl and coworkers, 
who noted that patients with ventilator-associated pneumonia who had the T3SS-producing 
bacteria had a higher mortality rate (66%) than patients who were infected with non-T3SS 
producing bacteria (33%). 8  While the T3SS system is critical for virulence, it is not involved 
in a physiological processes of bacteria, making it an attractive target for inhibition because of 
the lower potential to develop resistance. 1   
The phenotypes associated with NA22598A1 and guadinomine B and our conclusion 
that they are in fact the same compound led to the hypothesis that both molecules had the 
same mode of action that produced the different phenotypes. In order to identify a potential 
protein target, the key features of the molecules were evaluated.  Due to the highly polar 
fuctional groups on NA22598A1, it will likely be dicationic at physiological pH and therefore 
unlikely to permeate the cell membrane.  The carbamoyl guanidine moiety is aligned such that 
it would form a six membered ring if it were to chelate a metal ion.  This led to the hypothesis 
that NA22598A1 would act on a surface protein containing a catalytic metal cation.  Because 
metal cations often act as cofactors, we hypothesized that it was more likely to be a 
competetive inhibitor of its protein target rather than allosteric inhibitor.  In addition, the 
dipeptide tail could mimic the amino acid backbone of a protein, a common motif in enzymatic 
recognition.  
Through an investigation of the literature, matrix metalloproteinases (MMPs) emerged 
as a viable protein target for NA22598A1.  MMPs are zinc-based endopeptidases that are 
responsible for extracellular matrix remodeling through the cleavage of collegen and gelatine; 





coordinated to a zinc ion.  In addition, MMPs are also responsible for signalling through the 
liberation of a number of cytokines, chemokines, and growth factors. 9   From a structural 
standpoint, the MMP active site is well suited for binding NA22598A1.  An initial comparsion 
can be made between NA22598A1 and tissue inhibitor of metalloproteinases (TIMP); TIMP 
uses an -aminoacid functionality to chelate the zinc ion and NA22598A1 has this same 
functionality in the right-hand portion of the molecule (Figure 4.1). 
However, the impetus for the metal chelating hypothesis came from the carbamoyl 
guanidine, which led to an exploration of the literature for similar molecules that act as MMP 
inhibitors.  Pyrimidine-triones are potent MMP inhibitors that not only chelate the zinc ion 
but also provide the necessary hydrogen bond to the glutamate residue disrupting the 
glutamate-H2O hydrogen bond which is required for catalysis. 10  While these inhibitors are 
structurally different from NA22598A1, the carbamoyl guanidine on NA22598A1 could mimic 
their binding and not only chelate the metal cation but also provide additional hydrogen bonds 
to His 201 and Glu 202 (Figure 4.2).  Structually MMPs are a viable target protein for 
NA22598A1,  and this led to an examination of the role of MMPs in the pathology of both 
T3SS producing bacteria and cancer cells capable of AIG. 
The biggest concern with proposing MMP inhibition as a mode of action was the 
conserved nature of the active site across all 23 isoforms of human MMPs.  However, we 
explored this family of proteases to see if inhibition of a specific MMP could result in the 
phenotypes seen for both NA22598A1 and guadinomine B.   
 
4.2 The Correlation between MMPs and Metastasis and T3SS Virulence 
While exploring the literature, it became clear that the gelatinases MMP-2 and MMP-






Figure 4.1: The potential binding of NA22598A1 to the catalytic site of MMP 3. 
 
 
Figure 4.2: Hypothetical binding of NA22598A1 via the carbamoyl guanidine. 
 
 the MMP subfamily known as the soluble gelatinases, which proteolytically degrade gelatin 
(denatured collagen).  MMP-2 is ubiquitously expressed as a proenzyme (proMMP-2), which 
is activated by forming a complex with TIMP-2 generating a substrate for MMP-14, which is 
responsible for cleaving the prodomain to activate MMP-2. 9  MMP-2 degrades basal 
membrane, is involved in neovascularization, and directly involved in the migration of cells via 
degradation of the basement membrane.  The role of MMP-2 in cell signaling may be much 





neutrophils, although it can be induced by stress in other cells.  The greatest difference in 
selectivity between MMP-2 and MMP-9 is MMP-9’s inability to directly proteolyze collagen I.   
The overexpression of MMP-2 and MMP-9 have been related to malignance in a vast 
number of cancers.  There is a positive correlation between gelatinase expression and the 
invasive potential of tumors in a number of cancers, implicating the gelatinases in metastasis.  
9   We specifically wanted to assess the role of either MMP-2 or MMP-9 in colon cancer to 
determine if NA22598A1’s activity could be explained by MMP inhibition.  MMP-9 was 
identified as a noninvasive diagnostic marker for colorectal cancer because elevated levels were 
detected in the fecal matter of patients with cancer versus a control group. 11   
The relationship between MMPs and Gram-negative infection is not as clear cut as the 
relationship between MMPs and cancer. However, a number of the effects exerted by T3SS 
producing bacteria on the host cells can be traced to MMP containing pathways.  T3SS bacteria 
induce an inflammatory response in host cells. The release of inflammatory cytokines can 
disrupt tight junctions and increase permeability promoting barrier damage and disease 
progression. 6  TNF-α is a cytokine that is elevated in pathogenic bacterial infection and leads 
to increased permeability of the epithelial monolayer.  The suppression of MMP-2 showed a 
significant decrease in the secreted levels of TNF-α. 12  IL-1β is another cytokine that is 
upregulated in an immune response, and it was shown to induce MMP-2 expression; however, 
the inhibition of MMP-2 essentially eliminates the observed effects of increased IL-1β.  13   
The gelatinases MMP-2 and MMP-9 are indicated in both tumor metastasis and 
potentially in T3SS mediated infection.  To determine if NA22598A1 was a potential gelatinase 
inhibitor, a manual docking was performed with Biovia and a minimization of the ligand was 
performed using a Drieding-like forcefield to optimize the geometry in the MMP-9 active site 






Figure 4.3: Model of NA22598A1 docked to MMP-9.  
 
binding the Zn2+ ion, the γ alcohol formed a hydrogen bond with the glutamate, as did the 
amine.  Additionally, the valine residue provided hydrophobic interaction to increase binding 
affinity.  
 
4.3 Evaluation of NA22598A1 and Molecular Fragments as MMP Inhibitors 
A hypothesis was generated that NA22598A1 was a gelatinase inhibitor, and through 
this mechanism of action produced the anti-metastatic phenotype seen in DLD-1 colon cancer 
cells, and the T3SS inhibition seen with guadinomine B.   To test the validity of this hypothesis, 
NA22598A1 was tested in vitro against MMP-2 and MMP-9 using a colorimetric assay that 
measured the catalytic activity of the MMPs.  In order to determine if there was any selectivity 





against MMP-3, a stromelysin, and MMP-8, a collagenase.  In addition to NA22598A1, we also 
wanted to evaluate the synthesized natural product fragments 2-4; we had proposed Zn2+ 
binding by either the carbamoyl guanidine moiety or the diamine moiety; we hoped by testing 
the fragments we could determine which moiety contributed to NA22598A1’s activity (Figure 
4.4). 
Colorimetric MMP assays were used to evaluate the potential inhibitors NA22598A1 
and fragments 2-4.  A range of concentrations, 100 µM, 10 µM, and 1 µM, for the fragments 
2-4, and 100 µg/ml, 10 µg/ml, and 1 µg/ml for the natural product, were incubated with the 
MMP at 37 °C for 1 hour before addition of the substrate.  After the addition of the substrate, 
the assays were incubated for an additional hour before the inhibition was measured (Table 
4.1).  
The results of the MMP inhibition assays were suprising.  All of the compounds 
showed inhibitory activity against MMP-2, but it was interesting to note that the 100-fold 
concentration range did not produce a range of inhibition.  MMP-3 appeared to be activated 
by all of the compounds, but there was no correlation between the concentration of the 
compounds and the percentage of activation.  MMP-8 and MMP-9 were largely unaffected by 
any of the compounds. 
 









The selective inhibition of MMP-2 over MMP-9 and the limited but consistent 
inhibition of MMP-2 at all of the tested concentrations prompted us to revisit our hypothesis 
of competitive inhibition.  MMP-2 has broader substrate selectivity than MMP-9; therefore, a 
competitive inhibitor that acts on MMP-2 should act on MMP-9.  The basis of our competitive 
inhibitor hypothesis was that the carbamoyl guanidine could bind zinc.  To determine if the 
carbamoyl guanidine was a Zn2+ chelator, 3 was titrated with ZnCl2 and it was discovered that 
the carbamoyl guanidine was not binding Zn2+. 14  The inability of the carbamoyl guanidine to 





TFA salt.  However, we predicted that at physiological pH, the guanidine would also be 
protonated and therefore unlikely to be able to chelate Zn2+ in the enzyme.   
The inability of the carbamoyl guanidine to bind Zn2+ as well as the MMP-2 selectivity 
and non-dose-dependent inhibition led us to consider that NA22598A1 may be a 
noncompetitive or uncompetitive inhibitor.  To determine if the lack of dose response was 
simply due to the maximum inhibition being achieved at very low concentrations, NA22598A1, 
3, and 4, were tested against MMP-2 at lower concentrations (Table 4.2). The lower 
concentrations of NA22598A1, 3, and 4, did display a measure of dose response activity against 
MMP-2.  
Seeing approximately 50% inhibition at concentrations between 1µM and 0.1 µM was 
consistent with the phenotypic data collected for NA22598A1 and guadinomine B which 
exhibited IC50’s in that range. 1 2  One key piece of data that was not clearly elucidated by the 
MMP assays was which functional groups were responsible for the biological activity.  While 
the diamine fragment 4 showed consistent inhibition down to lower concentrations, the 
carbamoyl guanidine 3 had similar potency to the natural product as low as 1 µM.  The 
inhibition of MMP-2 by NA22598A1 and the fragmented pharmacophores 3, and 4 was very 
interesting and deserves further investigation. 
 
4.4 Further Studies to Investigate the Inhibition of MMP-2 by NA22598A1 
The initial MMP inhibition exhibited by NA22598A1 requires a more detailed 
hypothesis for the inhibitor-enzyme interaction.  A Lineweaver-Burk plot was generated to 
determine the kind of inhibitor NA22598A1 is, but the substrate used in the MMP assay had 
a very slow cleavage rate and the results were inconclusive. In addition to determining the type 









NA22598A1 is in fact an allosteric inhibitor, it may bind to proMMP-2 and inhibit the MMP-
14 cleavage to form the active enzyme.  The basis for this hypothesis is that proMMP-2 must 
bind to TIMP-2 before it can be cleaved; this interaction occurs through the C-terminal 
domains of both proteins excluding an inhibitory interaction between TIMP-1 and MMP-2.  15  
We can envision NA22598A1 binding at the C-terminal of proMMP-2 and blocking the 
binding of TIMP-2, which would keep the enzyme from being activated. 
 We also want to examine the T3SS inhibition more thoroughly.  Ideally, we would be 
able to find an assay that directly measures T3SS inhibition rather than measuring the effects 







4.5 Supporting Information  
4.5.1 MMP Inhibition Assays 
MMP inhibition assays were carried out using Enzo Life Sciences Colorimetric drug 
discovery kits. Each assay utilized a thiopeptide as a chromogenic substrate (Ac-PLG-[2-
mercapto-4-methyl-pentanoyl]-LG-CO2H5), which upon cleavage produced a sulfhydryl 
group that reacted with DTNB to form 2-nitro-5-thiobenzoic acid.  2-nitro-5-thiobenzoic acid 
absorbance was then detected at 412 nm.   
The compounds of interest (10 µl) were added to wells of a 96-well plate which each 
contained 60 µl of buffer.  Twenty µl aliquots of enzyme solution were added to the wells and 
the plate was pre-incubated for 1 hour at 37 °C.  Ten µl of the substrate solution was then 
added to each well and the plate was incubated at 37 °C for 1 hour.  At 10 minute intervals, 
the absorption values were measured at 412 nm.   
Each compound of interest was tested in duplicate and the absorption values were 
averaged.  The absorption values measured at 60 minutes showed the maximum inhibition, 
and are the values reported.  
 
4.5.2 Zn2+ Titration Experiment  
Compound 3 was divided into six portions (39.8 µM each) in CD3OD and treated with 
0.0, 0.1, 1.0, and 2.0 equivalents of ZnCl2.  The 1H NMR spectra of each solution was 
measured.  The NMR data did not change with the increasing concentrations of ZnCl2 as we 
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THE SYNTHESIS OF ZNA AND ANALOGS 
 
5.1 Natural Product Inspiration 
Marine sponges Leucetta and Clathrina sp. are a rich source of imidazole alkaloids, many 
of which have shown an interesting array of biological activity. 1 The compounds that were of 
most interest to us were the naamidines, particularly naamidine A (Figure 5.1).  Naamidine A 
was tested in an EGF mitogenic assay and it was found to preferentially inhibit EGF 
dependent cell proliferation (IC50 = 11.3µM, NIH3T3) verses insulin dependent cell 
proliferation (IC50 = 242µM, NIH3T3). 2  This selectivity made naamidine A attractive for 
further investigation because EGF is frequently overexpressed in cancer cells, specifically its 
link to breast cancer. 2, 3   
In addition to the interesting biology, naamidine A was appealing to our group due to 
its 2-aminoimidazole core, which could be constructed from the hydroamination of propargyl 
guanidines previously explored in our lab. 4  Dr. Joseph Gibbons, a former coworker, 
undertook the synthesis of naamidine A. 5  First, a Cu(I)-mediated 3CC of an aldehyde, a 
secondary amine, and an alkyne provided the protected amine 1 (Scheme 5.1).  
This was a robust reaction that tolerated a range of substitution on all three 
components providing easy access to diversification.  Deallylation with thiosalicylic acid and 
catalytic Pd(PPh3)4 gave the secondary propargyl amine 2 in good yield.  The guanidine was 






Figure 5.1: Naamidine A, a biologically active compound isolated from Leucetta sp. 
 
 










quantitative yield providing the monoacylguanidine 3. 6  An AgNO3 mediated cyclization 
yielded the 5-exo-trig cyclized guanidine 4 as a single regioisomer.  A Pd(OH)2/C catalyzed 
hydrogentation performed multiple functions, as it cleaved the Cbz group, isomerized the ene-
guanidine to the 2-aminoimidazole, and cleaved the benzyl ether to provide naamine a, 5.  
Ohta’s method was then used to install the hydantoin, and provided naamidine A, 6, in good 
yield (Scheme 5.1). 7  This concise and high yielding synthetic route to access naamidine A was 
ideal for the synthesis of analogs.   
 
5.2 Synthesis of Initial Naamidine A Analogs  
 When thinking about naamidine A analog design, altering the benzyl substituents 
could be easily done by changing the 3CC components, but altering the hydantoin presented 
a more significant challenge.  However, an N2-acyl-2-aminoimidazole would produce a 
bioisosteric amide that we hoped would mimic the heterocycle.  The challenge in designing 
such a bioisostere was selectively generating the N2-monoacyl-2-aminoimidazole.  Jiang and 
coworkers encountered difficulty in their synthesis of naamidine A analogs with their attempt 
to acylate free 2-aminoimidazoles, resulting in a mixture of monoacylated and diacylated N2 
products (Scheme 5.2). 8 
The intermediate 4 presented an interesting substrate for selective N2-acylation 
because N3 is protected, and the imino tautomer of the exocyclic N2 should only undergo 
monoacylation.  To test this hypothesis, ene-guanidine 4 was treated with a range of aryl and 
alkanyl chlorides; to our delight, this reaction produced a range of N2-monoacylguanidines 7a-
e (Table 5.1).  An alteration to the hydrogenation conditions provided the deprotected and 
isomerized 2-aminoimidazoles 8a-f.  






Scheme 5.2: Jiang’s synthesis of naamidine A derivatives  
 









prompted an expansion of the analog library.  The C5-phenyl and C4-benzyl analogs 9a and 9b 
were constructed with the same methodology that produced the ene-guanidine 4. The selective  
N2-monoacylations proceeded in excellent yield to afford 10a-i.  The 2- aminoimidazoles  
11a-i were then generated from a Pd/C hydrogenation at 60 psi H2 (Table 5.2).   
Naamidine A and all of the analogs synthesized were evaluated in a university-wide 
screen to identify new drug leads for the treatment of breast cancer. 9  The screen was run 
against primary metastatic tumor cells isolated from patient-derived malignant pleural 
effusions at the Huntsman Cancer Institute.  These cells created a model to assess molecules 
against chemoresistance developed from current therapies.  Additionally, compounds were 
 







screened against normal epithelial cells from reduction mammoplasty to determine the 
therapeutic window. 9  Naamidine A was not identified as a viable lead due to its cytotoxicity; 
however, analog 11h, known as zinaamidole (ZNA), displayed remarkable selectivity.  ZNA 
showed cytotoxicity against all tested breast cancer cell lines regardless of estrogen receptor 
subtype (MCF-7, T47D, MDA-MB-231, and PE10005339), but showed almost no effect on 
untransformed tissues (MCF-10A, hTERT-HMEC).  What set ZNA apart was not its EC50 
against MCF-7 cells, which was comparable to naamidine A, 3.3 µM, but rather its lack of a 
measurable EC50 against MCF-10A cells, as opposed to naamidine A which had an EC50 = 
8.1µM against MCF-10A cells.  The significant change in selectivity between ZNA and 
naamidine A suggested that the phenotype displayed by ZNA was the product of a different 
mechanism of action than that of naamidine A.  In order to explore the mechanism of action 
and the structure activity relationship of ZNA, the synthesis of an analog library was 
undertaken. 
 
5.3 Synthesis of ZNA Analogs  
The ideal synthetic route to ZNA and its analogs would be one in which the N2-acyl-
2-aminoimidizole could be formed directly from the propargyl guanidine. We hypothesized 
that the single regioisomer seen in the AgNO3 cyclization was due to the preferred 
confirmation of the imino tautomer being in conjugation with the acyl group.  If our 
hypothesis was correct, then treating the propargyl guanidine with base would deprotonate the 
N3 nitrogen and promote cyclization through the anion, resulting in the N2-acyl ene-guanidine 
(Scheme 5.3). 10 
To test this hypothesis, propargylguanidine 12 was treated with one equivalent of NaH 






Scheme 5.3: Proposed mechanism for a base catalyzed of the monoacylated guanidine  
 
N3 nitrogen, but the isomerization was induced in situ to provide the N2-acyl-2-aminoimidazole 
11h in a single step from the propargylguanidine (Scheme 5.4).  To ensure that this compound 
was the same as ZNA, the NMR spectra was compared and they appeared identical; a crystal 
structure of 11h definitively confirmed that the base catalyzed cyclization product was identical 
to ZNA.  This synthetic route allowed access to the N2-acyl-2-aminoimidazoles in four steps 
without protecting groups.   
To explore the versatility of this transformation, a series of mono-N-
acylpropargylguanidines were prepared from potassium salts of N-cyanobenzamides activated 
by TMSCl and respective secondary propargylic amines (Table 5.3).  All of the performed 
reactions proceeded in good yield at room temperature, usually reaching completion within 20  
 
 











minutes.  As a trend, the more electron-deficient N-cyanobenzamides performed better in the 
guanidinylation step, presumably because of the increased reactivity of their N-
silylcarbodiimide intermediates.  
An investigation into the scope of the NaH mediated hydroamination of mono-N-
acylpropargylguandidines proved that the reaction could tolerate electron-donating and 
withdrawing aryl substituents at the R1 and R4 positions. Introduction of a cyclopropyl group 
at the R3 position gave comparable yields to aryl substituents, 15i-15l.  Carbamoyl guanidines 
also cyclized selectively under these conditions as illustrated by 15m. The regiochemistry was 
further supported by the X-ray structure of 15m (Figure 5.2). Interestingly, this N2-carbamoyl 






Figure 5.2: Crystal structure of 15m 10 
 
at N2, previously obtained in our laboratory, which exist predominantly as the exocyclic N2-
imino tautomers. 
 
5.4  The Exploration of the Structure-Activity Relationship 
The EC50 values for various analogs were determined by a firefly luciferase-mediated 
ATPlite assay, which was completed by Dr. Rachel Vaden.  This assay was run with 
untransformed epithelial MCF-10A cells, and breast cancer MCF-7 cells.  The limited range 
of EC50 values in the MCF-7 cell line suggested that the peripheral aryl rings did not play a 
critical role in selectivity, though 15e, the 4-chlorophenyl, showed the best results (Figure 5.3).  
The cluster of EC50 values, all within 20 µM, prompted Justin Salvant, a fellow graduate 
student, to prepare a more diverse library of analogs.  
In addition to optimizing the structure-activity relationship, our group, in 
collaboration with the Welm group, set out to determine the mechanism of ZNA’s arrest of 






Figure 5.3: Dose-response curve of ZNA analogs  
 
3/7, 8 or 9, which suggests a different biological target than naamidine A.  Dr. Rachel Vaden 
performed a series of RNAseq profiling experiments to characterize the transcriptome 
changes induced by ZNA.  The genes most upregulated by ZNA were metal trafficking 
metallothionein genes MT1F, MT1X, and MT2A.  More specifically, the profiling of the 
transcriptome showed an increase in the Zn2+ transport genes SLC30A1 and SLC30A2. 11 The 
upregulation of these genes suggests that ZNA effects the intracellular Zn2+ concentration.  In 
order to assess the intracellular Zn2+ concentration of cells treated with ZNA, a fluorescent 
Zn2+ indicator, Fluo-Zin 3 stain, was used.  These assays showed a 13-fold increase of 
intracellular Zn2+ in MCF-7 cells after 48 hours, in contrast to the 2-fold increase of 
intracellular Zn2+ in MCF-10A cells in the same time frame. 11  The influx of Zn2+ into the cell 
generated a hypothesis that a ZNA bound to the metal ion might be the species responsible 
for cytotoxicity.  The formation of the ZNA-Zn2+ complex was supported by the initial 
isolation of naamidine A, which was isolated as a zinc bound dimer; because ZNA was 
designed as a bioisostere, it was reasonable to think that it would act in the same way (Figure 
5.4).  12   To confirm the structure of a ZNA-Zn2+ complex, ZNA was treated with ZnSO4 in 








































Figure 5.4: The naamidine A Zn dimer and the ZNA Zn dimer 
 
To determine how Zn2+ affected ZNA’s cytotoxicity, MCF-7 and MCF-10A cells were 
treated with 30 µM ZNA and 30 µM ZnSO4 and intracellular Zn was measured after 3 hours.  
The MCF-7 cells treated with ZNA and ZnSO4 showed a 170-fold increase in intracellular Zn 
compared to those treated with ZnSO4 alone.  This was drastically different from the MCF-
10A cells which showed only a 9-fold increase when treated with ZNA and ZnSO4 rather than 
ZnSO4 alone.  When additional ZnSO4 was added to the ZNA dosing media, there was a 
synergistic reduction in the viability of MCF-7, T47D, and MDA-MB-231 breast cancer cell 
lines.  These results demonstrate that ZNA has a unique ability to affect Zn2+ trafficking 
differentially between cancer cells and untransformed cells. 11 
The exact mechanism by which ZNA induces zinc dyshomeostasis has not yet been 
elucidated; however, this project is ongoing in our lab.  The robust four step synthesis from 
commercially available starting materials provides access the N2-acyl-2-aminoimidazoles 
without protecting groups.  The ZNA analogs generated can be used to further probe the 
structure-activity relationship of the N2-acyl-2-aminoimidazoles and understand the complex 







5.5 Supporting Information  
Unless otherwise noted, all starting materials were either known compounds or were 
obtained from commercial sources and used without purification. All reactions requiring 
anhydrous conditions were performed under a positive pressure of argon using flame-dried 
glassware. Dichloromethane (CH2Cl2), and triethylamine (Et3N), were distilled from CaH2 
immediately prior to use. Tetrahydrofuran (THF), diethylether (Et2O), toluene (PhMe), and 
dimethylformamide (DMF) were degassed with argon and passed through a solvent 
purification system (J.C. Meyer of Glass Contour) containing either alumina or molecular 
sieves. Flash chromatography was performed on Merk silica gel Kieselgel 60 (230-400 mesh) 
from EM science with the indicated solvent.  
1HNMR spectra were recorded on a Varian VXR-500 MHz spectrometer. The 
chemical shifts (d) of proton resonances are reported relative to CHCl3, DMSO-d5, HOD, or 
HD2COD using the following format: chemical shift [ multiplicity  (s = singlet, d = doublet, t 
= triplet, q = quartet, m = multiplet, app = apparent), coupling constant(s) (J in Hz), 
integral].13,14 13CNMR spectra were recorded at 75, 100, or 125 MHz. The chemical shifts of 
carbon resonances are reported relative to the deuterated solvent peak. 
Infrared spectra were recorded on a Nicolet 380-FT IR spectrometer fitted with a 
SmartOrbit sample system. All absorptions are reported in cm-1 relative to polystyrene (1601 
cm-1). 
 







 In a 50 mL round bottom flask containing a magnetic stir bar were 
added 2a (97 mg, 0.48 mmol), chlorotrimethylsilane (64 µL, 0.50 mmol), and 
acetonitrile (10 mL) under N2.  The solution was stirred at room temperature 
for 10 minutes. A solution of 13a (100 mg, 0.40 mmol) in acetonitrile (5 mL) 
was then added, and the reaction mixture was allowed to stir at room temperature for 1 hour. 
The solvent was then removed under reduced pressure and the crude product was re-dissolved 
in EtOAc (50 mL).  The organic layer was washed with NaHCO3 (20 mL) and brine (20 mL) 
and dried and filtered over Na2SO4.  The crude product was purified via flash chromatography, 
(6:4 hexanes/EtOAc) to give 14a as a foamy white oil (124 mg, 75% yield). Rf = 0.16 (6:4 
hexanes/EtOAc); 1H NMR (CDCl3, 500 MHz): δ 8.06 (t, J = 12.5 Hz, 1H), 7.65 (s, 1H), 7.58-
7.51 (m, 4H), 7.38-7.32 (m, 4H), 7.18 (t, J = 13.0 Hz, 1H), 7.07 (t, J = 13.0 Hz, 1H), 6.92 (d, J 
= 14.5 Hz, 2H), 3.81 (s, 3H), 2.86 (s, 3H) ppm. 13C NMR (CDCl3, 125 MHz): δ 175.5, 162.0 
(d, JCF  = 254.3 Hz), 160.7. 159.7. 148.0. 138.4. 132.2. 132.1 (2), 129.0, 128.8 (d, JCF  = 24.6 Hz), 
128.6, 123.6 (d, JCF  = 3.9 Hz), 122.6, 116.8 (d, JCF  = 23.2 Hz), 114.7, 114.2 , 87.0, 75.4, 55.6, 
50.9, 29.3 ppm. IR (thin film) 1673, 1588, 1560, 1533, 1509, 1452, 1423, 1355, 1304, 1247, 
1218, 1173, 1153, 1030, 897, 845, 758, 732, 691, 590, 550 cm-1. HRMS (ESI+) Calculated for 
C25H22N3O2NaF m/z 438.1594 (M+Na), Obsd. 438.1599. 
 
4-Methoxy-N-(N-(1-(4-methoxyphenyl)-3-phenylprop-2-yn-1-yl)-N-
methylcarbamimidoyl)benzamide (14b).  
Prepared by guanylation of 13a (100 mg, 0.40 mmol) with 2b (103 
mg, 0.48 mmol), with flash chromatography purification eluting with 6:4 
hexanes/EtOAc to yield a foamy white oil (119.8 mg, 70% yield).  R f = 0.13 











2H), 7.65 (s, 1H), 7.58 (d, J = 9.0 Hz, 2H), 7.55-7.52 (m, 2H), 7.37-7.35 (m, 3H), 6.92-6.91 (m, 
2H), 3.84 (s, 3H), 3.81 (s, 3H), 2.87 (s, 3H) ppm. 13C NMR (CDCl3, 125 MHz): δ 176.9, 162.3, 
160.7, 159.7, 132.1, 131.8, 131.3, 129.0, 128.6, 122.7, 114.3, 113.3, 87.0, 85.5, 55.6, 55.5, 50.8, 
29.4 ppm. IR (thin film) 1583, 1558, 1528, 1508, 1464, 1424, 1351, 1305, 1263, 1248, 1173, 
1155, 1032, 893, 788, 730, 701, 653, 554 cm-1. HRMS (ESI+) Calculated for C26H25N3O3 m/z 
(M+H) 450.1818, Obsd. 450.1799. 
 
4-Chloro-N-(N-(1-(4-methoxyphenyl)-3-phenylprop-2-yn-1-yl)-N-
methylcarbamimidoyl)benzamide (14c).  
Prepared by guanylation of 13a (100 mg, 0.40 mmol) with 2c (105 mg, 
0.48 mmol), with flash chromatography purification eluting with 6:4 
hexanes/EtOAc to yield a foamy white oil (140 mg, 81%). Rf = 0.22 (6:4 
hexanes/EtOAc); 1H NMR (CDCl3, 500 MHz): δ 8.20 (d, J = 8.5 Hz, 2H), 
7.65 (s, 1H), 7.57-7.51 (m, 4H), 7.38-7.33 (m, 5H), 6.92 (d, J = 8.5 Hz, 2H), 3.82 (s, 3H), 2.89 
(s, 3H) ppm. 13C NMR (CDCl3, 125 MHz): δ 176.1, 160.9, 159.8, 137.5, 137.4, 132.1, 130.8, 
129.4, 129.0, 128.9, 128.6, 128.3, 122.6, 114.3, 87.2, 85.2, 55.6, 50.9, 29.5 ppm. IR (thin film) 
1583, 1582, 1528, 1508, 1488, 1464, 1421, 1350, 1304, 1246, 1171, 1116, 1111, 1086, 1058, 
1034, 1012, 996, 974, 893, 853, 801, 772, 755, 733, 710, 689, 621, 587, 553 cm-1. HRMS (ESI+) 
Calculated for C25H23N3O2Cl m/z 432.1479 (M+H), Obsd. 432.1489. 
 
N-(N-(1-(4-Methoxyphenyl)-3-phenylprop-2-yn-1-yl)-N-





Prepared by guanylation of 13a (100 mg, 0.40 mmol) with 2c (81 mg, 
0.48 mmol), with flash chromatography purification eluting with 6:4 
hexanes/EtOAc to yield a foamy white oil (121.3 mg, 76% yield).  R f = 0.22 
(6:4 hexanes/EtOAc); 1H NMR (CDCl3, 500 MHz): δ 8.28 (d, J = 7 Hz, 2H), 
7.71 (s, 1H), 7.58 (d, J = 9 Hz, 2H), 7.55-7.52 (m, 2H), 7.47-7.33 (m, 7H), 6.92 (d, J = 8 Hz, 
2H), 3.82 (s, 3H), 2.89 (s, 3H) ppm. 13C NMR (CDCl3, 125 MHz): δ 177.2, 160.9, 159.7, 139.0, 
132.1, 131.3, 129.6, 129.4, 129.0, 128.9, 128.6, 128.1, 122.6, 114.2, 87.1, 85.4, 55.6, 50.9, 29.4 
ppm. IR (thin film) 1587, 1556, 1530, 1508, 1489, 1448, 1422, 1353, 1299, 1247, 1171, 1067, 
1026, 891, 756, 733, 710, 689, 621, 587, 553 cm-1.  HRMS (ESI+) Calculated for C25H23N3O2Na 
m/z 420.1688 (M+Na), Obsd. 420.1697. 
 
N-(N-(1-(4-Chlorophenyl)-3-phenylprop-2-yn-1-yl)-N-methylcarbamimidoyl)-2-
fluorobenzamide (14e).  
Prepared by guanylation of 13b (100 mg, 0.39 mmol) with 2a (81 mg, 
0.47 mmol), with flash  chromatography purification eluting with 6:4 
hexanes/EtOAc to yield a foamy white oil (90 mg, 62% yield). R f = 0.32 (6:4 
hexanes/EtOAc);  1H NMR (CDCl3, 500 MHz): δ 8.03 (t, J = 7.5 Hz, 1H), 
7.69 (s, 1H), 7.58 (d, J = 8.5 Hz, 2H), 7.53-7.51 (m, 2H), 7.39-7.33 (m, 6H), 7.14 (t, J = 8.0, 
1H), 7.13-7.05 (m, 1H), 2.87 (s, 3H) ppm. 13C NMR (CDCl3, 125 MHz): δ 175.6, 162.0 (d, JCF  
= 254.6 Hz), 160.7, 136.1, 134.3, 132.2 (d, JCF  = 8.8 Hz), 132.0 (3), 128.1, 129.0 (2), 128.6, 
126.6 (d, JCF  = 15.2 Hz), 122.3, 116.8 (d, JCF  = 23.3 Hz), 87.5, 84.5, 50.9, 29.4 ppm  IR (thin 
film) 1683, 1589, 1560, 1531, 1488, 1452, 1426, 1353, 1327, 1290, 1263, 1218, 1175, 1152, 
1130, 1091, 1062, 1032, 1014, 897, 844, 791, 756, 737, 691, 669, 539 cm-1. HRMS (ESI+) 






methoxybenzamide (14f).  
Prepared by guanylation of 13b (100 mg, 0.39 mmol) with 2b (101 
mg, 0.47 mmol), with flash chromatography purification eluting with 6:4 
hexanes/EtOAc to yield a foamy white oil (94 mg, 56% yield). Rf = 0.21 (6:4 
hexanes/EtOAc); 1H NMR (CDCl3, 500 MHz): δ 8.21 (d, J = 9.0 Hz, 2H), 
7.73 (s, 1H), 7.59 (d, J = 8.5 Hz, 2H), 7.53-7.51 (m, 2H), 7.36-7.33 (m, 5H), 6.89 (d, J = 9.0 
Hz, 2H), 3.83 (s, 3H), 2.86 (s, 3H) ppm. 13C NMR (CDCl3, 125 MHz): δ 177.0, 162.4, 160.7, 
136.3, 134.3, 132.1, 131.6, 131.3, 129.1, 128.7, 122.4, 113.3, 87.5, 84.7, 50.6, 50.8, 29.5 ppm. 
IR (thin film) 1654, 1603, 1455, 1383, 1300, 1273, 1257, 1169, 1125, 1069, 1035, 1011, 932, 
914, 855, 769, 685, 639, 612 cm-1. HRMS (ESI+) Calculated for C25H22N3O2NaCl m/z 
454.1298 (M+Na), Obsd. 454.1296. 
 
4-Chloro-N-(N-(1-(4-chlorophenyl)-3-phenylprop-2-yn-1-yl)-N-
methylcarbamimidoyl)benzamide (14g).  
Prepared by guanylation of 13b (100 mg, 0.39 mmol) with 2c (102 
mg, 0.47 mmol), with flash chromatography purification eluting with 6:4 
hexanes/EtOAc to yield a foamy white oil (80 mg, 47% yield). R f = 0.37 (6:4 
hexanes/EtOAc); 1H NMR (CDCl3, 500 MHz): δ 8.17 (d, J = 8.5 Hz, 2H), 
7.68 (s, 1H), 7.57 (d, J = 8.5 Hz, 2H), 7.54-7.52 (m, 2H), 7.39-7.35 (m, 7H), 2.89 (s, 3H) ppm. 
13C NMR (CDCl3, 125 MHz): δ 176.2, 173.2, 160.9, 137.5, 137.3, 136.0, 134.5, 132.1, 130.8, 
129.2, 129.1, 129.0, 128.7, 128.3, 122.3, 87.7, 84.4, 51.0, 29.6 ppm. IR (thin film) 3310, 3169, 
1684, 1586, 1556, 1523, 1488, 1469, 1422, 1358, 1323, 1290, 1242, 1159, 1031, 1089, 1064, 





C24H20N3ONaCl2 m/z 436.0983 (M+H), Obsd. 436.0988. 
 
N-(N-(1-(4-Chlorophenyl)-3-phenylprop-2-yn-1-yl)-N-
methylcarbamimidoyl)benzamide (14h).  
Prepared by guanylation of 13b (100 mg, 0.39 mmol) with 2d (81 mg, 
0.47 mmol), with flash chromatography purification eluting with 6:4 
hexanes/EtOAc to yield a foamy white oil (90 mg, 57% yield). R f = 0.27 (6:4 
hexanes/EtOAc); 1H NMR (CDCl3, 500 MHz): δ 8.26 (d, J = 8.0 Hz, 2H), 
7.55 (s, 1H), 7.60 (d, J = 8.5 Hz, 2H), 7.58-7.52 (m, 2H), 7.48-7.33 (m, 8H), 2.88 (s, 3H) ppm. 
13C NMR (CDCl3, 125 MHz): δ 177.3, 160.9, 138.8, 136.2, 134.4, 132.1, 131.4, 129.4, 129.1, 
128.7, 128.1, 122.3, 87.6, 84.6, 50.9, 29.5 ppm. IR (thin film) 1585, 1580, 1509, 1490, 1456, 
1356, 1329, 1250, 1172, 1156, 1101, 1032, 892, 850, 788, 758, 692 cm-1. HRMS (ESI+) 
Calculated for C24H21N3OCl m/z 402.1373 (M+H), Obsd. 402.1374. 
 
N-(N-(3-Cyclopropyl-1-(4-methoxyphenyl)prop-2-yn-1-yl)-N-methylcarbamimidoyl)-
2-fluorobenzamide (14i).  
Prepared by guanylation of 13c (100 mg, 0.46 mmol) with 2a (93 mg, 
0.46 mmol), with flash chromatography purification eluting with 6:4 
hexanes/EtOAc to yield a foamy white oil (74% yield). Rf = 0.21 (6:4 
hexanes/EtOAc); 1H NMR (CDCl3, 500 MHz): δ 8.02 (dt, J = 1.8, 7.8 Hz, 
1H), 7.45 (d, J = 8.5 Hz, 2H), 7.38-7.33 (m, 1H), 7.18 (t, J = 7.8 Hz, 1H), 7.06 (dd, J = 1.0, 8.3 
Hz, 1H), 6.87 (d, J = 7.3 Hz, 2H), 3.79 (s, 3H), 2.76 (s, 3H), 1.39-1.31 (m, 1H), 0.85-0.80 (m, 
2H), 0.78-0.73 (m, 2H) ppm. 13C NMR (CDCl3, 125 MHz): δ 175.4, 162.9 (d, JCF  = 254.4 Hz), 











= 3.8 Hz), 116.8 (d, JCF  = 23.2 Hz), 113.9, 90.7, 71.2, 55.5, 50.4, 8.5 (2) ppm. IR (thin film) 
3336, 2933, 1588, 1559, 1536, 1509, 1453, 1425, 1353, 1248, 1173, 1031, 897 cm-1.HRMS 
(ESI+) Calculated for C22H22N3O2NaF m/z 402.1594 (M+Na), Obsd. 402.1601. 
 
N-(N-(3-Cyclopropyl-1-(4-methoxyphenyl)prop-2-yn-1-yl)-N-methylcarbamimidoyl)-
4-methoxybenzamide (14j).  
Prepared by guanylation of 13c (100 mg, 0.46 mmol) with 2b (100 
mg, 0.46 mmol), with flash chromatography purification eluting with 6:4 
hexanes/EtOAc to yield a foamy white oil (83% yield). Rf = 0.16 (6:4 
hexanes/EtOAc); 1H NMR (CDCl3, 500 MHz): δ 8.2 (d, J = 6.0 Hz, 2H), 
7.47 (d, J = 7.5 Hz, 2H), 6.87 (t, J = 7.5 Hz, 4H), 3.83 (s, 3H), 3.78 (s, 3H), 2.77 (s, 3H), 1.40-
1.32 (m, 1H), 0.86-0.80 (m, 2H), 0.79-0.73 (m, 2H) ppm. 13C NMR (CDCl3, 125 MHz): δ 176.7, 
162.0, 160.5, 159.5, 131.1, 128.7, 113.9, 113.0, 90.67, 71.2, 55.4, 8.6, 8.5 ppm. IR (thin film) 
2933, 1585, 1528, 1507, 1462, 1349, 1346, 1152, 1029 cm-1. HRMS (ESI+) Calculated for 
C23H26N3O3 m/z 392.1974 (M+H), Obsd. 392.1974. 
 
4-Chloro-N-(N-(3-cyclopropyl-1-(4-methoxyphenyl)prop-2-yn-1-yl)-N-
methylcarbamimidoyl)benzamide (14k).  
Prepared by guanylation of 13c (100 mg, 0.46 mmol) with 2c (100 mg, 
0.46 mmol), with flash chromatography purification eluting with 6:4 
hexanes/EtOAc to yield a foamy white oil (80% yield). Rf = 0.35 (6:4 
hexanes/EtOAc); 1H NMR (CDCl3, 500 MHz): δ 8.17 (d, J = 8.4 Hz, 2H), 
7.45 (d, J = 7.9 Hz, 2H), 7.43 (d, J = 9.1 Hz, 2H), 6.87 (d, J = 8.4 Hz, 2H), 3.79 (s, 3H), 2.78 











MHz): δ 175.9, 160.8, 159.5, 137.6, 137.3, 130.7, 128.7, 128.1, 114.2, 91.0, 71.1, 55.8, 50.5, 8.6, 
8.5 ppm. IR (thin film) 3355, 2932, 1552, 1530, 1508, 1422, 1349, 1246, 1172, 1087, 1030, 1013 
cm-1. HRMS (ESI+) Calculated for C22H22N3O2NaCl m/z 418.1303 (M+Na), Obsd. 418.1300. 
 
N-(N-(3-Cyclopropyl-1-(4-methoxyphenyl)prop-2-yn-1-yl)-N-
methylcarbamimidoyl)benzamide (14l).  
Prepared by guanylation of 13c (100 mg, 0.46 mmol) with 2d (85 mg, 
0.46 mmol), with flash chromatography purification eluting with 6:4 
hexanes/EtOAc to yield a foamy white oil (65% yield). Rf = 0.26 (6:4 
hexanes/EtOAc); 1H NMR (CDCl3, 500 MHz): δ 8.25 (d, J = 7.2 Hz, 2H), 7.48 
(d, J = 9.7 Hz, 2H), 7.44 (d, J = 7.9 Hz, 1H), 7.39 (d, J = 7.9 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 
3.79 (s, 3H), 2.78 (s, 3H), 1.4-1.33 (m, 1H), 0.86-0.81 (m, 2H), 0.79-0.75 (m, 2H). 13C NMR 
(CDCl3, 125 MHz): δ 176.9, 160.8, 159.4, 139.1, 131.2, 129.3, 128.8, 127.9, 114.0, 90.7, 77.4, 
71.2, 55.4, 55.4, 8.6, 8.5 ppm. IR (thin film) 3346, 2962, 1588, 1552, 1536, 1467, 1423, 1353, 
1329, 1168, 1066, 893 cm-1. HRMS (ESI+) Calculated for C22H23N3O2Na m/z 384.1688 
(M+Na), Obsd. 384.1693. 
 
Benzyl (Z)-5-benzylidene-2-imino-4-(4-methoxyphenyl)-3-methylimidazolidine-1-
carboxylate (3m).  
Prepared by guanylation of 13a with 2e, with purification on silica gel 
eluting with 1:1 hexanes/EtOAc to give a dark orange oil (2.97 g, 82%). Rf = 
0.48 (1:1 hexanes/EtOAc); 1H NMR (CDCl3, 300 MHz): δ 7.51-7.43 (m, 6H), 
7.36-7.25 (m, 7H), 6.90 (d, J = 6.3 Hz, 2H), 5.18 (s, 2H), 3.80 (s, 3H), 2.80 (s, 





128.4, 128.0, 127.7, 122.2, 113.9, 86.6, 85.2, 66.9, 55.3, 50.6, 29.7 ppm. IR (thin film) 3403, 
2932, 1646, 1584, 1532, 1508, 1488, 1440, 1376, 1273, 1246, 1121, 1150, 1110, 1027, 908, 845, 
799, 775, 755, 729, 690, 647, 586, 552 cm-1. HRMS (ESI+) Calculated for C26H26N3O3 m/z 
428.1974 (M+Na), Obsd. 428.1979. 
 
N-(N-Allyl-N-(1-(4-methoxyphenyl)-3-phenylprop-2-yn-1-yl)carbamimidoyl)-2-
fluorobenzamide (3n).  
Prepared by guanylation of 13d with 2a, with flash chromatography 
purification eluting with 6:4 hexanes/EtOAc to yield a foamy white oil (54% 
yield).  1H NMR (CDCl3, 500 MHz): δ 8.08 (dt, J = 8.0 Hz, 2.0 Hz, 1H), 7.64 
(s, 1H), 7.61 (d, J = 9.0 Hz, 2H), 7.40-7.3 (m, 2H), 7.15 (t, J = 7.5 Hz, 1H), 
7.08 (dd, J = 11.0 Hz, 8.5 Hz, 1H), 6.91 (d, J = 9.0 Hz, 2H), 5.77-5.72 (m, 1H), 5.32 (d, J = 
17.0 Hz, 1H), 5.25 (dd, J = 10.0 Hz, 1.5 Hz, 1H), 3.95 (ABq, J = 15 Hz, 38 Hz, 2H), 3.82 (s, 
3H) ppm. 13C NMR (CDCl3, 125 MHz): δ 175.8, 162.0 (d, JCF  = 254.6 Hz), 161.0, 159.8, 134.0, 
132.2 (d, JCF  = 8.3 Hz), 132.1 (d, JCF  = 1.5 Hz), 132.0, 129.7, 129.2, 128.9, 128.6, 127.8 (d, JCF  
= 3.8 Hz), 123.6 (d, JCF  = 3.8 Hz), 122.6, 118.5, 114.2, 87.1, 85.7, 55.6, 50.8, 47.1 ppm. IR (thin 
film) 1586, 1560, 1510, 1452, 1327, 1248, 1219, 1173, 1152, 1096, 1031, 906, 836, 757, 726, 
690, 668, 646 cm-1. HRMS (ESI+) Calculated for C27H25N3O2F m/z 442.1931 (M+H), Obsd. 
442.1925. 
 
NaH-mediated Cyclizations:  
N-(4-Benzyl-5-(4-methoxyphenyl)-1-methyl-1H-imidazol-2(3H)-ylidene)-2-





In a 25 mL round bottom flask containing a magnetic stir bar were 
added 14a (402.5 mg, 0.97 mmol) and THF (30 mL) under N2. The solution 
was stirred at room temperature, and NaH (22.5 mg, 0.97 mmol) was added, 
resulting in a bright yellow solution. The reaction was stirred for 30 minutes, 
after which the solvent was removed under reduced pressure and the crude product was re-
dissolved in EtOAc (25 mL). The organic layer was washed with saturated aqueous NH4Cl (10 
mL) and brine (10 mL), dried over Na2SO4, filtered, and concentrated.  The resulting yellow 
solid required no further purification (330 mg, 82%). Rf = 0.41 (6:4 hexanes/EtOAc); 1H NMR 
(CDCl3, 500 MHz): δ 8.07 (t, J = 8.0 Hz, 2H), 7.34-7.32 (m, 1H), 7.32-7.27 (m, 4H), 7.21 (t, J 
= 8.5 Hz, 1H), 7.19-7.16 (m, 3H), 7.08 (t, J = 9.5 Hz, 1H), 7.00 (d, J = 8.5 Hz, 2H), 3.86 (s, 
3H), 3.81 (s, 2H), 3.44 (s, 3H) ppm. 13C NMR (CDCl3, 125 MHz): δ 171.8, 162.5 (d, JCF = 
253.4 Hz), 160.2, 148.7, 137.8, 131.8, 131.7 (d, JCF = 1.9 Hz), 131.6, 128.8, 128.2, 126.8, 126.4, 
124.8, 123.6 (d, JCF = 3.8 Hz), 119.9, 116.5 (d, JCF = 22.9 Hz), 114.5, 55.4, 31.0, 30.1 ppm.  IR 
(thin film) 2929, 2360, 2340, 1684, 1569, 1511, 1494, 1455, 1401, 1339, 1290, 1248, 1176, 1032, 
834, 815, 757, 731, 696, 667 cm-1. HRMS (ESI+) Calculated for C22H25N3O m/z (M+H) 
347.1998, Obsd. 438.1594. 
 
N-(4-Benzyl-5-(4-methoxyphenyl)-1-methyl-1,3-dihydro-2H-imidazol-2-ylidene)-4-
methoxybenzamide (15b).  
Prepared via NaH-mediated cyclization of 14b (31.5 mg, 0.074 
mmol) in THF as a yellow foam  (26.5 mg, 84%). Rf = 0.21 (6:4 
hexanes/EtOAc); 1H NMR (CDCl3, 300 MHz): δ 8.08 (d, J = 8.7 Hz, 2H), 
7.30–7.21 (m, 5H), 7.14 (d, J = 8.7 Hz, 2H), 7.01 (d, J = 9.0 Hz, 2H), 6.90 





125 MHz): δ 161.8, 160.2, 137.7, 131.6, 130.5, 128.5, 128.2, 126.8, 124.4, 119.9, 114.5, 113.1, 
55.4, 55.3, 30.7, 30.0 ppm. IR (thin film) 1671, 1603, 1567, 1508, 1454, 1414, 1398, 1349, 1308, 
1289, 1246, 1175, 1163, 1108, 1028, 1005, 882, 835, 799, 765, 733, 697, 608 cm-1. HRMS 




 Prepared via NaH-mediated cyclization of 14c in THF as a yellow 
foam (42.2 mg, 82%). Rf = 0.38 (6:4 hexanes/EtOAc); 1H NMR (CDCl3, 500 
MHz): δ 8.19 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 7.30–7.21 (m, 
5H), 7.12 (d, J = 7.5 Hz, 2H), 7.01 (d, J = 8.0 Hz, 2H), 3.86 (s, 3H), 3.82 (s, 
2H), 3.47 (s, 3H) ppm. 13C NMR (CDCl3, 125 MHz): δ 173.7, 160.5, 150.6, 
137.6, 137.2, 136.8, 131.8, 130.4, 129.2, 128.4, 128.2, 127.2, 124.5, 120.4, 119.8, 113.8, 55.6, 
50.8, 30.1 ppm. IR (thin film) 1670, 1603, 1566, 1508, 1453, 1348, 1307, 1280, 1242, 1174, 
1162, 1108, 1027, 835, 779, 733, 697, 607 cm-1. HRMS (ESI+) Calculated for C25H23N3O2Cl 
m/z 432.1479 (M+H), Obsd. 432.1480. 
 
N-(4-Benzyl-5-(4-methoxyphenyl)-1-methyl-1,3-dihydro-2H-imidazol-2-
ylidene)benzamide (15d).  
Prepared via NaH-mediated cyclization of 14d in THF as a yellow 
foam (55.4 mg, 63%). Rf = 0.47 (6:4 hexanes/EtOAc); 1H NMR (CDCl3, 500 
MHz): δ 8.27 (d, J = 7.0 Hz, 2H), 7.45-7.40 (m, 3H), 7.32-7.27 (m, 4H), 7.22-
? (m, 1H), 7.15 (d, J = 7.5 Hz, 2H), 7.01 (d, J = 9.0 Hz, 2H), 3.86 (s, 3H), 3.83 





128.9, 128.4, 128.1, 127.2, 124.5, 120.0, 114.8, 55.7, 32.4, 31.0 ppm.  IR (thin film) 3061, 2933, 
1675, 1636, 1566, 1541, 1494, 1464, 1453, 199, 1350, 1288, 1246, 1174, 1108, 1025, 1004, 906, 




fluorobenzamide (15e).  
Prepared via NaH-mediated cyclization of 14e in THF as a yellow 
foam (32.7 mg, 62%). Rf = 0.38 (6:4 hexanes/EtOAc); 1H NMR (CDCl3, 500 
MHz): δ 8.08 (t, J = 2.5 Hz, 1H), 7.46 (d, J = 8 Hz, 2H), 7.40 (m, 1H), 7.30-
7.25 (m, 4H), 7.22-7.10 (m, 5H), 3.84 (s, 2H), 3.43 (s, 3H) ppm.  13C NMR 
(CDCl3, 125 MHz): δ 170.1, 161.4 (d, JCF = 252.5 Hz), 147.9, 137.7, 135.2, 132.3 (d, JCF = 8.8 
Hz), 131.7 (d, JCF = 2.5 Hz), 131.5, 129.3, 128.9, 128.2, 126.9, 126.5, 124.3, 123.8 (d, JCF = 2.5 
Hz), 116.6, 116.4, 31.2, 30.5 ppm. IR (thin film) 1682, 1567, 1490, 1352, 1221, 1091, 1010, 906 
cm-1. HRMS (ESI+) Calculated for C24H20N3OFCl m/z 420.1279 (M+H), Obsd. 420.1278. 
 
N-(4-Benzyl-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2H-imidazol-2-ylidene)-4-
methoxybenzamide (15f).  
Prepared via cyclization of 14f in THF as an off-white foam (25.7 
mg, 74%). Rf = 0.38 (6:4 hexanes/EtOAc); 1H NMR (CDCl3, 300 MHz): 
δ 8.19 (d, J = 8.7 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 7.30-7.23 (m, 5H), 7.13 
(d, J = 8.4 Hz, 2H), 6.90 (d, J = 9.0 Hz, 2H), 3.84 (s, 2H), 3.83 (s, 2H), 
3.48 (s, 3H) ppm. 13C NMR (CDCl3, 125 MHz): δ 162.0, 137.5, 135.2, 





30.9, 30.2 ppm.  IR (thin film) 1671, 1568, 1513, 1491, 1452, 1346, 1309, 1248, 1174, 1162, 
1090, 881, 831, 779, 764, 728, 696, 607 cm-1.  HRMS (ESI+) calculated for C25H23N3O2Cl 
(M+H) m/z 432.1479, Obsd. 432.1480. 
 
N-(4-Benzyl-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2H-imidazol-2-ylidene)-4-
chlorobenzamide (15g).  
Prepared via NaH-mediated cyclization of 14g in THF as a yellow 
foam (35.1 mg, 64%). Rf = 0.68 (6:4 hexanes/EtOAc); 1H NMR (CDCl3, 
500 MHz): δ 8.18 (d, J = 8.5 Hz, 2H), 7.47 (d, J = 8.0 Hz, 2H), 7.35 (d, J = 
8.0 Hz, 2H), 7.30-7.25 (m, 5H), 7.12 (d, J = 7.0 Hz, 2H), 3.83 (s, 2H), 3.48 
(s, 3H) ppm. 13C NMR (CDCl3, 125 MHz): δ 137.1, 136.7, 135.8, 131.7, 
130.4, 129.7, 129.3, 128.3, 127.4, 126.2, 123.6, 30.8, 30.4 ppm. IR (thin film) 1571, 1492, 1397, 




ylidene)benzamide (15h).  
Prepared via NaH-mediated cyclization of 14h in THF as a white 
foam (39.3 mg, 77%). Rf = 0.40 (6:4 hexanes/EtOAc); 1H NMR (CDCl3, 500 
MHz): δ 8.24 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 8.0 Hz, 2H), 7.45-7.39 (m, 3H), 
7.30-7.20 (m, 5H), 7.12 (d, J = 7.0 Hz, 2H), 3.83 (s, 2H), 3.48 (s, 3H) ppm. 
13C NMR (CDCl3, 125 MHz): δ 174.1, 149.9, 137.8, 137.7, 135.4, 131.6, 131.1, 129.6, 129.1, 
128.9, 128.3, 128.1, 127.1, 126.6, 124.0, 122.6, 31.1, 30.5 ppm. IR (thin film) 1678, 1566, 1492, 





(ESI+) calculated for C24H20N3ONaCl (M+Na) m/z 423.1193, Obsd. 424.1203. 
 
N-(4-(Cyclopropylmethyl)-5-(4-methoxyphenyl)-1-methyl-1,3-dihydro-2H-imidazol-
2-ylidene)-2-fluorobenzamide (15i).  
Prepared via NaH-mediated cyclization of 14i in THF as a yellow foam (45.6 
mg, 86%). Rf = 0.3 (6:4 hexanes/EtOAc); 1H NMR (CDCl3, 500 MHz): δ 8.09 (dt, J = 
1.7, 6.1 Hz, 1H), 7.40-7.34 (m, 2H), 7.23 (d, J = 7.3 Hz, 2H), 7.16 (t, J = 8.4, 1H),  7.09 
(dd, J = 3.0 Hz, 8.4 Hz, 1H), 6.99 (d, J = 9.0 Hz, 2H), 3.86 (s, 3H), 3.42 (s, 3H), 2.40 
(d, J = 6.7 Hz, 2H), 0.97-0.88 (m, 1H),  0.56 (d, J = 8.3 Hz, 2H),  0.17 (d, J = 4.8 Hz, 2H) 
ppm. 13C NMR (CDCl3, 125 MHz): δ 172.5, 161.5 (d, JCF = 252.5 Hz), 160.1, 149.1, 131.7, 
131.6 (d, JCF = 2.5 Hz), 131.5 (d, JCF = 8.8 Hz), 127.1 (d, JCF = 8.8 Hz), 123.5 (d, JCF = 3.8 Hz), 
123.3, 122.4, 120.0, 116.5 (d, JCF = 22.5 Hz), 114.3, 55.3, 29.9, 29.3, 10.2, 4.5 ppm. IR (thin 
film) 2934, 1566, 1510, 1480, 1353, 1247, 1174, 1031 cm-1. HRMS (ESI+) calculated for 
C22H22N3O2FNa (M+Na) m/z 402.1594, Obsd. 402.1598. 
 
N-(4-(Cyclopropylmethyl)-5-(4-methoxyphenyl)-1-methyl-1,3-dihydro-2H-imidazol-
2-ylidene)-4-methoxybenzamide (15j).  
Prepared via NaH-mediated cyclization of 14j in THF as a yellow 
foam (63.2 mg, 84%). Rf = 0.27 (6:4 hexanes/EtOAc); 1H NMR (CDCl3, 
500 MHz): δ 8.27 (d, J = 8.2 Hz, 2H), 7.24 (d, J = 8.6 Hz, 2H), 7.00 (d, J = 
8.6 Hz, 2H), 6.92 (d, J = 8.2 Hz, 2H), 3.86 (s, 3H), 3.85 (s, 3H), 3.45 (s, 3H), 
2.39 (d, J = 6.8 Hz, 2H), 0.97-0.88 (m, 1H), 0.57 (d, J = 8.1 Hz, 2H), 0.17 
(d, J = 4.7 Hz, 2H) ppm. 13C NMR (CDCl3, 125 MHz): δ 174.6, 173.1, 161.9, 160.2, 131.8, 













1568, 1509, 1463, 1348, 1290, 1246, 1163, 1100, 1030 cm-1. HRMS (ESI+) Calculated for 
C23H25N3O3Na m/z 414.1794 (M+Na), Obsd. 414.1794. 
 
4-Chloro-N-(4-(cyclopropylmethyl)-5-(4-methoxyphenyl)-1-methyl-1,3-dihydro-2H-
imidazol-2-ylidene)benzamide (15k).  
Prepared via NaH-mediated cyclization of 14k in THF as a yellow 
foam (48.2 mg, 87%). Rf =  0.48 (6:4 hexanes/EtOAc); 1H NMR (CDCl3, 500 
MHz): δ 8.24 (d, J = 7.8 Hz, 2H), 7.37 (d, J = 8.5 Hz, 2H), 7.23 (d, J = 8.2 
Hz, 2H), 7.00 (d, J = 8.4 Hz, 2H), 3.86 (s, 3H), 3.45 (s, 3H), 2.40 (d, J = 6.8 
Hz, 2H), 0.97-0.88 (m, 1H), 0.57 (d, J = 7.1 Hz, 2H), 0.18 (d, J = 5.5 Hz, 2H) 
ppm. 13C NMR (CDCl3, 125 MHz): δ 173.8, 173.2, 160.3, 150.3, 137.3, 136.7, 131.8, 130.3, 
128.1, 123.2, 121.7, 120.0, 114.5, 55.6, 29.9, 29.3, 10.2, 4.7 ppm. IR (thin film) 2929, 1822, 
1725, 1569, 1512, 1466, 1348, 1289, 1248, 1162, 1087, 1013 cm-1. HRMS (ESI+) Calculated 
for C22H22N3O2NaCl m/z 418.1298 (M+Na), Obsd. 418.1302. 
 
N-(4-(Cyclopropylmethyl)-5-(4-methoxyphenyl)-1-methyl-1,3-dihydro-2H-imidazol-
2-ylidene)benzamide (15l).  
Prepared via NaH-mediated cyclization of 14l in THF as a yellow foam 
(52.3 mg, 91%). Rf = 0.55 (6:4 hexanes/EtOAc); 1H NMR (CDCl3, 500 MHz): 
δ 8.31 (d, J = 7.3 Hz, 2H), 7.47-7.39 (m, 4H), 7.24 (d, J = 9.0 Hz, 3H), 7.01 (d, 
J = 8.7 Hz, 2H), 3.87 (s, 3H), 3.47 (s, 3H), 2.41 (d, J = 7.3 Hz, 2H), 0.97-0.89 
(m, 1H), 0.58 (d, J = 7.8 Hz, 2H), 0.19 (d, J = 4.8 Hz, 2H) ppm. 13C NMR (CDCl3, 125 MHz): 
δ 174.9, 173.2, 160.2, 138.8, 130.7, 128.9, 128.0, 123.1, 120.2, 114.5, 55.6, 29.9, 29.3, 10.3, 4.7 





HRMS (ESI+) Calculated for C22H23N3O2Na m/z 384.1688 (M+Na), Obsd. 384.1690. 
 
Benzyl (4-benzyl-5-(4-methoxyphenyl)-1-methyl-1,3-dihydro-2H-imidazol-2-
ylidene)carbamate (15m).  
Prepared via NaH-mediated cyclization of 14m in THF as a yellow 
foam (3.0 g, 81 %). Rf = 0.22 (6:4 hexanes/EtOAc); 1H NMR (CDCl3, 500 
MHz): δ 7.41 (d, J = 6.9 Hz, 2H), 7.29-7.19 (m, 8H), 7.11 (d, J = 6.9 Hz, 2H), 
6.99 (d, J = 8.9 Hz, 2H), 5.15 (s, 2H), 3.84 (s, 3H), 3.77 (s, 2H), 3.32 (s, 3H) 
ppm. 13C NMR (CDCl3, 125 MHz): δ 162.9, 160.3, 150.2, 137.9, 137.8, 131.8, 
129.1, 128.5, 128.3, 128.1, 127.6, 127.1, 124.6, 121.2, 120.0, 114.6, 66.9, 55.6, 31.0, 30.2 ppm. 
IR (thin film) 1724, 1590, 1508, 1298, 1244, 1210, 1175, 1059, 906 cm-1. HRMS (ESI+) 
Calculated for C26H26N3O3 m/z 428.1974 (M+H), Obsd. 428.1974. 
 
N-(1-allyl-4-benzyl-5-(4-methoxyphenyl)-1,3-dihydro-2H-imidazol-2-ylidene)-2-
fluorobenzamide (15n).  
Prepared via NaH-mediated cyclization cyclization of 14n in THF as 
a yellow foam (42.6 mg, 54%).  Rf = 0.50 (6:4 hexanes/EtOAc); 1H NMR 
(CDCl3, 500 MHz): δ 8.06 (dt, J = 1.5 Hz, 8.0 Hz, 1H), 7.56-7.53 (m, 1H), 
7.29-7.26 (m, 4H), 7.23-7.20 (m, 1H), 7.15-7.12 (m, 2H), 7.09-7.05 (m, 1H), 
6.98 (d, J = 9.0 Hz, 2H), 5.91-5.83 (m, 1H), 5.12 (dd, J  = 1.0 Hz, 10.0 Hz, 1H), 4.96 (dd, J  = 
1.0 Hz, 17.5 Hz, 1H), 3.86 (s, 3H), 3.80 (s, 2H) ppm. 13C NMR (CDCl3, 125 MHz): δ 161.9 (d, 
JCF = 252.8 Hz), 160.5, 137.9, 132.9, 132.2, 132.1, 132.0 (3), 129.1, 128.4, 127.1, 123.7 (d, JCF 






2924, 1567, 1512, 1364, 1290, 1252, 1176, 1032, 759, 687 cm-1. HRMS (ESI+) Calculated for 
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